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Abstract 
Introduction: Ischemic heart disease (IHD) is a leading cause of death and disability 
worldwide. With the optimisation of treatment for patients with acute myocardial infarction 
(AMI), there has been a parallel increase in the survival of patients with severely 
compromised cardiac function. Pathological ventricular remodelling and myocardial 
dysfunction are key events in the progression of AMI, with heart failure remaining to be one 
of the most challenging conditions to prevent and manage in AMI patients. Therefore, the 
preservation of left ventricular (LV) function and prevention and reversal of cardiac fibrosis 
is essential for the management of these patients. However, to date, there remains a lack of 
effective therapeutic agents available for targeting these adverse processes post-AMI. 
Furthermore, the research field of cardio-protection has been plagued by numerous failed 
attempts to translate promising therapeutic strategies for preventing myocardial ischemic 
injury discovered in the basic science laboratory into the clinical setting. A major factor 
underlying this failure entails the inappropriate use of experimental animal models. 
Growth hormone secretagogues (GHS) have been demonstrated to improve cardiac function, 
attenuate inflammation, remodeling and modulate the autonomic nervous system (ANS) in 
models of cardiovascular disease (CVD). This work aimed to determine whether hexarelin 
(HEX), a synthetic GHS, could preserve LV function and attenuate inflammation and 
remodeling in mouse models of myocardial ischemia reperfusion and infarction. 
Methods: Myocardial ischemia was induced by either transient or permanent ligation of the 
left descending coronary artery in male C57BL/6J mice followed by chronic vehicle or HEX 
administration throughout the recovery period. High field magnetic resonance imaging (MRI) 
was employed to assess LV function and tissue characteristics. More specifically ischemia-
injured and sham mice were subjected to MRI using a T1-weighted late gadolinium 
enhancement sequence (LGE) at 9.4 Tesla (T) to measure LV function, mass and infarct size. 
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The development of novel techniques to assess area at risk at 16 T were also explored in this 
work. 
Results: In response to the ischemic insult, HEX-treated mice demonstrated a significant 
improvement in LV function compared with the VEH-treated group. A significant decrease in 
interstitial collagen, TGF-β1 expression and myofibroblast differentiation was also seen in 
the HEX-treated mice. HEX treatment shifted the balance of ANS towards a parasympathetic 
predominance, evidenced by a smaller low/high-frequency power ratio (LF/HF) and 
increased normalized high frequency power (nHF) measured by heart rate variability 
analysis. This was combined with a significant decrease in cardiac troponin-I and 
inflammatory cytokines, suggestive of a HEX-mediated anti-inflammatory effect and 
amelioration of cardiomyocyte injury based on a reduction in cardiac troponins. 
Conclusion:  These results demonstrate that GHS may preserve LV function and prevent 
adverse remodeling in mouse models of myocardial ischemia, reperfusion and infarction by 
attenuating cardiac fibrosis and cardiomyocyte injury, reducing inflammatory cytokine 
profiles and modulating the ANS. This work provides novel insight into the anti-fibrotic 
effects of HEX and is suggestive of a potential translational application of this synthetic 
peptide for AMI patients. Importantly, in this work we were able to clearly demonstrate the 
cardioprotective effect of HEX therapy using clinically-relevant models, where HEX was 
administered prior to myocardial reperfusion, representing a protocol that could be employed 
in the reperfusion unit. Therefore, this work signifies a noteworthy contribution to the field of 
cardio- protection.  
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1.&Introduction&&
1.1#Ischemic#Heart#Disease##
Ischemic heart disease (IHD) is a leading cause of morbidity and mortality worldwide 
and is associated with considerable health care costs (1-3). The introduction of 
reperfusion therapies have substantially reduced mortality and morbidity amongst 
acute myocardial infarction (AMI) patients, however, there are limited therapies 
designed for targeting the prevention of myocardial ischemia-reperfusion injury (IRI) 
and the chronic sequelae of AMI (3)  Thus, despite improvement in treatment 
protocols,  concern for the development of chronic cardiac morbidities and sudden 
cardiac death continue to negatively influence prognosis and result in substantial 
health care costs (1, 2).   !
Myocardial ischemia occurs when coronary blood flow and oxygen availability are 
insufficient to meet the oxygen requirements of the heart (4). The consequences of 
myocardial ischemia are dependent on the nature and severity of the ischemic episode 
and elapsed time to subsequent re-establishment of coronary blood flow (4). If the 
coronary artery is occluded for more than 20 minutes irreversible damage can occur, 
with lesser periods causing myocardial tissue dysfunction and loss (3, 5). Deprivation 
of oxygen and nutrient supply results in a series of abrupt biochemical and metabolic 
changes within the myocardium (3). The absence of oxygen halts oxidative 
phosphorylation, leading to mitochondrial membrane depolarization, adenosine 
triphosphate (ATP) depletion and inhibition of myocardial contractile function (3). 
During an acute myocardial infarction (AMI), occlusion of a coronary artery territory 
leads to necrosis of the myocytes, following a ‘wavefront’ pattern, spreading from the 
subendocardial layers to the subepicardium (6). Without collateral blood supply or 
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reperfusion, complete necrosis can occur in the territory devoid of perfusion. ‘Area-
at-risk’ is the term given to the total amount of myocardium at risk of necrosis (7). In 
the absence of reperfusion, very few interventions are able to limit infarct 
development (3, 8).!
The treatment of IHD has entered a new era in which mortality can approximately be 
halved by procedures that allow the rapid reperfusion of blood flow to the ischemic 
zone of the myocardium (3, 9). Reperfusion allows the return of blood flow to the 
ischemic area, re-admission of oxygen and metabolic substrates with washout of 
ischemic metabolites (8). Timely myocardial reperfusion via primary percutaneous 
coronary intervention or thrombolytic therapy is essential to salvage viable 
myocardium, limit infarct size, preserve left ventricular systolic function, and prevent 
the onset of heart failure (3, 9). !
Although essential, the process of myocardial reperfusion can itself induce further 
cardiomyocyte death in a phenomenon known as myocardial reperfusion injury (10). 
Reperfusion may lead to further complications such as diminished cardiac contractile 
function (stunning), arrhythmias and irreversible cell injury leading to necrosis and 
apoptosis (3, 9). Early reperfusion therapy and other recent advances in the treatment 
of AMI have substantially reduced mortality and morbidity amongst these patients, 
however, there remains no effective therapy for the prevention of myocardial 
reperfusion injury and its sequelae (3). Early arrhythmias can often prove fatal and 
chronic left ventricular (LV) remodelling and heart failure continue to be major 
determinants of prognosis after AMI (11, 12). A key event in the progression to heart 
failure is the pathological remodelling of the LV secondary to cardiac fibrosis (12). 
To date, there remains no effective therapy able to successfully target and alleviate 
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excessive fibrosis post-AMI (12-14).!
The development of cardioprotective agents to improve myocardial function, decrease 
the incidence of arrhythmias, delay the onset of necrosis, limit the total extent of 
infarction and prevent adverse LV remodelling are of significant clinical importance 
in the AMI patient. There are limited pharmacological agents capable of targeting 
these adverse processes both acutely, ie, in the catheter laboratory, as well as after 
discharge of the patient. Furthermore, quantifying critical zones such as the area-at-
risk and irreversible myocardial injury can allow determination of myocardial 
salvage and therapeutic efficacy but these are challenging to accurately assess non-
invasively in both pre-clinical and clinical studies. !
1.2#Assessment#of#myocardial#injury#in#situ### #
 
The most critical determinant of prognosis in patients with AMI is infarct size. Infarct 
size is a predictor of chronic LV function and clinical outcome in patients after AMI, 
and is inversely related to prognosis (15). An important goal in cardiovascular drug 
development is to achieve infarct size-limiting agents, to aid this; animal models of 
infarct size are of great clinical importance in preclinical drug development (8). 
Accurate determination of the extent of infarction is necessary to evaluate 
interventions that may delay the onset of necrosis and limit the extent of infarct size 
during ischemia-reperfusion (IR) (8).  
 
Historically, two-dimensional echocardiography has been the most commonly used 
non-invasive method for measuring cardiac function in in vivo experimental animal 
models (16), however, magnetic resonance imaging (MRI) allows more accurate 
three-dimensional characterization of cardiac structure and function (17). MRI has 
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thus emerged as a powerful and reliable tool to non-invasively study the 
cardiovascular system in clinical practice (18, 19).  
 
Cardiac MRI (cMRI) is considered one of the most important imaging tools in 
assessment of the heart after AMI (19, 20). Pathological changes in the injured 
myocardium, such as in the presence of fibrosis, haemorrhage and oedema, influence 
the signal intensity on T1- and T2- weighted imaging (21, 22).  Early identification of 
patients with sub-optimal cardiac recovery after AMI is of great importance to 
improve clinical management. Therefore, both functional and structural 
characterization of the infarcted myocardium is important for risk stratification of 
patients after AMI (19, 20). cMRI has the key unique strength of allowing myocardial 
tissue characterization in addition to cardiac volume and function quantification. This 
strength permits better diagnosis, prognostication and tracking of therapy and holds 
advantages over the traditional echocardiographic approach in AMI assessment (7, 8).  
 
Murine cMRI is very challenging due to the small size of the mouse heart and rapid 
heart rate (400-600 beats/min). High field strengths (>7 Tesla (T)) are generally 
required to obtain sufficient signal-to-noise ratio to perform murine cMRI studies (16, 
23), compared to human clinical MRI, which is commonly in the range of 1-3T. It has 
been shown that murine LV function can be reliably measured using cMRI. Studies in 
mice measuring global LV function have demonstrated that the global ejection 
fraction in healthy adult mice (60-75%) is similar to that reported in humans (23).  
 
Accurate quantitative assessment of LV function and structural abnormalities of 
myocardial tissue are of key importance in both the clinical AMI patient and in 
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disease models. Accurate determination of the extent of infarction is necessary to 
evaluate interventions that may delay the onset of necrosis and limit the extent of 
infarct size during IR. These are important concepts in developing preclinical AMI 
models (8). 
1.3#Growth#Hormone#Secretagogues## #
1.3.1$Ghrelin$
Growth hormone secretagogues (GHS) have recently been identified as synthetic 
compounds (mostly peptides) that stimulate growth hormone (GH) release from the 
pituitary gland through the G-protein-coupled receptor (GHS-R) expressed mainly in 
the pituitary and hypothalamus (24, 25). The endogenous ligand, ghrelin, was 
originally isolated from the stomach wall in 1999 (26). Ghrelin is a peptide of 28 
amino acids, in which the serine 3 residue is n-octanoylated (26). There are two 
distinct circulating forms of ghrelin: acylated ghrelin and des-acyl ghrelin. Acylated 
ghrelin binds to the growth hormone secretagogue receptor 1a (GHS-R) and features a 
post-translational modification of O-n-octanoylation at serine 3 which is required for 
its multifaceted endocrine functions (26). Des-acyl ghrelin is the major molecular 
form secreted into the circulation and lacks this post-translational modification. Des-
acyl ghrelin is speculated to bind to an unidentified receptor distinct from GHS-R (27-
29).  
 
Ghrelin is a pleiotropic peptide and has many functions other than the control of GH 
release (30). The wide distribution of the ghrelin receptor indicates multiple paracrine, 
autocrine and endocrine roles for ghrelin (31). The GHS-R receptor is expressed in 
many peripheral organs including the stomach, intestine (32), pancreas (33), kidney 
(34), heart and aorta (35).  
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Ghrelin plays a major role in the regulation of systemic metabolism and has been 
shown to exert a number of central and peripheral actions such as regulation of food 
intake, control of energy balance, glucose metabolism and insulin release, and 
stimulation of gastric acid secretion and motility (25, 36-39). The presence of GHS-R 
within blood vessels and cardiac tissue suggests that ghrelin also has cardiovascular 
effects (35, 40, 41).  
1.3.2$Hexarelin$
Hexarelin (HEX) is a synthetic hexapeptide belonging to the GHS family that has 
been reported to feature cardiovascular activity (42, 43). HEX is recognized to be 
both chemically more stable and functionally more potent than ghrelin (26, 42-44). 
Specifically, HEX has been demonstrated to be more potent in improving heart 
function after myocardial infarction (MI) when compared with ghrelin (45). HEX has 
also been shown to significantly prevent damage induced by myocardial ischemia-
reperfusion injury (IRI) (46, 47). Ghrelin has been demonstrated to be far less 
effective in preventing increases in LV end diastolic pressure, coronary perfusion 
pressure and release of creatine kinase in the heart perfusate of isolated working 
hearts (48). 
 
GHS-R appears to mediate the action of HEX, however some studies report that in 
addition, the CD36 receptor may at least be partly responsible for the actions of HEX 
within the heart and cardiomyocytes (44). The half-maximal effective concentration 
for the GHS-R of HEX (1.7nM) is comparable to that of ghrelin (1.0nM), therefore, 
the additional beneficial effects of HEX are speculated to be the result of CD36 
activation (42, 49). Other studies report identical effects of HEX and ghrelin on 
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cardiomyocytes via activation of GHS-R, although the molar dosages of ghrelin were 
demonstrated to be 10 times that of HEX (50-52).  It has therefore been speculated 
that ghrelin plays a minor role in the control of heart function and actions of HEX are 
mediated in part by GHS-R and largely by interactions with CD36 (44, 48). 
 
1.3.3$Growth$Hormone$Secretagogues$in$Clinical$Trials$ $$
 
There are accumulating reports describing the application of GHS in clinical trials 
(53-56). Ghrelin has been demonstrated to improve LV function, remodelling and 
cardiac cachexia in rats with chronic heart failure (57). The same group proceeded to 
show that in human patients with chronic heart failure, repeated ghrelin 
administration over 3 weeks improved LV function, exercise capacity and muscle 
wastage (53). Chronic heart failure patients treated with an intravenous (IV) ghrelin 
infusion showed a significant decrease in mean arterial blood pressure with no 
significant effect on heart rate. Ghrelin treatment was seen to markedly increase 
cardiac index and stroke volume index in the absence of renal effects in these patients 
(54).  
The cardiovascular effect of a constant rate infusion of ghrelin was studied in healthy 
young men and demonstrated that persistent supraphysiological ghrelin levels 
stimulated LV function without changing endothelium-dependent vasodilation (55). 
In healthy volunteers, IV administration of human ghrelin reduced cardiac afterload 
and increase cardiac output without increasing heart rate (56).  Furthermore, infusion 
of HEX has been shown to exert an inotropic effect in healthy male patients without 
significant effects on mean arterial blood pressure or heart rate (41). These effects 
suggest that HEX may influence the baroreceptor reflex.   
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In a randomized, controlled trial investigating the effect of exercise training on 
ghrelin levels in the setting of heart failure with preserved ejection fraction (HFpEF), 
exercise training had a significant impact on endogenous ghrelin levels (58). Exercise 
training was found to increase ghrelin levels. Patients with lower ghrelin levels at 
baseline were found to experience a more pronounced increase in ghrelin under the 
training intervention (58).  
Ghrelin has been proposed as a potential biomarker and prognostic indicator in 
patients with chronic heart failure (57, 59). Recent data suggests that the GHS-
R/ghrelin axis shows potential as a marker of cardiac dysfunction (60). In this study, 
tissue ghrelin was found to be a more sensitive indicator than b-type natriuretic 
peptide in detecting the biochemical processes characteristic of heart failure. Thus, 
eluding to the potential of ghrelin as a cardiac-specific biomarker in pre-clinical 
stages of heart failure (60). At the preclinical-level, researchers have also shown 
decreased levels of GHS-R in rodent models of diabetic cardiomyopathy (61). 
 
HEX has already been utilized in human studies of cardiovascular disease (CVD), 
demonstrating that it is a both safe and efficacious peptide. However, the potential 
therapeutic effects of HEX remain largely unexplored, particularly in the setting of 
myocardial IR. Ghrelin is an unstable natural peptide that can easily be transformed 
and degraded and limits clinical use. Hexarelin is a more potent and stable 
alternative to ghrelin. Studies conducted to date warrant further investigation and 
clarification of underlying mechanisms leading to cardioprotection.  
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1.4#Growth#Hormone#Secretagogues:#influence#on#myocardial#remodeling#and#
function#
1.4.1$Cardiac$Fibrosis$$ $
It is well known that a major determinant of survival after recovery from AMI is LV 
remodelling (62). Myocardial infarction can lead to progressive ventricular 
remodelling, increased myocardial wall stress and can ultimately result in heart failure 
(14). 
 
Following AMI, cardiac fibroblasts are key effector cells in inflammation, repair and 
remodelling of the heart (63). Phenotypically transformed fibroblasts, termed 
myofibroblasts, are instrumental in all fibrotic conditions and are activated in 
response to myocardial injury and chronically increased mechanical load (64). 
Myofibroblasts are central to fibrogenesis at the site of remodelling following 
infarction (65, 66). These transformed fibroblasts are not residents of normal cardiac 
tissue and appear at the site of an infarct with a hallmark expression of α- smooth 
muscle actin (SMA) (67, 68).  
 
Timely activation of the endogenous pathways that inhibit inflammation is important 
to prevent the catastrophic consequences of uncontrolled inflammation on cardiac 
geometry and function post-MI (63). Induction of pro-inflammatory cytokines, such 
as interleukin (IL)-1 and tumour necrosis factor (TNF)-α play an important role in 
acquisition of a pro-inflammatory phenotype by cardiac fibroblasts during the early 
stages following AMI and have been demonstrated to play a role in cardiac 
remodelling and progression of heart failure (69-72). Sustained presence of 
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inflammatory cytokines leads to activation of matrix metalloproteinases (MMPs), 
resulting in ventricular dilation through slippage of collagen (73, 74). Myocyte 
hypertrophy and progressive fibrosis lead to dysfunction of the LV, eventually 
resulting in heart failure and potentially, sudden cardiac death (63). HEX has been 
demonstrated to reduce the presence of proinflammatory cytokines and transforming 
growth factor (TGF)-β1, a major pro-fibrotic cytokine (75) (Fig. 1).   
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Figure 1 (from (75)): AMI induces dynamic alterations in fibroblast phenotype, 
initiates an inflammatory response and activates neurohormonal pathways. These 
alterations collectively result in cardiac remodelling, mechanical dysfunction and 
electrical disturbances in the failing heart, increasing the risk of sudden cardiac death 
(12). TFG-β1 is markedly augmented following AMI and is the most potent 
profibrotic cytokine known, causing excessive extracellular matrix production, 
inducing its own secretion and driving myofibroblast activation (12). Inflammatory 
cytokines exert potent pro-inflammatory actions on cardiac fibroblasts and can 
negatively affect LV function. Similarly, the renin-angiotensin-aldosterone system 
and sympathetic nervous system activation play a critical role in activation of 
myofibroblasts and influence LV remodelling & dysfunction (12, 67). HEX may 
attenuate and actively reverse cardiac remodelling and myocardial fibrosis by 
targeting these pathways (indicated by “x”) and thus holds promise in returning the 
failing heart to a functional state. Figure from (75) 
 
1.4.2$Remodelling$and$Sequelae$$ $
Adverse sequalae of cardiac remodelling and fibrosis includes the development of 
arrhythmias and risk of sudden death (63). Ventricular tachycardia and fibrillation are 
major causes of morbidity and mortality in patients with AMI. Sympathetic 
hyperinnervation and heterogenous cardiac nerve sprouting have been demonstrated 
to contribute to ventricular arrhythmogenesis and sudden cardiac death in human and 
animal MI models (76-80). The autonomic nervous system (ANS) plays an intricate 
role in the pathophysiology of arrhythmias leading to sudden cardiac death and a bulk 
of evidence describes the potent protective effect of vagal activation on the ischemic 
heart resulting in a lower risk of lethal arrhythmias (81, 82). As such, neuraxial 
modulation has emerged as an important avenue of scientific inquiry and therapeutic 
intervention (83-85). Ghrelin has been clearly demonstrated to attenuate sympathetic 
re-innervation and modulate the ANS (11, 86-93). These effects may contribute to the 
prevention of ventricular arrhythmias and sudden cardiac death in GHS-treated 
models of MI and may hold relevance for clinical translation.  
 
Cardiac remodeling has been associated with gap junction heterogeneities after AMI 
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(94, 95). A growing body of evidence suggests that fibroblasts and cardiomyocytes 
may contribute to cardiac homeostasis by intracellular communications known as 
connexins (63). Connexin (Cx)-43, a principal component of ventricular gap-junction 
proteins, contributes to intercellular communication and electrical coupling of 
cardiomyocytes. During ischemia, uncoupling can occur, leading to pro-arrhythmic 
effects that contribute to the genesis of ventricular arrhythmias (96-99). Cx43-
deficient mice have been reported to be markedly susceptible to ischemia-induced 
ventricular arrhythmias and sudden death (98, 100).  
A loss of phosphorylated Cx43 has been associated with sympathetic nervous system 
activation in AMI and leads to increased ventricular arrhythmias (100). Vagal nerve 
stimulation during AMI has been shown to modify ANS activity and exert an 
antiarrhythmic effect that is accompanied by a preservation of phosphorylated Cx43 
(101, 102). Soeki et al. demonstrated a reduction in ventricular arrhythmias and 
preservation of phosphorylated Cx43 in rats administered ghrelin during AMI in 
comparison with sham-operated rats. Co-administration with atropine or blockade of 
vagal afferent nerves diminished these effects (103). Additional studies also indicate 
that cardiomyocyte coupling may be improved through neural modulation mediated 
via GHS (45, 104).  
In the setting of MI, myocyte death is accompanied by a neural remodeling process 
beginning acutely after coronary occlusion. This process may lead to denervation, 
nerve sprouting and hyperinnervation and can lead to a higher risk of life-threatening 
arrhythmias (80). Nerve growth factor (NGF) is a neurotropin regulating 
differentiation, survival and synaptic activity of the peripheral nervous system; 
expression of NGF rises after AMI and drives the regeneration process of the 
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sympathetic nerves. The level of NGF synthesized is correlated with innervation 
density (105, 106). Post-MI, inflammatory cells express large amounts of NFG which 
is temporo-spatially linked with nerve sprouting and sympathetic hyperinnervation 
density (107, 108). AMI is associated with a cytokine-driven inflammatory reaction 
where cytokine activation of the nuclear transcription factor (NF)-κβ mediates the 
tissue inflammatory response and neurotrophin-regulated signaling pathways (109, 
110). NF-κβ activity is linked with endothelin (ET)-1 expression, which induces NFG 
production (111). Yuan et al demonstrated that ghrelin treatment in rats after MI 
inhibited neural remodelling, attenuated the inflammatory response through 
suppression of IL-1β, and TNFα and decreased NGF levels. Furthermore, NF-κβ 
activation was inhibited and decreased ET-1 mRNA expression was observed in the 
infarcted heart (112).  
ET-1 is a highly pro-fibrotic agent, enhancing collagen expression in myocardial 
fibroblasts and inducing myofibroblast phenoconversion. Increased levels of ET are 
seen in response to tissue damage, hypoxia and induction of TGF-β1 and angiotensin 
(AT)-II (113-123). IL-1 and TNFα can stimulate ET-1 and ET-1-mediated electrical 
remodeling has been shown to correlate with reduced Cx43 expression and function 
(124, 125). GHS have been demonstrated to inhibit myocardial and neural 
remodelling through an anti-inflammatory effect, this has been shown to be mediated 
(at least in part) via inhibition of ET-1 expression in the infarcted heart (112, 126). 
Chronic treatment with ghrelin has been recently demonstrated to attenuate acute MI-
induced arrhythmogenic properties via modulation of Cx43, likely through increased 
expression of Cx43 via inhibition of ET-1 (94).  
Pharmacological modulation of NGF expression may represent a novel strategy to 
 24 
prevent the nerve-sprouting phenomenon occurring just after AMI, which appears to 
be involved in the genesis of arrhythmias. Given the biological effects of IL-1β, 
TNFα, NF-κβ, the anti-inflammatory effect of HEX could be linked to decreased 
NFG, ET-1 and sympathetic nerve sprouting, and likely to be associated with a 
preservation of phosphorylated Cx43 (Fig. 2).  
Furthermore, it has been suggested that modulation of the myofibroblast cytoskeleton 
may also have anti-arrhythmic effects (127). Experimental evidence suggests that α-
SMA-containing stress fibres contribute to the arrhythmogenic potential of 
myofibroblasts and thus targeting the fibroblast may hold promise in treatment of 
infarct-related arrhythmias (127). Myofibroblast modulation may represent a strategy 
explaining HEX’s anti-arrhythmic properties and is likely to link to cardiac 
fibroblasts, Cx43 regulation and electrical remodelling (68, 94).  
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Figure 2: GHS have clear effects on preservation of Cx43 and modulation of the 
myofibrocyte phenotype in addition to reductions in ET-1, NGF and sympathetic 
hyperinnervation. These effects appear to ultimately cumulate in a reduction in 
cardiac fibrosis and preservation of myocardial function. It is unclear as to whether 
these effects are directly associated with GHS treatment or are indirect via autonomic 
modulation and the anti-inflammatory actions of GHS. See text for further details. 
Key: orange arrows represent enhancement; blue arrows represent a protective 
modulation. *It is unclear whether these effects are direct or indirect via autonomic 
modulation. Abbreviations: ANS, autonomic nervous system; Cx, connexin; ET, 
endothelin; GHS, growth hormone secretagogues; MI, myocardial infarction; NGF 
nerve growth factor. 
 
 
Adverse ventricular remodelling is key factor underlying the deterioration in cardiac 
function ultimately leading to increased morbidity and mortality. The discovery of 
novel approaches to halt these detrimental remodelling pathways prior to the 
establishment of chronic cardiac disease is critical. Recent evidence suggests that the 
autonomic nervous system can have profound effects on CV function, remodelling, 
inflammation, IRI and mortality. In the following section we will introduce the novel 
and largely undiscovered link between GHS, cardiovascular disease and the 
autonomic nervous system.  
 
1.5# The# Autonomic# nervous# system,# cardiovascular# disease# &# GHS:# A# novel#
approach#to#cardioprotection?##
 
1.5.1.$Sympathetic$Activity$in$cardiovascular$disease:$$ $
 
Activation of the sympathetic nervous system (SNS) in heart failure patients has been 
studied in detail and shown to contribute significantly to disease progression (128-
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131). The extent of elevation of norepinephrine concentration in patients with heart 
failure has been demonstrated to correlate directly with the severity of LV 
dysfunction and inversely with prognosis. Plasma norepinephrine has been shown to 
be elevated even in patients with asymptomatic LV dysfunction and increases with 
progression to overt heart failure (128-132). Ghrelin has recently been proposed as a 
similarly useful biomarker and prognosticator in chronic heart failure (133). 
The high mortality in MI has been strongly associated with an adverse and sustained 
increase in cardiac sympathetic nervous system activity (CSNA), initiated within the 
first hour of infarction (11, 88, 134). By providing inotropic support to the heart after 
MI an increase in sympathetic nervous activity appears to have an initial benefit. 
However, long-term, sympathetic overstimulation is detrimental to the myocardium 
and is associated with an increased risk of potentially fatal ventricular arrhythmias, 
LV remodelling and heart failure (135, 136).  
Through the suppression of CSNA activity, beta-adrenergic blockade has been shown 
to reduce the incidence of ventricular arrhythmias, attenuate adverse ventricular 
remodelling and decrease mortality after MI (135, 137, 138). Beta-adrenergic 
blockers have been shown to improve many important outcomes, including 
hospitalization and total mortality in chronic heart failure patients, amelioration of LV 
remodelling and improvement in functional class (137-140). 
The mechanisms underlying the increase in CSNA after MI remain to be fully 
elucidated (11, 134). Despite the fact that sympathetic activity has long been 
implicated in morbidity and mortality associated with MI, limited information is 
available on the time course and degree of sympathetic activation post-MI. 
Furthermore, the mechanisms that trigger the initial increase in sympathetic activation 
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(SNA) after acute MI may not be the same as those that sustain the increase in SNA in 
chronic heart failure (11). Studies indicate that the increase in CNSA follows an 
unpredictable time course post-MI (134). In a conscious sheep model, direct 
continuous recordings taken from the post-ganglionic cardiac thoracic nerves pre- and 
post-MI, showed a transient increase in CSNA, significant by the second hour after 
MI. The increase in CSNA was sustained for at least seven days (134).  
Accumulating evidence indicates that inhibition of CSNA improves survival post-MI 
and mitigates LV remodelling and dysfunction (11, 134, 141). The initial increase 
within the few first hours after MI contributes significantly to ventricular arrhythmias 
and consequently, a high mortality. This may represent an important time-point for 
therapeutic intervention in AMI patients (11, 90, 134). There is an intricate causal 
relationship between early and chronic changes in the neural control of cardiac 
function in heart failure (134). Although chronic therapeutic interventions are 
developing for chronic heart failure patients, it is the period immediately after MI, 
before autonomic modulation of cardiac function becomes irreversibly activated, that 
may appears critical for optimizing short and long-term outcome by therapeutic 
intervention (11).  
1.5.2$GHS$and$cardiac$sympathetic$nerve$activation$$
Therapeutic administration of GHS in experimental animal models undergoing 
iatrogenically- induced MI has been promising. The efficacy relating to the temporal-
relationship of dose administration requires further description and, specific 
investigation in IR models. 
In a rat model of MI, early ghrelin treatment was shown to prevent the increase in 
CNSA after MI, reduce the incidence of arrhythmias and improve early survival 
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prognosis (90). Schwenke et al, demonstrated that a single bolus of ghrelin, with a 
plasma half-life of < 60 minutes, given within 30 minutes of left anterior descending 
coronary artery (LAD) ligation, prevented an increase in CSNA (90). This inhibition 
was sustained for at least 2 weeks and attenuated the magnitude of ventricular 
remodelling and dysfunction and reduced mortality (11). When administration of 
ghrelin was delayed (>24hrs) to a point where SNA was maximally increased, daily 
ghrelin administration was seen to only transiently reduce sympathetic tone after MI 
(11). In conscious rats after MI, acute administration of ghrelin also decreased CSNA 
when assessed by heart rate variability analysis (91).  
Similarly, mice that received one oral dose of HEX within 30 minutes of MI had a 
higher ejection fraction and fractional shortening measured 14 days post-MI with 
lowered plasma epinephrine and dopamine levels. The authors concluded that early 
HEX treatment protected against chronic cardiac dysfunction after AMI (104).  
Therapeutic doses of ghrelin have been demonstrated to have little influence on 
arterial blood pressure, heart rate and CSNA at baseline and it has been speculated 
that ghrelin may have a stronger effect on the activated SNS compared with the non-
activated system (88, 91). Ghrelin has also been shown to decrease arterial blood 
pressure without altering heart rate, suggesting that the normal compensatory 
responses to lowering of blood pressure (i.e. SNS-mediated increase in heart rate) are 
inhibited by ghrelin-mediated inhibition of SNA (142-144). In healthy human 
subjects, ghrelin has been shown to suppress CNSA and stimulate cardiac 
parasympathetic nerve activity (PSNA) (92). Furthermore, the sympathoinhibitory 
effects of ghrelin are not evident in vagotomised humans and the response is 
diminished in obese individuals (86).  
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Studies employing ghrelin knock-out mice have demonstrated that endogenous 
ghrelin plays a crucial role in preventing CSNA, arrhythmias and improving survival 
prognosis post-MI (88). Catecholamine concentrations are dramatically increased 
after MI in Ghrelin knock-out mice, reflecting stronger sympathetic nerve activation. 
These findings imply that endogenous ghrelin may have important effects on 
balancing the dysregulated ANS (88). The beneficial effects of ghrelin were seen to 
be abolished after blockade of the vagal nerves by administration of methylatropine 
bromide or perineural treatment of both cervical vagal trunks with the afferent 
neurotoxin, capsaicin. Thus suggesting that these effects may be mediated through the 
action of ghrelin on the vagal afferent nerves (88). 
Endogenous ghrelin also plays a crucial role in improving ventricular remodelling and 
protecting myocardial function after MI (145). Telemetric assessment in conscious 
animals showed that deteriorated ventricular function in ghrelin knock-out mice was 
accompanied by excessive CSNA and decreased PSNA. Treatment with metoprolol or 
ghrelin was shown to suppress CSNA activation, decrease circulating catecholamines 
and prevent ventricular remodelling and dysfunction (145). Thus, evidence is 
accumulating to support an indirect cardioprotective effect of ghrelin via central and 
peripheral modulation of the autonomic nervous system potentially via cardiac vagal 
activation (11, 88). 
The GHS-R is located within the main cardiovascular control centre in the nucleus 
tractus solitarius (NTS) where baroreceptor and chemoreceptor afferents terminate 
(87). Studies have also demonstrated the existence of GHS-R in the infarcted 
myocardium (91, 146).  Co-staining with acetylcholine-esterase suggests that the 
GHS-R is localized in the vagal nerve (VN) terminals of the heart, with afferent 
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projections to the NTS (147). The location and signalling pathway of ghrelin and the 
GHS-R in the heart shows a striking resemblance with that of the gastrointestinal 
system (148). Within the mouse heart, the GHS-R has been detected in very close 
proximity to the choline actyltransferease positive nervous terminals (90, 91, 147). It 
is possible that peripheral ghrelin modulates the cardiac vagal afferent nerve and NTS 
signalling, resulting in a decrease in sympathetic activity and enhancement of PSNA 
(90). This has been suggested in a rat model of MI (91).  
A number of studies demonstrate that ghrelin may also act centrally to modulate the 
sympathetic nervous system (149). The NTS is an important regulator of blood 
pressure and the SNS. Ghrelin has been shown to induce c-fos expression within the 
NTS (150) and central administration of ghrelin has been demonstrated to act directly 
on the NTS to suppress SNA and decrease arterial blood pressure (87, 89). 
Intracerebroventricular injection of ghrelin has been seen to decrease SNA in 
conscious rabbits and suppress SNA in brown adipose tissue in rats (89, 93).  
The intertwined effects of GHS, the ANS and cardiac function are intriguing and may 
represent a novel therapetutic approach to cardioprotection. HEX remains 
unexplored in this setting, specifically as a therapeutic agent in reperfused ischemic 
heart disease.   
1.5.3$Vagal$activity$in$cardiovascular$disease$ $
Autonomic imbalance, characterized by vagal withdrawal and sympathetic 
predominance has been linked to impaired cardiovascular function and elevated 
mortality in various cardiovascular diseases including heart failure, arrhythmias, IRI, 
and hypertension (151-154). Traditionally, the cardiovascular function of the VN has 
entailed regulating sinus rhythm and atrioventricular node conduction. However, 
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recent evidence indicates that the VN can have profound effects on LV remodelling, 
cardiovascular function, IRI, arrhythmias and mortality (155).   
 
Congestive heart failure and AMI are diseases associated with essential perturbations 
in the ANS (139). Reduced vagal tone, characterized by depressed heart rate 
variability and blunted baroreflex sensitivity is closely related to disease progression 
and poor clinical outcome in these patients (156, 157). Defective parasympathetic 
cardiac control may occur before, or in parallel with, elevation in sympathetic tone in 
the development of heart failure (139). Both experimental and clinical studies have 
demonstrated the close association between reduced vagal reflexes and increased 
cardiovascular mortality (158). 
 
Conventionally, pharmacological interventions, such as beta-blocker treatment has 
primarily targeted suppressing sympathetic over-activation, while vagal modulation 
has been neglected (159). Parasympathetic tone restoration/augmentation has 
recently emerged as a promising therapeutic approach for normalising autonomic 
imbalance and preventing the progression of heart failure (160). The mechanisms and 
causal relationship between the withdrawal of parasympathetic tone and chronic 
heart failure progression remain uncertain (139).  
1.5.4$GHS$and$the$Vagus$Nerve$
The VN has been shown to have an important role in signalling between peripheral 
ghrelin and central appetite centres (142). Intravenous administration of ghrelin has 
stimulatory effects on gastric motility and gastric acid secretion with these effects 
abolished by atropine pre-treatment or bilateral cervical vagotomy (161-163).  
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Centrally administered ghrelin has been demonstrated to activate efferent cardiac 
vagal nerves in anaesthetized rabbits resulting in increased acetylcholine (ACH) 
release into the sinoatrial node and a subsequent reduction in heart rate. ACH was 
seen to recover to baseline level after vagotomy (147). Interestingly, the maximum 
dialysate ACH concentration after intracerebroventricular injection of ghrelin has 
been shown to reach a concentration almost equivalent to that induced by electrical 
stimulation of the right cervical VN at 10-20Hz (164). Thus, ghrelin may act as an 
important mediator in the central nervous system (CNS) to activate the cardiac VN 
(147). In this study, ghrelin did not change norepinephrine release (147), thus, it has 
been speculated that ghrelin has a stronger inhibitory effect on the activated 
sympathetic nervous system (90, 91).   
1.5.5$Inflammation$and$the$Vagus$nerve$
Balanced inflammatory responses are essential elements of a successful host response 
after injury. However, excessive and sustained inflammatory responses can lead to 
severe tissue damage (165). The VN has been suggested as an important link between 
the involuntary nervous system and proinflammation for over 70 years (166). The 
afferent sensory fibres and efferent motor fibres suggest that the VN can sense 
continuing inflammation and can act rapidly and efficiently to suppress it. Thus, the 
vagus can act as an endogenous mechanism to regulate the magnitude of innate 
immune responses and subsequently attenuate inflammation (165).   
It is well known that activation of efferent VN fibres can modulate local and systemic 
inflammatory responses (165, 167-169). This motor arc of this inflammatory reflex is 
termed the ‘cholinergic anti-inflammatory pathway’ (CAP) and was first described by 
Tracey et al (165). Cytokines produced by immunoactive cells secondary to 
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exogenous or endogenous stimuli are registered by afferent vagus neurons (170, 171). 
Information travels centrally to the NTS to communicate with the brainstem, 
hypothalamus and forebrain, affecting glucocorticoid release, inhibiting 
proinflammatory cytokines and reflexively activating efferent vagal pathways (171-
173). The CAP consists of VN signaling leading to an ACH-dependant interaction 
with the α-7 nicotinic acetylcholine receptor (α7nAChR) subunit on macrophages 
and monocytes and the subsequent reduction of inflammatory cytokines (170, 174, 
175). The CAP is considered a mechanism by which the CNS may regulate excessive 
inflammation and limit self damage (176). The precise mechanism of how VN 
activation exerts its protective effects is highly complex and further mechanistic 
studies need to be conducted in this field.  
Activation of the CAP is possible via vagal nerve stimulation (VNS) or 
pharmacologically via administration of selective α7nAChR agonists or inhibitors of 
acetylcholinersetase (177, 178). Cholinergic agonists have been shown to produce the 
same effects as VNS (179). Cholinergic stimulation has been demonstrated to reduce 
pro-inflammatory cytokine production and prevent lethal tissue injury in multiple 
models of local and systemic inflammation and sepsis (180), including acute lung 
injury (181, 182), arthritis (183), burns (184, 185), cerebral ischemia (186), colitis 
(187), encephalomyelitis (188), haemorrhagic shock (189, 190), intracerebral 
haemorrhage (191), myocardial (192), renal (193) and splanchnic IRI (194), 
pancreatitis (195), polymicrobial abdominal sepsis (196-198) and post-operative ileus 
(199).  
Pharmacological activation of the CAP is intriguing concept requiring exploration as 
a therapeutic strategy for IRI in IHD 
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1.5.6$The$cholinergic$antiLinflammatory$pathway:$Mechanism$of$action$
Inflammation has been demonstrated to play a major role in IRI (200, 201). The anti-
inflammatory function of the VN is mediated through several pathways, some of 
which remain controversial (202). Briefly, these pathways are proposed as: the 
hypothalamic-pituitary-adrenal axis whereby stimulation of vagal afferent fibres 
ultimately results in release of cortisol from the adrenal glands. Secondly, in the 
splenic sympathetic anti-inflammatory pathway, the VN stimulates the splenic nerve 
to release norepinephrine which interacts with the β2 adrenergic receptor of splenic 
lymphocytes to release ACH & ultimately inhibit the release of TNFα from splenic 
macrophages via the α7nAChR (202). Lastly, the CAP is mediated through vagal 
efferent fibres that synapse onto enteric neurons and release ACH. ACH binds to the 
α7nAChR on macrophages and inhibits release of TNFα and pro-inflammatory 
cytokines (202) (Fig. 3).  
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Figure 3: Pathways of vagal function, figure modified from (202). Inflammatory 
cytokines can activate the afferent VN, which projects to the NTS. Ghrelin binds to 
the GHS-R and can also modulate this reflex.  Ghrelin and VNS can result in central 
modulation of inflammation via influencing the efferent VN and the CAP (see text). 
Activation of the splenic pathway is controversial. Abbreviations: Ach, acetylcholine; 
α7nAChR, α−7−nicotinic acetylcholine receptor; β2-R, beta 2 adrenergic receptor; 
CAP, cholinergic anti-inflammatory pathway; celiac G, celiac ganglion; NTS, nucleus 
tractus solitaries; TNFα, tumour necrosis factor α; VN, vagal nerve; VNS, vagal 
nerve stimulation. 
 
Several studies indicate that action potentials transmitted in the VN traverse the 
subdiaphragmatic VN, the celiac ganglion and the splenic nerve. Vagal innervation of 
the spleen is controversial, some report it to be under the control of the VN 
terminating on macrophages expressing α7nAchR and inhibiting TNFα release (203-
207) (see Fig. 3). The spleen is a major source of circulating TNF α and interestingly, 
splenectomy has been shown to lower TNF α similarly to VNS (203, 208). 
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Furthermore, splenectomy has been shown to reverse cardiac remodelling and 
inflammation in heart failure animals. In a mouse model of MI-induced heart failure, 
splenocytes transferred from these mice to normal mice were observed to migrate to 
the heart and induce LV dilation, dysfunction and fibrosis (142). These results suggest 
that the spleen may modulate cardiac inflammation. The metabolic activity of the 
spleen has also been shown to independently predict risk of subsequent cardiovascular 
disease events in humans (144).  It remains unclear whether vagus activation has 
direct cardiac or indirect anti-inflammatory effects (or both), there does however, 
appear to be convincing evidence of a cardiosplenic axis (144) 
Efferent vagal fibres release ACH in the reticulo-endothelial system (spleen, liver, 
gastrointestinal tract). The nicotinic subunit, α7nAchR, is present on macrophages, 
monocytes, dendritic cells, T-cells and endothelial and non-neuronal cells. Activation 
of α7nAchR present on macrophages stimulates JAK and STAT anti-inflammatory 
pathways, inhibits NFκΒ and prevents cytokine synthesis and release (206, 209, 210). 
Vagal stimulation has been demonstrated to inhibit TNFα synthesis in wild-type, but 
not α7-deficient mice, thus demonstrating the essential role of the α7-subunit 
modulating the CAP response (180, 204, 211). Nicotinic agonists for the α7nAchR 
have been suggested as therapeutic targets to treat sepsis (212). Efferent vagal 
activation inhibits TNFα in endotoxaemia without augmenting corticosteroid or IL-10 
levels in animals with intact vagi (213).  
α7nAChR-dependent cholinergic signalling is also implicated in suppressing 
production and release of HMGB1, a late cytokine mediator of the systemic 
inflammatory response (212). Administration of nicotine decreased serum levels of 
HMGB1 and improved survival in a rat model of sepsis (212). Transcutaneous VNS 
 37 
has also been shown to reduce serum HMGB1 levels and improve survival of mice 
with sepsis (143).  
1.5.7$Inflammation,$Vagal$Nerve$Activation$and$Ghrelin$$
It has been well established that increasing parasympathetic tone, through VNS 
decreases inflammation in various models of physiologic insult, including myocardial 
IRI, cecal ligation and puncture, lipopolysaccharide injection, severe burn injury and 
traumatic brain injury (165, 174, 214-217).  
Pharmacological stimulation of the VN may offer a novel approach to anti-
inflammatory therapy, this is particularly exciting in the setting of IHD.. Beyond its 
anti-inflammatory effects, the VN aids as a conduct for neuro-enteric communication, 
whereby enhanced VN activity (of both central and peripheral divisions), leads to 
increased pancreatic exocrine function, gastrointestinal motility and changes in 
neuroendocrine profiles (218), this will be discussed further in the following chapters.  
Ghrelin has been shown to have several anti-inflammatory properties involving vagus 
activation. Intravenous ghrelin administration in septic mice has been shown to 
decrease levels of the pro-inflammatory cytokines IL-1 and IL-6. Subdiaphragmatic 
vagotomy completely abolishes this inhibitory effect (196). Vagotomy also abrogated 
ghrelin’s protective effect on sepsis-induced organ function parameters such as 
aspartate aminotransferase, alanine aminotransferase and lactate (196). Similar 
findings were also demonstrated after ghrelin treatment in a rat model of endotoxemia 
(219, 220). Intravenous administration of ghrelin decreased both circulating 
norepinephrine and TNFα levels in a model of sepsis. Administration of a specific 
ghrelin receptor antagonist increased the release of norepinephrine and TNFα in 
normal rats, demonstrating that ghrelin may modulate the overstimulated sympathetic 
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nerve in sepsis (221). Interestingly, the inhibitory effect of ghrelin on norepinephrine 
release was completely blocked by intracerebroventricular administration of a GHS-R 
receptor antagonist, whereas its down-regulatory effect on TNFα release was only 
partially diminished (221).  
Circling levels of ghrelin were significantly decreased in a rat model of polymicrobial 
sepsis induced by caecal ligation and puncture; with the GHS-R being markedly 
elevated in early sepsis (222, 223). Down-regulation of ghrelin in sepsis appears to 
play a role in activating sympathostimulatory nuclei in the brain and increasing 
norepinephrine release from the sympathetic nerve fibres (221, 224). Furthermore, 
enterectomy prior to onset of sepsis has been demonstrated to markedly reduce 
circulating levels of norepinephrine, indicating that the gut is the major source of 
norepinephrine release during sepsis. It has been described that approximately 50% of 
the norepinephrine released in the body is produced by the sympathetic fibres in the 
gut (225-227).  
Ghrelin has been demonstrated to have no direct effect on cytokine release from 
kupffer cells or peritoneal macrophages isolated from normal rats, suggesting an 
indirect anti-inflammatory mechanism (196). Ghrelin’s beneficial effect in inhibiting 
cytokine release in sepsis is likely to be mediated by combined action of activation of 
the VN and the inhibition of SNA. Ghrelin appears to have the potential to rebalance 
the dysregulated sympathetic/parasympathetic nervous system in sepsis (221). It also 
seems possible that ghrelin may be a major player in the enteric arm of the CAP. The 
neuroinflammatory-modulating properties of GHP may also hold true in CVD.  
Inflammation has been demonstrated to play a major role in IRI (228, 229). Ghrelin 
has been demonstrated to activate the CAP in various models of ischemia-reperfusion 
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(IR) (230). Administration of ghrelin after gut-IR attenuated excessive inflammation 
and reduced organ injury demonstrated through the rapid activation of the CAP (231). 
In a rat model of renal IR, ghrelin administration during reperfusion attenuated both 
the systemic and renal-specific inflammatory response and was mediated through the 
VN (232). Ghrelin was also demonstrated to have protective effects in cisplatin-
induced nephrotoxicity through inhibition of inflammatory reactions (233). Ghrelin 
administered as a single dose immediately following sepsis was also found to protect 
the kidneys from injury by attenuating the pro-inflammatory markers, it was thought 
that was likely to be mediated through the VN (234) 
Using a mouse model of pressure-overload cardiac hypertrophy it was demonstrated 
that the absence of endogenous ghrelin resulted in severe cardiac hypertrophy and 
diastolic dysfunction (235). This was accompanied by an increase in the 
proinflammatory cytokines IL-6 and IL-1β. Administration of ghrelin suppressed the 
increase in IL-6 and IL-1β and improved cardiac function; it was thought that this was 
mediated through the CAP (235). Huang et al recently demonstrated that HEX 
protected cardiomyocytes from IRI partly through modification of the IL-1 signaling 
pathway, including down-regulation of IL-1β expression and up-regulation of IL-1Rα 
expression in the IR myocardium. This was mediated via activation of the GHS-R 
(47). 
1.5.8$AntiLinflammatory$benefits$of$vagal$nerve$stimulation$in$the$heart$
A lack of progression in the development of new drug therapies has stimulated 
interest in new, non-pharmacological approaches for the management of heart failure 
secondary to LV systolic dysfunction (192, 214, 236, 237). VNS has been shown to 
address the imbalance between the sympathetic nervous system (SNS) and 
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parasympathetic nervous system (PNS) (158). GHS may also hold promise in 
influencing the ANS in heart failure patients (230).   
An improvement in LV ejection fraction, ventricular arrhythmias and survival has 
been demonstrated secondary to VNS in heart failure models (132, 238-241). Vagal 
stimulation has been seen to improve cardiac autonomic control and significantly 
attenuate heart failure development in various animal models (242, 243).  
An increase in the pro-inflammatory cytokines TNFα, IL-1β, IL-6, IL-18 have been 
observed in models of chronic heart failure (244, 245). Increased morbidity and 
mortality has also been associated with cytokine release in chronic heart failure 
patients (246). VNS has been demonstrated to reduce these markers to near normal 
(214, 247-249).  Importantly, regulation of inflammation may improve cardiac 
performance and outcome (214, 247). VNS has been shown to reduce LV end-
diastolic pressure, increase cardiac output and survival in a rat model of MI (238, 
239). In rodents, increased infarct size has been associated with elevated levels of 
TNFα, with VNS shown to decrease levels of inflammatory markers and infarct size 
(250, 251). VNS appeared to ameliorate ischemia-induced cardiac dysfunction by 
inhibiting TNFα-mediated signalling in a number of similar studies (252-254). 
Using a swine MI model, VN stimulation was seen to decrease episodes of ventricular 
fibrillation, reduce infarct size and improve ventricular function (255, 256). Similarly, 
in a canine model of coronary artery occlusion and myocardial infarction, VNS 
protected against ventricular fibrillation and improved systolic function (257, 258). 
Low-level VNS normalized C-reactive protein, IL-1-6, TNFα, pro-ANP, pro-BNP 
levels and improved LV function in a canine ventricular pacing-heart failure model 
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(132). Furthermore, VNS was seen to attenuate the reduction in baroreflex sensitivity, 
rise in plasma norepinephrine and angiotensin II (132, 257). Similar findings were 
demonstrated by Zhang who employed a canine myocardial IRI model (259). In a 
canine chronic heart failure model induced by multiple sequential coronary micro-
embolism, VNS decreased LV end systolic volume, end diastolic volume and 
increased ejection fraction (257). Addition of VNS to beta blockade increased LV 
ejection fraction and decreased LV end systolic volume more than that obtained by B-
blockade alone (238, 257).  
A major determinant of survival after recovery from MI is LV remodeling (260). 
VNS has been demonstrated to improve LV remodeling by down-regulation of MMP-
9 and TGF-β1 protein expression post-MI (239, 261, 262). MMP-9 and TGF-β1 both 
play key roles in the progression of post-MI remodeling (263, 264).  Inflammatory 
cytokines such as IL-1 can regulate fibroblast phenotype, activity and the activation of 
MMPs/TIMPs and thus can influence changes in degradation of the extracellular 
matrix and collagen deposition (47, 74, 265). VNS has also been demonstrated to 
attenuate interstitial fibrosis and collagen degradation in the non-infarcted 
myocardium with concurrent improvement in cardiac function (266). Interestingly, it 
is possible to substitute low-level transcutaneous electrical stimulation of the auricular 
branch of the VN for VNS to reverse cardiac remodeling in a canine model of post-
ischemic heart failure (266, 267).  
1.5.9$Vagal$nerve$stimulationL$Clinical$trials$$
Animal data indicates that the VN regulates an anti-inflammatory reflex in the heart 
and VNS can affect cardiac remodelling and survival outcomes (214). To date, similar 
data has not yet translated to the clinic, however, there does appear to be a 
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relationship between VN activation and inflammation in humans (214, 268). 
Recently, the CARDIA study (coronary artery risk development in young adults) 
revealed an inverse relationship between heart rate variability and inflammatory 
markers, demonstrating that efferent vagus activity is inversely associated with 
inflammation and cytokines (268).  
Implantable electric devices for stimulation of the cervical VN have been used in 
clinical practice for over 20 years and were initially designed for treatment of epilepsy 
and depression (269). Schwartz et al. conducted the first clinical approach of chronic 
VNS using an implantable neurostimulator system for the treatment of severe chronic 
heart failure and demonstrated a significant improvement in New York Heart 
Association (NYHA) class, quality of life, LV end systolic volume and trend towards 
a reduction in LV end diastolic volume after 6 months (270). De Farrari et al. further 
demonstrated a significant improvement in NYHA quality of life, LV ejection 
fraction and systolic pressure after one year (243). Furthermore, the ANTHEM-HF 
(Autonomic Neural regulation Therapy to Enhance Myocardial function in Heart 
Failure) trial demonstrated that chronic VNS was safe in heart failure with reduced 
ejection fraction (HFrEF) patients and improved LV ejection fraction, end systolic 
volume, heart rate variability, exercise intolerance and NYHA functional class (271). 
Conversely, NECTAR-HF (NEural Cardiac TherApy foR Heart Failure), a double 
blinded, randomized study of 96 patients comparing VNS to medical therapy, failed 
to demonstrate a significant effect on measures of cardiac remodelling and functional 
capacity in symptomatic heart failure patients (160). However, there was a significant 
improvement in quality of life (272).  
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INOVATE-HF (Increase of Vagal Tone in Heart Failure) was the first large multi 
centre, randomized, phase III study of VNS for the treatment of symptomatic heart 
failure (273). The results of this study showed that VNS did not improve the risk of 
death or heart failure events among patients with reduced LV ejection fraction. 
However, VNS improved quality of life, functional status and 6-min walk time in 
chronic heart failure patients (274). It is worthy to note, that the patients enrolled in 
this study did not have inflammatory markers present. Thus, we might postulate that 
those with chronic fibrotic cardiomyopathic diseases may not benefit from an anti-
inflammatory approach to therapy. When there is the potential for remodeling, (ie, 
post- acute event) VNS may be more likely to have beneficial results (214, 272). This 
theory has been unexplored to date.  
In conclusion, the VN plays a vital role in maintaining normal cardiac function and 
reduced vagal tone is a hallmark of a variety of cardiovascular diseases (275). Given 
that traditional cardiovascular drugs have minimal influence on the inflammatory 
reflex or cytokines present in cardiovascular disorders, modulating the inflammatory 
response may represent a largely unexplored therapeutic strategy to reduce infarct size 
and improve recovery of cardiac function in the AMI patient. Identifying a means to 
physiologically modulate this inflammatory reaction might provide a rationale 
solution to protect against myocardial IRI and progression of heart failure. GHS may 
represent a plausible answer. 
Ghrelin is likely to be one of the most important mediators in the CNS that activates 
the VN. GHS may regulate an endogenous pathway to reduce inflammation and 
protect cardiac function via restoration or augmentation of vagal tone. The 
therapeutic potential of GHS to modulate the ANS is clearly a feasible and promising 
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therapeutic target deserving further study and one of the overarching themes of this 
thesis.  
1.6#The#gut#brain#axis#and#metabolic#actions#of#GHS# #
IHD in humans is a complex disorder caused by, or associated with other systemic 
diseases or conditions. IHD develops as a consequence of a number of etiological risk 
factors and coexists with other disease states that exert multiple biochemical effects 
on the heart and can potentially interfere with responses to cardioprotective 
interventions (9). These risk factors include systemic arterial hypertension and LV 
hypertrophy, hyperlipidemia, atherosclerosis, aging, diabetes and insulin resistance 
and heart failure (9). 
1.6.1$Metabolic$disease$and$Inflammation$
Chronic diseases such as obesity, diabetes, cardiovascular and inflammatory bowel 
disease (IBD) share common features in their pathophysiology (276). It has been well 
described that inflammation is associated with metabolic alterations and, 
simultaneously, metabolic disorders often exhibit strong inflammatory underpinnings 
(276). Levels of acute phase-proteins such as C-reactive protein and proinflammatory 
cytokines are increased in individuals with obesity, indicative of chronic 
inflammation (277-279).  Furthermore, chronic inflammation secondary to immune 
and metabolic dysregulation has been linked with hyperglycaemia, insulin resistance, 
dyslipidaemia and hypertension (277).  
Obesity and the metabolic syndrome are closely associated with impaired 
cardiovascular regulation and atherosclerosis (277). The inflammatory responses 
associated with metabolic disease can cause cardiac injury and ventricular 
dysfunction. Elevated cytokine levels have been shown to relate directly to 
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deterioration of functional class and LV ejection fraction (244, 280). Cytokines can 
induce hypertrophy, influence myocardial contractility and promote apoptosis 
contributing to ventricular remodeling and dysfunction (281). Circulating 
inflammatory cytokines are independent predictors of mortality in patients with 
advanced heart failure (244, 280). Chronic inflammation has been linked to 
progression of heart failure, myocardial injury and cardiovascular death (214) (Fig. 
4). 
Given that traditional cardiovascular drugs have little influence on cytokines or the 
inflammatory reflex present in heart failure, recent evidence suggests that regulation 
of inflammation may improve cardiac performance and outcome (247, 282)   
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Figure 4: Proposed effects of cytokines. Ultimately, these effects can negatively 
influence left ventricular function. 
 
1.6.2$Enteroendocrine$cells$and$the$immunoendocrine$axis$
Recently, the intestine and intestinal epithelial cells have been recognized as key 
players in maintaining both immune and metabolic homeostasis (283). 
Enteroendocrine cells (EEC) can regulate secretion, gastrointestinal motility and 
insulin release via the release of peptide hormones (276). These cells are also capable 
of sensing the lamina propria and luminal environment, including the microbiota, and 
can modulate signaling by the secretion of endocrine, metabolic, immune and 
neuronal mediators (276).  
It has been increasingly recognized that gut-liberated mediators can influence brain 
function by acting as an interface between the gut enteric nervous system and CNS, 
thus effectively linking the CNS and immune system (283). The immune system has 
been shown to communicate with the brain via various pathways; the humoral route 
describes the transport of cytokines (or hormones) produced from the gut, immune 
cells or periphery to the brain via the circulation. Secondly, EEC and immune cells 
can communicate with afferent sensory nerve fibers through production of endocrine, 
metabolic, immune or neuronal mediators (284). Finally, circulating immune cells can 
be trafficked to the brain and influence the CNS via the liberation of inflammatory 
mediators (283).  
During inflammation, both murine and human studies have demonstrated alterations 
in EEC cell number and secretions (285, 286). EEC cells can be considered 
integrators of inflammatory and metabolic signaling by acting as front-line pathogen-
detectors releasing cytokines or peptide hormones that can directly influence immune 
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function (276, 286). Immune cells express an array of receptors for EEC-secreted 
peptides, suggesting the potential of bi-directional signaling in the immunoendocrine 
axis (286, 287). Importantly, mediators liberated by these cells can indirectly 
influence immune responses via the triggering of vagal afferents (286).  
1.6.3$Vagus$Nerve$and$Gut$Peptides$
The VN links the exchange signals between the periphery and CNS and is an essential 
pathway in the regulation of energy metabolism and food intake (148). Electrical 
stimulation, pharmacological and nutritional interventions have been reported to 
stimulate the anti-inflammatory actions of the VN. Subdiaphragmatic vagotomy 
prevents these actions (165, 288).  
A number of appetite-regulating peptides are expressed in both the peripheral organs 
and CNS (148). The nodose ganglion is a constellation of vagal afferent neurons that 
synthesize receptors for gut peptides regulating feeding and energy homeostasis (289-
291). These receptors are transported to afferent terminals in the gastrointestinal 
mucosa and are optimally positioned to monitor mediators released from 
gastrointestinal EEC (289). Gut peptides can modulate the activity of the VN by 
binding to receptors at the vagal afferent terminal that extend into the mucosal layer 
of the digestive tract (148, 284) (Fig. 5).  
Ghrelin receptors are synthesized in the nodose ganglion and are transported to the 
vagal terminals on the digestive tract end (148). Once bound, information is conveyed 
to the NTS and the arcuate nucleus within the hypothalamus to modulate appetite-
regulation (148, 289). Ghrelin is produced both centrally and in the periphery. A 
fasting state promotes an increase in plasma ghrelin levels (284), administration of 
exogenous ghrelin promotes food-seeking behaviour (288, 292). The reported 
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mechanisms by which ghrelin exerts its biological activities are complex. Ghrelin 
activates MAPKs, including ERK1/2 which are involved in the activation of nuclear 
transcription factors (293, 294). 
1.6.4$Microbiota$and$GHS$
The enteric nervous system has been described as an important signal transducer 
between the CNS and the gut (288). Interestingly, a number of disease states show a 
shift in the structure of the intestinal microbiota and this is thought to play an integral 
role in disease pathogenesis and clinical course (283, 295). Mice fed a high fat diet 
have been demonstrated to develop gastrointestinal inflammation; this is 
communicated to the hypothalamus through a vagal afferent pathway. It is thought 
that this may partly result from changes in the intestinal flora (289). Furthermore, the 
composition of the intestinal microbiota is thought to play an important role in 
altering host immune responses and influencing cytokine profiles, ultimately with the 
capacity to affect brain function (283). CNS pathologies such as autism, anxiety and 
depression are thought to be associated with dysbiosis of the intestinal microbiota 
(288). In mice, ischemic or traumatic brain injury has been demonstrated to drive 
changes in the intestinal microbiota (296). Components of the microbiota may be able 
to regulate intestinal motility and gut pain responses, indirectly via production of 
neuroactive mediators, such as ghrelin (297, 298).  Circulating levels of ghrelin are 
increased by stress in human patients and rodent models (299, 300) and ghrelin 
administration has been demonstrated to have anxioloytic and anti-depressant effects 
in mice following calorie restriction (301). Furthermore, mice with elevated plasma 
ghrelin levels show less anxiety and depressive-like behaviours (301).  
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1.6.5$Metabolic$disease,$gut$peptides,$the$vagus$nerve$and$inflammation$$
Obesity has been shown to evoke a broad array of inflammatory and metabolic 
responses cumulating in low-grade local inflammation, disruption of metabolic 
homeostasis and defective insulin receptor signaling (302). A loss of glycemic control 
is seen in patients with sepsis and in animal models of endotoxin-induced 
inflammation (303, 304).  
Decreased VN activity has been reported in obesity and metabolic derangements can 
alter the response of the VN to gut peptides (148, 277). An alteration in the VN 
response towards ghrelin has also been shown to occur in the obese state (289). 
Biosynthesis of ghrelin is downregulated in obesity, and fasting plasma ghrelin 
concentrations in humans are negatively correlated with body weight, percentage 
body fat, and fat mass (305, 306).  
Studies suggest that ghrelin may play a crucial role in regulating the gastrointestinal 
inflammatory process and there is strong evidence supporting ghrelin’s protective 
effect against intestinal inflammation (288, 307). High serum ghrelin levels have been 
reported in patients with IBD and experimental colitis with exogenous ghrelin shown 
to have an anti-inflammatory role (307, 308).  Similarly, vagal alterations have also 
been implicated in the pathophysiology of Crohn’s disease and inflammatory bowel 
syndrome (309). In patients with active ulcerative colitis and Crohn’s disease, ghrelin 
is positively correlated with TNFα and C-reactive protein and negatively correlated 
with bodyweight (310). Ghrelin administration has a potent anti-inflammatory effect 
through the regulation of both pro-inflammatory and anti-inflammatory cytokines 
produced by LPS-stimulated macrophages (311). Furthermore, in sepsis, down-
regulation of ghrelin appears to play a role in activation of sympathostimulatory 
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nuclei in the brain and increased norepinephrine release from sympathetic nerve 
fibers. Ghrelin treatment has also been seen to attenuate intestinal IRI in mice through 
the inhibition of pro-inflammatory cytokine release and a decrease in neutrophil 
infiltration via regulation of the NF-κβ pathway (312). Within the immune system, 
human mononuclear cells, monocytes, neutrophils, and B and T cells express GHS-R 
and T lymphocytes, B lymphocytes, and neutrophils express ghrelin and its receptor 
(313, 314). Through the modulation of the T-cell immune response, the protective 
effects of ghrelin have been demonstrated in an experimental model of chronic 
intestinal inflammation (315).  
It is thought that the increased ghrelin levels could result as a consequence of tissue 
injury whereby intestinal inflammation and damage stimulate endogenous ghrelin 
production (316). It is possible that enhanced ghrelin expression could be interpreted 
as a response that results in increased anti-inflammatory mediators in order to 
counteract pro-inflammatory responses from activation of the NF-κβ pathway (317). 
Studies have suggested that the anti-inflammatory mechanisms of ghrelin are 
mediated through both the vagal pathway and directly through immune cells (307).    
The exact anatomical interaction between the VN and the intestinal immune system is 
still controversial as the VN does not directly interact with the gut resident 
macrophages (202). The VN preferentially interacts with enteric neurons located 
within the intestinal muscularis layer. The nerve endings of these enteric neurons are 
located close to resident macrophages (202). Vagal modulation of intestinal resident 
macrophages is indirect, likely through these enteric neurons (202, 318). It seems 
likely that appetite-regulating peptides, such as ghrelin, may be a crucial factor in the 
anatomical link mediating this pathway. It is highly likely that our intestinal 
microbiome is able to influence our entire immune system via regulation of the 
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production of immunomodulatory enteroendocrine hormone peptides (286). This may 
represent an important component of the enteric limb of the CAP, and a pathway 
directly influenced by ghrelin.  
 
Figure 5: The enteric anti-inflammatory pathway: an insult results in induction of 
inflammatory cytokines and liberation of neuroendocrine mediators from 
enteroendocrine cells which activate the afferent vagus nerve. The CAP is mediated 
through vagal efferent fibres that synapse onto enteric neurons and release ACH. 
ACH binds to the α7nAChR of macrophages and inhibits release of TNFα and pro-
inflammatory cytokines. Key: ACH, acetyl choline; CAP, cholinergic anti-
inflammatory pathway. Green circles represent ghrelin, orange circles represent 
inflammatory cytokines. 
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1.6.6$Cholinergic$antiLinflammatory$pathway$
As previously outlined, the inflammatory reflex is a centrally integrated physiological 
mechanism in which afferent VN signaling is activated by cytokines or EEC derived 
peptides (277). This signaling is functionally associated with efferent VN-mediated 
output to regulate proinflammatory cytokine production and inflammation (277) (Fig. 
5). The inflammatory reflex has been exploited as a therapeutic mechanism in 
preclinical models of diseases etiologically characterized by excessive inflammation 
and inflammatory responses (277). The safety profile of VN stimulation has been well 
described given the historical use of surgically implanted devices for epilepsy and 
depression (319, 320). 
VN efferents provide brain-derived output to the liver, gastrointestinal tract and 
pancreas (321). Metabolic molecules such as ghrelin can act directly within the brain 
to trigger efferent output that can influence and regulate metabolic homeostasis (277). 
In obesity, insufficient efferent VN cholinergic output may provide a causative role in 
the dysfunctional immune and metabolic regulation, especially given that activation 
of the efferent arm of the cholinergic inflammatory reflex is seen to attenuate both 
inflammation and metabolic derangements (277, 322-324). Similarly, activation of 
both arms of the inflammatory reflex by ghrelin appears to reverse metabolic 
complications (325, 326).  
 Cholinergic inhibition of cytokine production is mediated via activation of α7nAChR 
and suppression of NF-κβ nuclear translocation (277). There appears to be a critical 
role for α7nAChR in maintaining metabolic homeostasis; this has been specifically 
linked to suppression of inflammation thereby, controlling obesity-associated 
metabolic complications (277). Immune cells express α7nAchR and GHS-R; 
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therefore it is possible ghrelin may either attenuate the inflammatory activity of 
immune cells directly or via vagal stimulation (215, 327). 
The chronic inflammatory state in metabolic disease has been shown to activate the 
SNS and dysregulate the VN, ghrelin has been shown to simultaneously modulate 
both. Evidence indicates that VN activity is impaired in obesity. By enhancing 
cholinergic signaling, this has can help suppress obesity-associated inflammation and 
the associated negative implications (277). Obesity, type 2 diabetes mellitus and CVD 
are directly linked. In obesity and type 2 diabetes mellitus, the VN activities 
regulating cardiac function and hepatic glucose metabolism are both impaired (277). 
Activation of pancreatic insulin secretion by efferent VN-derived cholinergic 
activation is also well documented. These findings suggest that augmentation of 
efferent VN activity could be beneficial in patients with insulin resistance, 
hyperglycaemia, and CVD (277).  
Thus, VN dysregulation might contribute to the pathogenesis of obesity and its 
plethora of comorbidities. Ghrelin is an endogenous peptide that may be an effective 
cholinergic modulator for the alleviation of inflammation, metabolic complications 
and CVD (277, 328). Exogenous HEX appears to also activate these pathways.  
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Figure 6: The influence of VNS and α7nAchR agonists on metabolic parameters. 
GHS modulate these parameters and are thought to have a protective effect similar to 
VNS and α7nAchR agonists. At this time it is unclear whether GHS themselves are 
direct α7nAchR agonists. Abbreviations: CVD, cardiovascular disease; GHS, growth 
hormone secretagogue; T2DM, type 2 diabetes mellitus; VNS, vagal nerve 
stimulation. *Pharmacological or device-induced VNS. Dotted line – negative 
influence. 
 
1.6.7$GutLbrain$axis$conclusion$$$
The gut–brain – (heart) axis presents an opportunity for the development of novel 
pharmacological (and nutritional) strategies that may be favorable in disorders where 
CVD and gastrointestinal diseases coexist (288). Anti-cytokine therapy and/or 
manipulation of the intestinal microbiota may simultaneously influence and uncouple 
pathological brain-gut signaling (297). Through its influence on the VN, ghrelin may 
target and disrupt proximal drivers of aberrant disease processes in both metabolic 
and cardiac disease. The likelihood of these comorbidities to occur concurrently in 
the western world means that ghrelin holds the potential to fulfill a unique therapeutic 
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niche. To the authors knowledge, GHS therapy in the obese, cardiac patient, remains 
completely unexplored.  
 
 
 
Figure 7: The Gut-brain-Heart Axis. In the enteric system, an insult results in the 
induction of inflammatory cytokines and liberation of neuroendocrine mediators from 
enteroendocrine cells that subsequently activate the afferent enteric vagus nerve. 
Similarly, an ischemic insult in the heart induces inflammatory cytokine release; it is 
possible that this insult also stimulates release of endogenous ghrelin. GHS can bind 
to the GHS-R localized in the vagal nerve terminals of the heart and activate the 
cardiac vagal afferent nerve. Furthermore, IHD, through mechanisms that reduce 
cardiac output (ie, systolic dysfunction, arrhythmias) can result in hypoperfusion of 
the gastrointestinal tract, this secondary “insult” will further liberate inflammatory 
cytokines and neuroendocrine mediators from the EEC to activate the vagal afferent 
nerve (orange arrow). This may explain how mediators from the gut can influence 
cardiac inflammation. The efferent arm of the vagus – the CAP – is activated to blunt 
inflammation (blue arrows). Key: CAP, cholinergic anti-inflammatory pathway; EEC, 
enteroendocrine cells; H, hypothalamus; NTS, nucleus tractus solitarius. Green circles 
represent ghrelin, orange circles represent inflammatory cytokines.  
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2.&Aims&and&hypotheses&&
 
The research field of cardio-protection has been plagued by numerous failed attempts 
to translate promising therapeutic strategies for preventing myocardial ischemic injury 
discovered in the basic science laboratory into the clinical setting. 
A major factor underlying this failure results from the inappropriate use of 
experimental animal models.  Most preclinical studies in this field consist of 
experimental protocols that fail to clearly assess the critical interaction of ischemia, 
reperfusion injury and the subsequent therapeutic intervention. Early reperfusion 
therapy is paramount to improving outcome in AMI, thus, there is a clear need for 
studies employing reperfusion techniques at the preclinical level to allow for more 
seamless translational application. 
In this thesis we aim to develop and utilise an experimental animal model that 
closely simulates the critical “door-to-PPCI time” and thus, represents a model 
more readily applicable to the human clinical setting by emulating the interaction of 
the ischemia and reperfusion.  
 
The most critical determinant of prognosis in patients with AMI is infarct size. Infarct 
size is a predictor of chronic LV function, clinical outcome and is inversely related to 
prognosis. Accurate assessment of myocardial function and structural abnormalities 
are of key importance in the clinical environment and in disease models.  
It is important to quantifying critical zones such as the area-at-risk and irreversible 
myocardial injury to allow determination of myocardial salvage and therapeutic 
efficacy. Here we aimed to develop non-invasive imaging techniques to allow 
accurate quantitative assessment of LV function and the extent of infarction. 
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Accurate determination of these factors are necessary in order to critically evaluate 
interventions that may delay the onset of necrosis and limit the extent of infarct size 
during myocardial IR.  
 
The development of cardioprotective agents to improve myocardial function, delay 
the onset of necrosis, limit the total extent of infarction and prevent adverse LV 
remodelling are of significant clinical importance in the AMI patient. There are 
limited pharmacological agents capable of targeting these adverse processes. HEX, 
despite having similar actions to ghrelin, is chemically more stable and can be easily 
administered by the parenteral route, making it a potentially superior therapeutic 
alternative to ghrelin. Furthermore, HEX has already been utilized in human trials, 
demonstrating that it is a both safe and efficacious peptide. However, the potential 
therapeutic effects of HEX remain largely unexplored, particularly in the setting 
of myocardial IR. Studies conducted to date involving HEX are mostly in the context 
of non-reperfused experimental models, these studies warrant further clarification of 
underlying mechanisms leading to cardioprotection, specifically in reperfused 
disease models.  
 
A lack of progression in the development of new drug therapies has stimulated 
interest in novel approaches for the prevention of myocardial ischemia- reperfusion 
injury and the chronic sequelae of AMI, such as heart failure. Traditional 
cardiovascular drugs have little influence on cytokines or the inflammatory reflex 
present in heart failure and evidence suggests that regulation of inflammation may 
improve cardiac performance and outcome. Restoration and augmentation of 
parasympathetic tone has also emerged as a promising therapeutic approach in 
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CVD. More recently, pharmacological activation of the CAP has become an 
intriguing concept requiring exploration as a therapeutic strategy for IRI in IHD. 
Ghrelin appears to have the potential to rebalance the dysregulated autonomic nervous 
system in various disease states. Ghrelin may be a major player in the enteric arm of 
the CAP. It is possible that the neuroinflammatory-modulating properties of GHS 
may also similarly influence the diseased CV system. The intertwined effects of 
GHS, the ANS, inflammation and cardiac function are intriguing and may 
represent a novel therapeutic approach to cardioprotection. HEX remains 
unexplored in this setting, particularly as a therapeutic agent for reperfused 
IHD.  These hypotheses will be addressed throughout this thesis.  
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3.&Materials&and&Methods&(part&1)&
 
3.1#Ethical#declaration##
All experiments were approved by the Animal Ethics Committee of the University of 
Queensland (see Appendix) and were performed in accordance to national guidelines 
(Ethics number SBMS/200/13/NHMRC).  
 
3.2#Surgical#Methods# #
3.2.1$Myocardial$ischemia$reperfusion$and$infarction$model$
a.!Anaesthesia!and!Intubation!! !
Mice were anaesthetized using a combination of medetomidine and ketamine (Table 
1) administered by intraperitoneal (IP) injection. Subsequently, mice were intubated 
using a self-made instrumentation kit described as follows: a plastic mount was used 
to suspend the mouse at approximately 45° by using a loop of suture to secure the 
upper incisors. A flexible fiber-optic light arm was positioned to allow trans-
illumination of the larynx. The mouse was positioned on the mount and the tongue 
displaced laterally to maximize oropharyngeal exposure (Fig. 8). 
Table 1: Anaesthesia and analgesia protocols 
Drug Ketamine Medetomidine Atipamezole Carprofen 
Dose (mg/kg) 75 1 1 5 
Concentration 
(mg/ml) 
100 1 0.05 0.5 
Route IP IP SC SC 
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Figure 8: Visualisation of the oropharynx for endotracheal intubation, X delineates 
the tongue and the arrow points to the glottis. 
 
Using a dissecting microscope, the glottis was identified by observing abduction of 
the vocal folds & a 20g over-the-needle intravenous catheter was inserted ~3mm into 
the trachea replacing the needle with a handmade guide wire. After successful 
intubation, the mouse was removed from the mounting and attached to a mouse 
ventilator (Harvard Apparatus) using a modified Y-shaped connector to minimize 
mechanical dead space. The tidal volume and ventilation rate were calculated based 
on body weight (i.e., 30g mouse: 135bpm, 0.2ml) as described by Tarnavski et al 
(329). Successful intubation was confirmed by visualizing the rhythmic movements of 
the chest synchronized with the ventilator. 100% oxygen (~0.5l/min) was loosely 
connected to the inflow inlet of the ventilator to provide oxygen-enrichment to room 
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air. Positive-end-expiratory pressure was set at ~1-3cm H2O. During the procedure 
the anaesthetic plane was monitored constantly by assessing mucous membrane 
colour, respiratory pattern, HR and pedal reflex. 
 
Figure 9: Rodent ventilator (Harvard Apparatus) 
 
b.!Optimization!of!endotracheal!intubation!! !
This method has been highly efficient, generally resulting in successful intubation 
within 30 seconds of positioning the animal. This method is non-invasive and negates 
employment of invasive methods such as a tracheotomy, thus decreasing the chance 
of postoperative complications. Faster and consistent placement of the endotracheal 
tube was achieved with surgical-microscope guidance, as the glottis could be more 
easily visualised. This approach appears to be novel as most papers describe a direct 
visualization approach for intubation without microscopic guidance (329, 330). 
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Figure 10: Surgical set up – the mouse is intubated with a 22g IV catheter (red arrow), 
positioned in right lateral recumbency and connected to the small animal ventilator 
(not shown). ECG leads are attached. Abbreviations: ECG, electrocardiography; IV, 
intravenous.  
 
3.2.2$Surgical$Model$
a. Permanent#coronary#artery#occlusion:#myocardial#infarction#model#
The chest of the mouse was shaved before endotracheal intubation. After intubation 
the mouse was placed on a heated pad (warmed to approximately 36-37°) and 
positioned in right lateral recumbency with the left forelimb extended cranially. The 
mouse was secured using surgical tape to extend the left foreleg cranially and the tail 
caudally. A suture was placed around the maxillary incisors to stabilize the head and 
prevent the endotracheal tube kinking and becoming obstructed. The surgical site was 
aseptically prepared using a chlorhexidine scrub with a final ethanol scrub. 
Lubricating tears were dispensed into both eyes to protect against corneal ulceration.  
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The surgical procedure was performed with the aid of a surgical microscope as 
follows:  
A dorsoventral cutaneous incision was made at approximately the 4
th
 intercostal space 
(caudal to the axillary region). The subcutaneous (SC) tissue and musculature was 
bluntly dissected using curved blunt forceps. A thoracotomy was performed at the 
~4
th
 intercostal space and expanded bluntly using the curved forceps. A magnetic 
retractor system with multi-positional retractors was positioned to allow visualization 
of the pleural cavity and expose the heart. 
 
Figure 11: Thoracotomy site and positioning for exposure of the LAD. The red arrow 
points to the retractor. Abbreviations: LAD left anterior descending coronary artery. 
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Figure 12: Visualisation of the LAD. The thoracotomy site is pictured and the heart is 
exposed with the LAD coursing over the surface (white arrow). 
 
The pericardium was gently removed using blunt forceps and the LAD visualized 
coursing beneath the left auricular appendage as a “bright” vessel (Fig. 12). The 
location for ligation was identified (Fig. 13A/B) and selected to induce ~30-40% 
ischemia of the LV (~3mm below the auricular appendage). A 7-0 prolene suture with 
BV-1 tapered needle was placed beneath the LAD with a portion of surrounding 
myocardium (Fig. 13C). The LAD was ligated and successful occlusion confirmed by 
observing a change in colour (pallor) distal to level of LAD occlusion (Fig. 14A) and 
characteristic electrocardiographic (ECG) changes (Fig. 14B/C).  
The multi-positional retractors were removed and the lungs reinflated by applying 
pressure to occlude the outflow circuit of the ventilator for 1-2 seconds. This helps to 
prevent atelectasis and poor recovery after surgery. Simultaneously, the thoracotomy 
site was closed as the lungs were reinflated and pressure applied to the thorax to 
minimize the occurrence of a pneumothorax. The chest wall was closed using 6-0 
 65 
polydioxanone in a cruciate pattern. The musculature and cutaneous tissue were 
closed using a 5-0 non-absorbable suture in a simple continuous pattern.  
Sham-operated mice underwent the above procedure excluding ligation of the LAD.  
After completion of the surgery the mice were administered atipamezole and 
carprofen SC to help with anaesthetic recovery and a 0.5ml saline bolus SC (Table 1). 
 
 
 
 
Figure 13: A - Schematic representation of the LAD and position of ligature 
placement. B - microscopic visualisation of LAD (arrow), C - placement of ligature at 
the correct location along the LAD ~3mm distal to the left auricular appendage. 
 
 
 
B C A 
A 
B 
C 
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Figure 14: A - pale region (white arror) is visualized in the coronary territory distal to 
the level of LAD occlusion; B - characteristic ECG changes – onset of occlusion 
(dotted line) results in a peaking of the T wave and ST segment elevation. C: Real 
time ECG changes throughout the 40 minute IR period. Note the distinct ECG 
changes at onset of ischemia and reperfusion (first and second dotted lines 
respectively). Abbreviations: ECG, electrocardiogram; IR, ischemia reperfusion; 
LAD, left anterior descending coronary artery.  
 
b.#Transient#Coronary#Artery#Occlusion:#IschemiaPReperfusion#model# #
This model was utilized in attempt to simulate AMI and reestablishment of blood 
supply (reperfusion) to the ischemic myocardium. Thus representing a more clinically 
relevant model.  
The “permanent ligation” procedure was followed as outlined above with the 
following modifications: 
1. A 1mm piece of sterile 2-0 suture was placed over the LAD, following the 
natural course of the artery.  
2. After placing the 7-0 sutures, the two ends were threaded through a 1-2mm 
piece of sterile PE10 tubing. The tubing was heat flared to create a blunt end 
thereby preventing the guide tubing from causing damage to the tissue where 
it contacts the heart.  
3. For induction of ischemia, tension was applied to the ends of the 7-0 suture, 
effectively creating a “noose” around the LAD & occluding the artery. The 
suture was then secured by tying a knot at the distal end of the of PE10 tubing 
(Fig. 15).  
4. During ischemia the retractors were removed to allow the chest wall to be 
reopposed and a saline-soaked swab was placed over the thoracotomy site.  
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5. Reperfusion was initiated after a period of 40 minutes by cutting the knot at 
the end of the PE tubing. The tubing, 7-0 & 2-0 sutures were subsequently 
removed. 
6. Ventricular hyperaemia was observed, confirming reestablishment of blood 
flow to the myocardium.  
Chest wall closure was performed as previously described.  
 
 
Figure 15: Transient LAD ligation model. Note PE tubing and suture encompassing 
LAD. 
c.#PostPoperative#care#
During the immediate post-operative period, ventilation was continued until 
spontaneous breathing was regained, at which point the mouse was removed from the 
ventilator with the endotracheal tube in place. The mouse was extubated once a 
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normal breathing pattern was reestablished, determined by the presence of a swallow 
reflex and the beginnings of voluntary motor function.   
Once mobile, mice were placed in a clean cage with easy access to food and water. 
Gel pack and crushed wet food were provided and the recovery cage was 
supplemented with oxygen to provide an oxygen-rich environment of ~40-50% FiO2. 
One half of the cage was positioned on top of a heating pad (at ~35°C) allowing the 
animal access to either warmth or ambient temperature. Mice were observed for the 
next 3-4 hours to monitor recovery & those that were not very active after this time 
remained in a heat-supplemented environment overnight.  
Mice were monitored twice daily using a score sheet to record changes in breathing 
character/pattern, movement, surgical site, body condition, weight loss and behavior.  
d.#Optimization#of#surgical#technique##
The IR model described in the methods section of this doctoral project is a novel LAD 
occlusion mechanism. This was developed for various reasons, which are discussed 
below:  
The literature describes various techniques for inducing myocardial IR in the mouse. 
Commonly, a piece of suture is placed over the LAD and a knot is tied over the suture 
to occlude the LAD. The suture is then released at the end of the ischemic period to 
allow reperfusion (329, 331). Various challenges were found with this technique: 1. 
Tension created by tying the knot often caused trauma (tearing) of the ventricular 
wall. 2. Knot placement was very close to the ventricular wall and thus was difficult 
to release without also causing ventricular trauma.  
A second, less commonly described technique involves threading the suture ends 
through a piece of PE tubing and subsequently tying a knot on top of the tubing to 
occlude the LAD (332). Using this model, ventricular trauma was still observed 
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secondary to tension transmitted through the PE tubing to the ventricular tissue and 
causing tearing.  
Trialing a variation of the above using both PE tubing and suture placement on top 
LV overlying the path of the LAD I was able to apply sufficient tension to occlude the 
LAD without visualising any microscopic ventricular trauma.  
An ischemic time of 40 minutes was employed for the IR model. The justification for 
this was related to post-operative survival. The 3-week survival rate in this project 
was consistently >90% in mice with a 40 min ischemic period. In a trial using 60 
minute ischemic time, 50% mice died in the 24hrs following surgery. This was likely 
related to the anaesthetic time in a mouse undergoing thoracotomy and difficulty 
maintaining adequate thermoregulation.   
 
3.3#Assessment#of#Myocardial#Injury###
3.3.1$Post$mortem$measurement$of$infarct$size$
a.#TTC# #
At the completion of the experiment, the mice were euthanized by cervical 
dislocation. The hearts were rapidly excised, trimmed of extracardiac tissue and 
rinsed with saline to flush out any remaining blood. Hearts were placed in a Zivic 
Mouse Heart Slicer Matrix (Zivic Instruments) and fixed in OCT compound at -20°C 
for 15 minutes to facilitate slicing. The heart was then transected into 6-8 short axis 
slices of 1mm thickness. Slices were thawed and immersed in 1% triphenyl 
tetrazolium chloride (TTC) in PBS at 37°C for 20 minutes whilst being constantly 
agitated. The slices were fixed in 10% neutral-buffered formalin overnight with each 
slice then photographed on each side with a digital camera mounted on a dissecting 
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microscope. Manual planimetry of viable and non-viable tissue was performed using 
ImageJ. Specifically, the total LV area and MI region were manually traced for each 
image and MI size was determined as a percentage of LV mass. 
 
Figure 16: TTC staining to determine infarct size. White region: non-viable teissue, 
red: TTC stained (viable) tissue.  
b.#Evans#Blue/TTC# #
The myocardial IR procedure was performed as described above. After reperfusion, 
the ligature was left in place while the mice recovered for 36 hours. To delineate the 
area-at-risk, the LAD was re-occluded (under repeat anaesthesia) and 3% Evans blue 
(mixed in saline), to a total volume of ~0.3ml, was infused via the tail vein. After 
approximately 2 minutes the mouse was euthanized by cervical dislocation. Hearts 
were then rapidly excised, trimmed of extracardiac tissue and rinsed with saline to 
flush out any remaining blood. Hearts were placed in a Zivic Mouse Heart Slicer 
Matrix (Zivic Instruments) and fixed in OCT compound at 20°C for 15 minutes. This 
provides the heart with enough rigidity to allow slicing. The heart was then cut into 6-
8 short-axis slices of 1mm thickness using the matrix and immersed in 1% TTC at 
37°C for 20 minutes whilst being constantly agitated. The slices were then fixed in 
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10% neutral-buffered formalin overnight to enhance contrast between viable and non-
viable tissue. Each slice was photographed on both sides with a digital camera 
mounted on a dissecting microscope and manual planimetry of viable and non-viable 
tissue performed using ImageJ. Specifically, the total LV area, area-at-risk, and MI 
were manually traced for each image. Evans Blue-stained sections indicate the area-
at-risk, TTC (red/pink) indicates viable tissue within the area-at-risk, and white 
indicates the necrotic MI. From these three regions of interest, area-at-risk as 
percentage of LV mass, MI as percentage of LV mass and MI as percentage of area-
at-risk was determined (Fig. 16 & 17).  
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Figure 17: Histologic assessment of infarct size and area-at-risk – Schematic (top), in 
-situ (middle) and post sectioning (bottom). Evans blue - blue, TTC - red, infarct - 
white. Salvageable tissue (reversibly injured) = red. 
 
3.3.2$Histology$and$morphometric$analysis$$
Serial paraffin-embedded LV sections from each group of mice studied were stained 
with 0.1% picrosirius red to detect interstitial collagen deposition. Additional serial 
LV sections from each corresponding group of mice studied were 
immunohistochemically stained for selected markers associated with collagen 
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turnover; utilizing polyclonal antibodies to TGF-β1 (sc-146; 1:200 dilution; Santa 
Cruz Biotechnology Inc., Santa Cruz, CA, USA) and MMP-13 (the predominant 
collagenase in mice; ab75606; 1:100 dilution; Abcam; Redfern, NSW, Australia); or a 
monoclonal antibody to α-smooth muscle actin (α-SMA; a marker of myofibroblast 
differentiation; M0851; 1:250 dilution; DAKO Antibodies, Carpinteria, CA, USA). 
Detection of primary antibody staining was detected using DAKO Envision anti-
rabbit or ARK biotinylation kits, respectively, and 3,3-diaminobenzidine. 
Morphometric analysis of picrosirius red- and immunohistochemically-stained 
sections was performed using Aperio software (Leica Biosystems, North Ryde, NSW, 
Australia) on whole tissue sections per mouse. In each case, the percentage staining of 
each marker analyzed per section was derived and expressed as the fold changes 
relative to the SHAM-VEH group, which was expressed as 1. 
3.3.3$Hydroxyproline$analysis$
Equivalent frozen portions of LV tissue from each animal studied were lyophilized to 
dry weight measurements before being hydrolyzed in 6M hydrochloric acid for 
determination of their hydroxyproline content, as described previously (333). 
Hydroxyproline values were then converted to collagen content by multiplying by a 
factor of 6.94 (based on hydroxyproline representing approximately 14.4% of the 
amino acid composition of collagen in most mammalian tissues (334), further 
expressed as a percentage of the tissue dry weight (to yield collagen concentration), 
and finally expressed as the fold change relative to the SHAM-VEH group (which 
was expressed as 1). 
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3.3.4$Cytokine$and$TroponinLI$determination$$$
Blood samples were collected into plain tubes from mice after each respective 
procedure at specified time-points (see Chapter 5). The blood was allowed to clot 
appropriately and samples were centrifuged for serum removal and stored at -80
0
 C 
until it was assayed. The serum concentrations of troponin-I (cTnI), IL-1β, IL-6 and 
TNF-α were measured at 24 hours and 21 days post operatively using a 
MILLIPLEX® map assay according to the manufacturer’s instructions (Merck 
Millipore).   
3.3.5$Heart$rate$variability$analysis$$$
HRV analysis is considered a sensitive and non-invasive, indirect measure of cardiac 
autonomic tone that has been extensively validated (335, 336).  
HRV analysis was performed at specified time-points after each respective procedure 
(see Chapter 5). ECG signals were recorded using a physiological analyzing system 
(Bio Amp, AD Instruments, CA, USA). Mice were anaesthetized with isoflurane 
(induced at 4% and maintained at 1.5%). After the HR stabilized, ECG signals were 
recorded for a minimum of 20 minutes. Using a technique described by Thireau et al. 
(335) and recently by Mao et al. (88); ANS function was examined by power spectral 
analysis of HRV (LabChart Pro 7.0, ADInstruments, Australia). HR was used to 
generate a power spectral density curve using a fast Fourier transformation. The area 
under the curve was calculated for the very-low-frequency (VLF: 0-0.15Hz), low-
frequency (LF: 0.15-1.5Hz), and high-frequency (HFr: 1.5-5Hz) band, based on 
previous studies (335). From these, the parameters: LF, HFr, normalized LF power 
(nLF), normalized HF power (nHFr), and ratio of LF to HFr power (LF/HF) were 
calculated as described in (88).  
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3.4#Basic#template#for#experimental#timeline###
 
Figure 18: Basic experimental timeline, MI model 
 
 
Figure 19: Basic experimental timeline, IR model 
 
#
3.5#Statistical#analysis###
 
The statistical analysis methods have been described in the relevant sections of 
Chapter 5: Results. 
C
e
rv
ic
a
l,
d
is
lo
ca
ti
o
n
 
 
PostVMortem 
   
Day,0 24,hours Day,14 Day,21 Day,V7 
Surgery 
 
Investigations,V,acute Investigations,V,chronic 
Veh 
Hex 
Acclimation 
Acclimation 
Surgery 
Surgery 
Bloods 
Bloods 
 
Vehicle, 
(continued,SID) 
Hex,(0.3mg/kg) 
(continued,SID) 
MRI 
MRI 
MRI 
MRI 
Bloods 
HRV 
Bloods 
HRV 
Histological, 
analysis 
Vehicle, 
Hex 
(0.3,mg/kg), 
C
e
rv
ic
a
l,
d
is
lo
ca
ti
o
n
 
 
PostVMortem 
   
Day,0 24,hours Day,21 Day,V7 
Surger
y 
 
Investigations,V,acute Investigations,V,chronic 
Veh 
Hex 
Acclimation 
Acclimation 
Surgery,IR 
Surgery,IR 
Bloods 
Bloods 
 
Vehicle, 
(continued,SID) 
Hex,(0.3mg/kg) 
(continued,SID) 
MRI 
MRI 
MRI 
MRI 
Bloods 
HRV 
Bloods 
HRV 
Histological, 
analysis 
Vehicle, 
Hex 
(0.3,mg/kg), 
 76 
4.&Materials&and&Methods&(part&2):&Non&invasive&imaging&&
4.1#Echocardiography###
4.1.1$Echocardiography$Technique$
a.#Anaesthesia#
Anesthesia was induced using 5% isoflurane in 100% medical grade oxygen with a 
flow rate of 1 L/minute into an induction chamber.  
In rodents, the necessity of performing general anaesthesia to obtain 
echocardiographic measurements is a limitation on all cardiac function studies as 
there is the potential for anaesthesia-induced effects on cardiac function. To address 
this, efforts were directed towards anaesthetizing mice to the same anaesthetic plane, 
allowing the heart rate to stabilize and remain within a target range before recording 
echo loops. The echocardiographic studies were short, with the total time from 
induction to recovery (including image acquisition) limited to 10 minutes/mouse. 
Once anaesthetized, the mouse was maintained with 1.5-2% isoflurane via a nose 
cone and body temperature was maintained with a warming pad. Transthoracic 
echocardiography was performed using a Philips iE33 ultrasound machine with a 15 
MHz linear transducer (Philips, Amsterdam, Netherlands) interfaced with a layer of 
ultrasonic transmission gel.  
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Figure 20: The general anaesthesia set up for echocardiographic studies, the blue 
arrow points to the vaporizer, yellow arrow: induction chamber, red arrow: scavenger 
system. A mouse is shown within the induction chamber. 
 
 
Figure 21: Mouse with nose-cone and transthoracic echocardiography performed 
using a 15 MHz transducer. 
 
 
b.#Image#acquisition##
A 2D parasternal short-axis imaging plane was used to direct M-mode imaging at the 
level of the LV papillary muscles. The data was acquired and then calculated based on 
the average of three consecutive beats. End-diastolic left ventricular internal 
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dimension (LVIDd) and end-systolic left ventricular internal dimension (LVIDs) were 
determined. Left ventricular anterior and posterior wall thickness in diastole 
(LVAWd/LVPWd) and systole (LVAWs/LVPWs) was also measured.   
Fractional shortening was calculated using the “leading edge method” by measuring 
the thickness from the leading edge of the upper echo interface to the leading edge of 
the lower echo interface (337). The following equation was used to calculate 
fractional shortening (FS):  
 
!"% = !"#$% − !"#$% !"#$% ∗ 100 
 
 
Figure 22: M-mode view of the LV at the level of the papillary muscles. The left 
ventricular end diastolic diameter and end systolic diameter are measured to calculate 
fractional shortening %. 
 
 
 
 
 
LVIDs LVIDd 
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4.2##MRI##
4.2.1$MRI$methods$
a.#In#vivo#MRI#setPup##
 
Anaesthesia was induced in a purpose-built chamber using 4-5% isoflurane (1 L/min) 
in 100% medical grade O2. After induction, the mouse was transferred to a heat pad, 
placed in lateral recumbency and a nose-cone applied to maintain anaesthesia. The 
isoflurane concentration was reduced to ~2% for maintenance of anaesthesia.  
Before contrast injection, supplemental heat (hot-water bottle) was applied to the tail 
of the mouse to allow vasodilation of the tail vein. Magnevist (Gadopentetate 
dimeglumine) was prepared (0.3 mmol/kg), warmed to body temperature and 
administered by IV injection into the lateral tail vein using a 30-gauge needle. The 
mouse was positioned in a purpose-built cradle (Bruker, Germany), secured in a 
supine position and maintained under anaesthesia with 1.5–2% isoflurane in 1-2 l/min 
O2 via nose cone. Core temperature was maintained with a water-circulation system 
and lubricating ointment was applied to prevent ocular desiccation. An 
electrocardiographic (ECG) signal was derived using a 3-lead system obtained from 
surface electrodes attached to the palmar aspect of both forefeet and the plantar aspect 
of the left hind. A pressure-transducer for respiratory gating was attached to the 
animal’s abdomen. Mice were imaged using a Bruker Biospec 9.4T small animal MRI 
scanner using a phase array coil and temperature-regulated small animal bed (Bruker 
Biospin, Ettlingen, Germany). Physiological monitoring (ECG and respiratory rate) 
was performed using a MRI-compatible SAII monitoring systems (Small Animal 
Instruments, NY, USA).  
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b.#Materials##
All experiments were carried out on a 40cm diameter horizontal bore 9.4 T scanner 
(Fig. 23), equipped with BGA 12S HP 660 mT/m gradients and interfaced with an 
86mm quadrature transmit only coil and a phase array coil. MRI data was acquired 
using Paravision 5.1 (Bruker Biospin GmbH, Ettlingen, Germany). Imaging was 
initiated using a three-planer localizer scan and a gradient echo (Fast Low Angle 
Shot/FLASH) imaging sequence to ensure correct positioning. The probe was 
manually matched and tuned.  
 
Figure 23: Bruker Biospec 9.4T small animal MRI scanner  
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c.#Cardiac#MRI#protocol##
After calibration using the Bruker standard adjustment protocol, which included 
shimming and RF pulse calibration, 2- and 4-chamber view scout scans were made to 
plan a single mid-cavity short-axis slice. Cine imaging was performed using a 
retrospectively-triggered (self-gated) INTRAGATE gradient-echo sequence (338), 
with the following parameters: TR = 5.6 ms, TE = 2.6 ms, number of movie frames = 
20, slice thickness = 1 mm, matrix = 512 x 512, field-of-view (FOV) = 4 x 4 cm
2 
Resulting in 78 x 78um in-plane resolution, with ~5mins acquisition per slice. 
Because of the slight difference in heart-size between mice, seven to nine short-axis 
slices with inter-slice distance of 1 mm and no slice gap were measured to cover the 
heart from apex to base. Late gadolinium enhancement (LGE) images in the slice 
locations were acquired 10-15 minutes after intravenous injection of Gd-DTPA 
(0.3mmol/kg BOW Magnevist; Bayer Germany).  
 
d.#Cardiac#synchronization#and#gating#techniques##
To minimize motion artefacts, ECG and respiratory gating is mandatory to obtain 
high-quality time-resolved cardiac images. MRI images are formed from a number of 
sequence repetitions, each triggered during the same phase of the cardiac cycle to 
minimize motion artefacts (17). 
In our studies, a retrospective gating sequence, INTRAGATE (338), was employed. 
This allows continuous cine-MRI data acquisition and simultaneous recordings of the 
synchronization source (ECG signal). The data is then re-ordered according to the 
sequential phase of the cardiac cycle using phase navigator echoes. In contrast, in 
prospective gating, a threshold ECG signal at each QRS complex triggers one data 
acquisition sequence at a time (339).  
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e.#Determination#of#cardiac#functional#parameters## # #
The MRI images were converted to DICOM format using Paravision 5.1 and 
processed with Osirix (340) software. The end-diastolic and end-systolic phases were 
identified on a slice-by-slice basis and the endocardial and epicardial borders were 
traced. The papillary muscles were excluded. LV end systolic volume (ESV), end 
diastolic volume (EDV), stroke volume (SV), and ejection fraction (EF) were 
computed from the traced borders. LV mass was obtained by multiplying the volume 
with the specific gravity of 1.05 g/cm3 (341).  
f.#Determination#of#infarct#volume## # #
The contrast-enhanced MRI images in DICOM format were processed in Osirix. 
Image contrast windowing was adjusted to enhance the signal from the hyperintense 
region and null the signal from the nonenhanced region. Manual planimetry was 
performed on the images obtained and for each slice, the hyperintense region and total 
LV myocardial area was calculated. Slice hyperintense areas were then summated to 
generate infarct volume as a percentage of LV myocardial volume.  
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Figure 24: A/B demonstrates T1w LGE imaging 24hrs post MI surgery, note the 
increased signal associated with the infarcted region (yellow and orange arrows). In 
addition, note the visible dyskinesia of the apex associated with the infarct in figure A 
(“ballooning” of the apex – yellow arrow). Images were acquired using T1w 
INTRAGATE sequence at 9.4T. Abbreviations: LGE, late gadolinium enhancement; 
MI myocardial infarction.  
 
 
 
Figure 25: LV 2-chamber view (left) and the corresponding LV short axis image 
(right) through the transverse plane indicated by the green line.  
 
A 
B 
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Figure 26: A- Tracing of endocardial, epicardial and infarct borders in systole. B- 
Untraced corresponding image in diastole. 
 
 
 
Figure 27: Osirix (340) software was used to perform manual planimetry on the 
images obtained for each slice. Here is an example of tracing of the endocardial, 
epicardial and infarct borders. 
 
g.#Measurement#of#the#chronic#infarct:#midline#length#measurement## # #
In addition to measuring infarct volume, the infarct was also measured using an 
alternative cMRI approach described as the “midline-length measurement”. This was 
performed 14 days post-MI using a technique modified from Takagawa et al (342). 
Briefly, the midline infarct length was determined by measuring the midline length of 
the infarct that included 50% of the whole thickness of the myocardial wall. The LV 
A B 
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myocardial midline was measured as a midline circumference. All of the 
measurements were taken in diastole. Infarct size was calculated by dividing the sum 
of the midline infarct length from all sections by the sum of the midline 
circumference from all sections and multiplying by 100.  
h.#MRI#optimization#and#considerations## # #
Discussion of gadolinium administration and inhalational anaesthesia in cMRI:  
IV administration is the optimal route of delivery of the contrast agent gadolinium 
(Gd) but is technically challenging in mice (341). A study by Bohl et al. determined 
characteristic pharmacokinetics for IV and intraperitoneal (IP) Gd injections. Both 
methods were found to retain sufficient T1 contrast over a broad time frame with 
intravenous T1 contrast peaking earlier and slightly higher than IP injection. It was 
concluded that IP injection could be employed as the method of choice in a routine, 
high-throughput setting due to the ease of administration (341). 
We initially trialled administering IP Gd following the protocol described by Bohl et 
al. Unfortunately, we were unsuccessful with this method as we did not observe any 
contrast-enhancement post Gd injection, it was unclear why this was, it may have 
been dose-related (Bohl et al used a dose of 0.5mmol/kg), or our TI could have been 
suboptimal. Thus, in this project, IV administration of Gd was utilized & success rates 
consistently approached 100% for administration of Gd by the intravenous route. In 
this study, a gadolinium dose of 0.3mmol/kg was used, this dose lies within the range 
reported for previous animal studies (343). 
Inhalational anaesthetic delivery in an ultra-high field magnetic resonance 
environment is challenging as long delivery lines are required to carry the gas from 
the vaporizer located outside the 5 gauss line to the to the cradle-system for delivery 
to the mouse. This system results in increased mechanical dead space and means that 
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the actual alveolar concentration of isoflurane is difficult to determine. Thus the plane 
of anaesthesia can be more challenging to control and the ability to monitor 
anaesthetic depth lies with the assessment of physiological parameters. The heart rate 
and respiratory rate were monitored using the SAII monitoring system (Small Animal 
Instruments, NY, USA) in order to maintain the depth of anaesthesia within an 
optimal plane (ie, respiratory rate: 40-60 bpm, heart rate: 300-400bpm).  
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5.&Results&&&
5.1#Part#A:#Method#establishment:#nonPinvasive#imaging#techniques##
5.1.1$Preliminary$Echocardiography$
a.#Introduction###
Early identification of patients with sub-optimal cardiac recovery after MI is of great 
importance in order to improve clinical management of these patients (15). Both 
functional and structural characterization of the infarcted myocardium is important for 
risk stratification of patients after AMI (344). 
Two-dimensional echocardiography is the most commonly used non-invasive method 
for measuring cardiac function in vivo in experimental animals (16) but has 
limitations, particularly in the assessment of AMI MI (16, 23). As a preliminary 
study, we sought to review the assessment of LV function in mice using 
echocardiography. 
b.#Method##! #
Fractional shortening (FS) was assessed in 12 normal 10-12 week old male C57BL/6J 
mice by recording 3 serial M-mode-derived measurements taken over 7 days (day 1, 4 
and 7). Anesthesia was induced using 5% isoflurane in 100% medical grade oxygen 
with a flow rate of 1 L/minute in an induction chamber then maintained with 1.5-2% 
isoflurane via a nose cone. Echocardiography was performed using a Philips iE33 
ultrasound machine with a 15 MHz linear transducer (Philips, Amsterdam, 
Netherlands) interfaced with a layer of ultrasonic transmission gel. A 2D parasternal 
short-axis imaging plane was used to direct M-mode imaging at the level of the LV 
papillary muscles. The data was acquired and then calculated based on the average of 
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three consecutive beats. End-diastolic left ventricular internal dimension (LVIDd) and 
end-systolic left ventricular internal dimension (LVIDs) were determined and 
fractional shortening was calculated. Left ventricular anterior and posterior wall 
thickness in diastole and systole were also measured.   
c.#Results###
Repeated echocardiography measurements (three times over 7 days, Table 2) of the 
average fractional shortening (FS) in 12 healthy mice showed that the average FS of 
healthy mice was 31.2 ± 1.61 % (mean ± SD). This preliminary study, however, also 
revealed that the echo-derived average FS measurements of each mouse could have a 
wide range of variance (0.6 to 54.3%).  
 
Table 2: Fractional shortening (%) measured from 12 healthy mice over 7 days 
Average Fractional Shortening (%) 
Mouse# Day 1 Day 4 Day7 Mean Variance 
1 32.0 31.2 28.6 30.6 3.2 
2 - 32.0 30.0 31.0 2.0 
3 32.4 29.6 32.6 31.5 2.8 
4 32.6 35.2 29.2 32.3 9.1 
5 25.3 30.3 30.7 28.8 9.1 
6 29.7 31.4 27.2 29.4 4.5 
7 31.7 32.0 33.2 32.3 0.6 
8 29.3 39.8 25.6 31.6 54.3 
9 31.3 36.8 32.0 33.4 9.0 
10 34.1 38.3 29.5 34.0 19.4 
11 34.6 28.8 29.0 30.8 10.8 
12 32.9 26.0 28.6 29.2 12.1 
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Furthermore, side-by-side visualisation of data acquired by MRI (Fig. 28, top panel) 
and echocardiography (Fig. 28, bottom panel) illustrates the lack of clarity of the 
echocardiographic images for measuring the LV dimensions in diastole and systole 
compared to MRI. This is important, as accurate delineation of endocardial and 
epicardial borders in systole and diastole is crucial to allow calculation of measures of 
systolic function, wall thickness and LV mass measurements.   
 
 
Figure 28: A/B: Example of a mid-cavity short axis view of LV in diastole (A) and 
systole (B) acquired using T1w INTRAGATE sequence at 9.4T. C/D: Corresponding 
2D echo images of LV in diastole (C) and systole (D). Note the marked difference in 
resolution between the two imaging methods.  
 
Furthermore, it was confirmed that infarct size determined using cardiac MRI 
matched that of TTC staining (Fig. 29), This finding is consistent with that reported in 
the literature and highlights the accuracy of infarct delineation when assessed by MRI 
(345).  
A B 
C D 
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Figure 29: Infarct size in a group of mice were assessed by both cMRI (n=4) and TTC 
(n=5) 24 hours after permanent ligation of the LAD. A paired T test confirmed that 
there was no difference between the modalities, confirming that infarct size 
determined using cardiac MRI matched that measured by TTC staining.  
 
d.#Discussion#
Although echocardiography is the most commonly used non-invasive method for 
measuring cardiac function in vivo in experimental animals (16), MRI allows more 
accurate three-dimensional characterization of cardiac structure and function within a 
single examination (17). MRI provides high spatial resolution, yielding detailed 
morphological information and allows the quantification of volumetric and functional 
changes in the heart (17). The resulting 3D image reconstruction means that analysis 
does not rely on geometrical assumptions for determination of LV volume, shape, or 
mass, which become problematic in the asymmetrical LV after MI (16, 23). MRI has 
emerged as a powerful and reliable tool to non-invasively study the cardiovascular 
system in clinical practice (23).  
 
Assessment of LV systolic function using M-mode echocardiography is highly angle 
dependent and relies on geometrical assumptions for determination of LV volume, 
M
R
I
TT
C
0
20
40
60
In
fa
rc
t 
s
iz
e
 (
%
 L
V
)
 91 
shape and mass (23). While this technique can be effective in assessing non-infarcted 
hearts characterized by essentially homogenous LV contractile function, this situation 
no longer exists in the LV after a large MI. Thereafter, geometric assumptions may 
not hold true in mouse hearts rendered asymmetric by a large MI (23). A study by 
Stuckey et al compared short-axis 2D echo and cine-MRI measurements over several 
days in the same group of rats after chronic MI. Cine-MRI measurements of EF were 
12 +/- 6% higher than those made using 2D-echo because of the higher spatial 
resolution of MRI. Repeated measurements showed cine-MRI was more reproducible 
than 2D-echocardiography, indicating that the accuracy of cine-MRI may allow 
identification of alterations in heart function which could be missed when using 2D-
echocardiography (16).  
Furthermore, cardiac MRI allows for accurate infarct size assessment. Late 
gadolinium enhancement (LGE) is considered the gold standard to assess infarct size 
after myocardial infarction and has been shown to predict functional recovery and 
mortality after myocardial infarction (19). 
e.#Conclusions#
There are challenges regarding the accuracy and reproducibility of cardiac function 
measurements in mice using echocardiography, particularly in ischemic models.  
Although murine CMRI is challenging, murine LV function and tissue structure can 
be reliably measured using CMRI. CMRI is unique in its ability to integrate, in a 
single examination, structural abnormalities of myocardial tissue and accurate 
quantitative assessment of LV function (21, 23). 
This doctoral project requires accurate assessment of LV function and tissue 
characteristics in mouse hearts rendered asymmetric by MI. Due to the superiority of 
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cMRI, it was agreed that this modality would be employed as the primary non-
invasive imaging technique for this work.  
 
5.1.2$MRI$methods$
a.#Introduction###
The area-at-risk describes the total amount of myocardium at risk of necrosis after 
AMI (Fig. 30). Early reopening of the occluded coronary artery interrupts this process 
by allowing reperfusion of this territory and salvage of (some) tissue within the area-
at-risk (7). Thus, after AMI, the area-at-risk is generally smaller than the irreversibly 
injured myocardium (chronic infarct).  Accurate quantification of the area-at-risk is 
important in studies aimed at determining the efficacy of infarct size-reduction 
therapies. Therefore, measurement of area-at-risk in addition to infarct size allows 
determination of myocardial salvage and thus therapeutic efficacy (346).  
Furthermore, although researchers may ligate the LAD at what appears to be the same 
location in each mouse, the inherent variation in coronary artery anatomy and territory 
of the myocardium supplied by the coronary means that there is potentially 
considerable variation in the area-at-risk (347, 348). Measurement of the area-at-risk 
allows for MI size to be expressed relative to area-at-risk. Quantitating these values is 
important as this approach accounts for variability in coronary artery anatomical 
supply and the effect of therapy on the salvaged myocardium can be appreciated (347, 
348). 
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Figure 30: Schematic representation of infarct size, area at risk and myocardial 
salvage. Image from (349). 
 
Iron oxide particles: 
Microparticles of iron oxide (MPIO) provide excellent negative magnetic resonance 
contrast (hypointensity) and remain intravascular. A recent study by Grieve et al. 
compared histological methods of area-at-risk and infarct delineation to cMRI 
methods using a combination of T2* contrast from MPIO to identify the area at risk, 
(by the absence of signal voids), together with Gd-based T1-weighted enhancement to 
define the established infarct zone (identified by high intensity on the T1 map) in a rat 
model of myocardial IR (347). This method was shown to improve the robustness in 
quantifying the salvageable myocardium.  
Here, we aimed to delineate area-at-risk and infarct size by quantifying both the iron 
oxide- induced hypointense region combined with the Gd enhanced area in mice 
undergoing IR using a 16.4 T magnet. We hypothesised that by evaluating T1, T2 and 
iron oxide T2* contrast-enhanced images we would be able to accurately distinguish 
the area-at-risk & infarct zones.  
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b.#Materials#and#Methods#
Paramagnetic!iron!microparticles!#
0.25 µm dextran covered microparticles of iron oxide particles (MPIO) (stock 
concentration of 25 mg/ml) were obtained from Kisker Biotech (Germany).  
Pilot!study!for!microparticle!dose!optimization#
A 4.5mg/kg microparticle dose was initially tested as described by Grieve et al (347). 
However, in our model, this concentration was not was not found to provide sufficient 
negative contrast to accurately delineate between perfused and infarcted tissue. 
Therefore, a second trial was performed to test the following MPIO doses: 4.5mg/kg, 
45mg/kg and 90mg/kg. Renal tissue was also harvested as a positive control to 
confirm perfusion of the iron particles (Fig. 31).  
 
 
Figure 31: MPIO dose: A) 4.5mg/kg (n=3); B) 45mg/kg (n=3); C) 90mg/kg (n=3); 
showing increasing negative contrast within the perfused ventricular tissue as the 
microparticle dose increases. (A) Reveals low negative contrast, whereas (C) shows 
A"
B"
C"
X 
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excessive saturation of negative contrast associated with the high dose of 
microparticles. Note the hyperintense signal associated with the infarcted tissue in 
panels A & B (arrows). X denotes renal tissue with evidence of diffuse negative 
contrast signal consistent with MPIO uptake.  
 
Quantification of the signal intensity within the perfused versus infarcted tissue was 
performed by analysis in Osirix (340). This was undertaken by drawing a circle 
within the representative region of interest (ROI) and recording the signal intensity 
within that tissue (see Fig. 32). The signal intensity was recorded from different 
positions and within different tissue slices, to allow calculation of the intensity ratio 
(perfused/infarcted). This was repeated for each MPIO dose (4.5 mg/kg (n=10), 45 
mg/kg (n=10) and 90 mg/kg (n=10)).  
 
Figure 32: Optimisation of MPIO dosage: A circle was drawn and placed within the 
two regions of interest (ie, infarcted tissue (blue circle) and perfused tissue (green 
circle)). The signal intensity was compared between the two locations. This was 
repeated for each MPIO dose, using various tissue slices and locations. This figure 
represents a dose of 45mg/kg.  
 
A paired t-test was performed to assess whether there was a difference in signal 
intensity between the infarcted and perfused tissue. For all doses (4.5 mg/kg, 45 
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mg/kg, 90 mg/kg) the t-valve was >> t-critical, therefore indicating there was a 
difference between the signal intensity between the ROIs (Fig. 33A). When using the 
dose of 45 mg/kg, the t-valve was much larger, indicating that this dose produced the 
largest difference in signal intensity between the ROIs (Fig. 33B/C), thus this dose 
was employed for all further studies.  
 
Dose 
(mg/kg) 
Infarcted Stdev Perfused Stdev t-
value 
Tissue contrast 
enhancement  
Stdev 
4.5 3614 87 3312 118 8.73 1.90 0.04 
45 8571 164 4627 228 97.21 1.86 .06 
90 716 63 583 51 9.23 1.23 0.09 
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Figure 33: A) A paired t-test was performed to assess whether there was a difference 
in signal intensity between the infarcted (n=10) and perfused tissue (n=10) for each 
dose of MPIO. The t-critical for two tails paired measurements was 2.262, therefore 
all doses had a t-value >> t-critical, thus rejecting the null hypothesis that there was 
no difference between the signal intensity between the ROIs. The t-value for the 45 
mg/kg dose was much larger than that of the other doses, indicating that this dose 
produced the greatest difference in signal intensity between the two tissue types.  
B) Signal intensity (unit less) measured from the ROIs (infarcted (n=10), perfused 
(n=10)) in Osirix for all three doses.  
C) The average signal intensity ratio (infarcted/perfused) calculated for each dose.  
 
c.#Animal#Model## #
C57BL/6 mice (weight 25-35g) were acclimatized for a period of 1 week prior to 
surgery. The myocardial IR technique was approached as described in Chapter 3.2.2 
(b) with ischemia induced for 40min. Following ischemia, the ligature surrounding 
the LAD was left in place while the mice recovered. After 36 hours, under repeat 
general anaesthesia, Gd (0.3mmol/kg) was infused via the tail vein. After a further 15 
minutes the LAD was re-occluded employing the same open-chest approach. A 
solution containing 45mg/kg microparticles mixed with 3% Evans blue, in a total 
volume of ~0.3ml was infused into the tail vein. After approximately 2 minutes the 
0.00 
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1.00 
1.50 
2.00 
4.5 45 90 
Infarcted/Perfused Tissue Contrast Enhancement 
C. 
 98 
heart was excised and fixed in 10% neutral-buffered formalin for 2 hours then 
transferred to 0.2% Gd solution overnight. The hearts were then transferred into 
perfluoro-ether Fomblin solution (Y06/06, Solvay Solexis, Italy) 24 hours prior to 
MRI assessment. Fomblin was utilized to provide a black background to enhance 
visualisation of the tissue contrast (Fig. 34). 
 
 
Figure 34: Illustration of MPIO/Gd 3D MRI technique. Modified from (347). 
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d. MRI Protocols 
Sample!preparation!for!imaging!#
A vertical 16.4 T magnet (Biospec, Bruker, Ettilingen, Germany) was employed for 
analysis of the cardiac samples. The samples were prepared into two groups for MRI 
analysis (Fig. 35).  
 
Figure 35: Three hearts were arranged into each test tube to allow for positioning 
within the bore of the 16.4 T magnet (right panel). The left panel shows the 
arrangement of the samples: Group 1: Heart 1 (H1), control- no infarct; H2/H3 hearts 
with an ischemic insult. Group 2: H4/H5/H6 -all hearts have an ischemic insult of a 
different size; this was due to purposeful LAD occlusion at different sites, thus 
rendering a different area-at-risk. The blue arrow indicates the ischemic region.  
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Figure 36: Preliminary “3D” view of gadolinium-enhanced infarct (arrows) (without 
microparticles) acquired using a T1/T2* weighted 3D FLASH sequence at 16.4T. 3D 
acquisition allows simultaneous axial, coronal and sagittal views of the heart 
(represented by the colour lines) that can be evaluated by “scrolling” through the 
tissue. 
 
e. MRI Sequences 
Three=dimensional!gradient!echo!fast!low!angle!shot!–!3DGE!(FLASH)!
Three dimensional (3D) gradient echo (GE) fast low angle shot (FLASH) was 
acquired with the following parameters: echo time (TE) = 6.735 ms, repetition time 
(TR) = 40 ms, flip angle 30 ° . The spatial resolution was 
0.040×0.039×0.039 mm/voxel with FOV of 25.60 mm ×10 mm × 10 mm and matrix 
size of 640 × 256 × 256. The number of averaging was 2 and the scan time was 
40 minutes. In this sequence, the predominantly T2*-weighted image contrast is very 
useful to detect the perfused and non-perfused area delineated by the MPIO. The non-
perfused region (area-at -risk) lacks the negative MPIO image contrast (Fig. 37).  
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Figure 37: 3D FLASH sequence using the 6 heart samples: 5 samples show a non-
perfused region (ie, lacking MPIO) representing the area-at-risk (grey arrows), H1 is 
the control. 
 
Three=dimensional!multi=slice!multi=echo!sequence!–!3DMSME!!
The second sequence was a 3D multi-slice multi-echo sequence (3DMSME) acquired 
with multiple TE of 14, 28, 42 ms, TR = 400 ms. The spatial resolution was 0.078 × 
0.078 × 0.078 mm/voxel, with a slice thickness of 10 mm and FOV of 25.600 × 10 × 
10 mm, the matrix size was 328 × 128 × 128 with a number of averaging of 1. The 
scanning time was ~ 50 mins. This dataset has an increasing T2 weighting, with the 
highest at 42ms. The different echo times had an impact on the signal to noise ratio, 
the longer echo times resulted in more signal decay. T2 -weighting allowed assessment 
of the area-at-risk by delineating the oedematous region (350, 351).  
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Figure 38: Images acquired with a 3DMSME sequence with TE of 42 ms. The arrow 
points to the odematous region (area-at-risk). 
!
T1!Map#
A T1 map was generated from the inversion recovery sequence with a TI of: 300, 500, 
700, 800, 1000 and 1500ms. TR: 4000 ms, the number of averaging was 1 and the 
acquisition time was 7 mins 15 s. The spatial resolution was 0.078 × 0.078 mm/voxel, 
FOV: 10 × 10 mm. The matrix size: 128 × 128 and slice thickness: 0.5 mm. The 
infarcted and perfused region could be delineated from the T1 map and the signal 
intensities were measured.  
Equation [1] was used to fit the T1 inversion recovery data: 
!! ! = !!! , !"(1− 2!
!!
!!)    [1] 
H6 
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T2!Map#
The T2 map was acquired using a spin multi echo sequence with a TE of: 11, 22, 33, 
44, 55, 66, 77, 88 ms), TR was 5000 ms,.The  number of averaging was 1, FOV: 10 
×10 mm, matrix size: 128 × 128 mm, slice thickness: 0.5 mm and spatial resolution: 
0.078 × 0.078 mm/pixel. The scan time was 11 mins.  The infarct is visualized on the 
T2 map as a hyperintense region (Fig. 39). As for the T1 map, from the T2 map the 
regions of interest (infarcted and perfused area) could be traced to measure the signal 
intensity in both.  
Equation [2] was used to calculate the T2 based on T2 exponential decay:         
                                  !!" ! = !!" 0 !
!!
!!      
 
 
Figure 39: T2 map, axial slice with the hyperintensity representing the infarct (arrow). 
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f.#Image#post#processing## #
T1!map!and!T2!map!evaluation! #
After generating the T1 and T2 map, the ROI was traced using Paravision 5.1 
software. The image contrast and colour-threshold were adjusted in order to achieve 
optimal image contrast for visual assessment. The ischemic area on the T2 map was 
seen as a hyperintense region with a high T2 value. The T2 value and standard 
deviation for each area was exported to Excel.  
The same process was applied to the T1 map. Visual assessment of the T1 map proved 
challenging as it was hard to distinguish between the ischemic and perfused areas. 
Therefore, the ROI determined from the T2 map was superimposed onto the same 
slice at the same location on the T1 map. Figure 40 displays the T1 and T2 map images 
with the outlined ROI. 
 
Figure 40: T1 map (left), T2 map (right). ROI - white arrow: ischemic zone, blue 
arrow: perfused zone. 
 
Image!segmentation!of!3DFLASH!and!3DMSME!sequences#
The area-at-risk had a different appearance depending whether the 3DFLASH or 
3DMSME sequences were employed. Segmentation was performed using ITK-SNAP 
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software to determine the normal and area-at-risk regions, and their volumes were 
shown using 3D rendering. By convention, the perfused area was coloured blue and 
the area-at-risk red. The segmentation was acquired manually, with the region of 
interest (ROI) coloured slice-by-slice in various orientations (axial-coronal and 
sagittal) to achieve the most accurate segmentation for the ROI. Delineation of the 
perfused area from the area-at-risk was based on visual assessment. The area-at-risk 
in the 3DFLASH sequence was seen as a non-perfused area, while in 3DMSME it 
was visualised as a hyperintense region. The size of the area-at-risk from the two 
sequences was compared, as each sequence had a different sensitivity for detection of 
these regions. After the segmentation was completed, the volumes were measured for 
both the perfused and area-at-risk regions using ITK-SNAP (Fig. 41). All 
measurements were exported into Excel to quantify the normally perfused region and 
area-at-risk in each sequence and determine the difference (“mismatch”) between 
area-at-risk measured between each sequence.  
 
Figure 41: 3DFLASH sequence: An example of image segmentation of 3 hearts with 
an ischemic insult: area-at-risk coloured red and perfused tissue in blue. 
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Mismatch!area!measurement#
Mismatch area: difference in the area-at-risk measured using the two sequences.  
During the process of manual visual segmentation of 3DMSME, it became clear that 
different echo times (TE = 42.28, 28 and 14 ms) produced different image contrasts 
and thus a different size area-at-risk. Differences in the area-at-risk using each TE 
was calculated by volume subtractions of the segmented areas using this FSL fslmaths 
command: 
 
(fslmaths 3DMSMETE42- sub 3DMSMETE28 mismatch42-28.nii). 
 
To measure the area-at-risk mismatch between 3DMSME and 3DFLASH, they were 
co-registered using FSL linear registration software (FLIRT). Subsequently, the 
segmented areas between the two datasets were subtracted using fslmaths.  
After the subtraction was completed, the image had three ROI: perfused, area-at-risk, 
mismatch. Figure 42 demonstrates delineation of the area-at-risk, perfused and 
mismatch zones in the 3D cross-sections, Using this approach, the ROIs can be 
visualised by the examiner when scrolling through the 3D reconstruction. 
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Figure 42: 3D reconstruction of a heart after subtraction of the 3DFLASH area-at-risk 
zone from that of the 3DMSME area-at-risk zone (using a TE 42ms). The perfused 
area is coloured blue, area-at-risk in red and the mismatch area between the two 
sequences is coloured in grey.  
 
g.#Results## #
Analysis!of!Regions!of!Interest! #
Figure 43 compares perfused, area-at-risk and mismatch area in the five ischemic 
hearts. Heart 1 (H1) was excluded, as there was no ischemic insult. The remaining 
five hearts, H2 (A), H3 (B), H4 (C), H5 (D) and H6 (E) each had a purposefully 
different area-at-risk based on level of LAD ligation. Assessment of the T2* FLASH 
sequence demonstrated signal loss as a negative contrast (secondary to MPIO in the 
perfused tissue), while there was an absence of MPIO within the area-at-risk (non-
perfused region). In contrast, with the MSME sequence, oedema within the tissue was 
visualised as a hyperintense signal, whereas there was a lower signal within perfused 
region.  
Perfused 
AAR 
Mismatch 
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Quantification of the ROI (area-at-risk) was different depending on which sequence 
was employed (FLASH vs MSME). The difference measured between the two 
sequences was described as the “mismatch”. With the FLASH sequence, we identified 
an area-at-risk of 8.6% in H2 (A), H3 (B): 22.8%, H4 (C): 26.9 %,H5 (D): 7.5% and 
H6 (E) 10.3%. Using the MSME sequence the results were found to vary depending 
on the TE used, For example, in H2 the perfused tissue ranged from 90.3% to 95.1% 
and the oedema (area-at-risk) ranged from 4.9% to 9.7% of the area. In H3 area-at-
risk: 22.9-34.3%, H4 area-at-risk: 30.6-33%, H5 area-at-risk: 17-27.7% and H6 area-
at-risk: 9-16.5% (Fig. 43). 
Comparison of the ROIs derived from the two different sequences showed that the 
area of oedema measured using MSME was typically larger than that of the non-
MPIO perfused region measured with the FLASH sequence, ie, area-at-risk 
measurement: MSME > FLASH. 
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Figure 43: The sequences’ (FLASH, MSME (TE 12, 28 and 42ms)) were all used to 
calculate the percentage of tissue that represented the area-at-risk (pink) and perfused 
tissue (blue) in each heart (n=5). Each sequence resulted in a slightly different area-at-
risk. Thus, the mismatch area (green) between sequences was calculated by 
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subtracting the segmented area-at-risk and perfused volumes derived from the 
FLASH sequence from the MSME images at each TE (ie, FLASH-MSME0; FLASH-
MSME1; FLASH-MSME2).  
 
Effect!of!echo!time!in!3D=multi!slice!multi=echo! ! #
The different echo times employed in the 3DMSME sequence resulted in variable 
signal intensity, with a longer TE producing less signal-noise ratio. Figure 44 
demonstrates the percentage area-at-risk volume of each heart at different echo times. 
Thus it is seen that each heart had a different area-at-risk based on the specific echo 
time. The results appear somewhat random as the area-at-risk volume in Heart 3 was 
greatest with an echo time of 14 ms, while for H5, it was greatest with an echo time 
28 ms and H2 & H6 at 42ms. Therefore, it is difficult to accurately conclude how the 
volume of MSME-measured oedema (area-at-risk) was influenced by the echo time. 
Instead, this variability may relate to tissue fixation, which may alter the oedema 
content in the ex-vivo samples, or user-associated inaccuracies in manual analysis of 
the ROIs. 
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Figure 44: Based on the echo time employed (TE = 14, 28, 42 ms), there was a 
difference in the volume of area-at-risk measured in each heart (n=5) using the 
3DMSME sequence.  
 
Image!analysis!of!the!T1!and!T2!map!!
The infarcted region was more clearly visible using the T2 map compared to the T1 
map (Fig. 40, above). Using planimetry, the ROI was traced as the infarcted 
(irreversibly damaged) area and the non-infarcted area. In order to achieve accurate 
measurements, 2 slices were selected using each the T1 and T2 maps (T1 (n=10); T2 
(n=10)). In both sequences, the signal intensity within the infarcted area was greater 
than the normal area. A paired T-test was used to determine whether there were any 
significant differences between the signal intensity of infarcted and non-infarcted 
tissue within the maps. T1 and T2 relaxations were both found to be longer in the 
infarcted tissue compared with the non-infarcted tissue (p = 0.04 and 0.001, 
respectively). This finding indicates that both the T1 and T2 maps were sensitive to 
detecting the differences between these two tissue populations (Fig. 46) 
 
The direction of these changes in signal intensity was not as expected, as the T1 
relaxation time was expected to decrease within the infarcted region (due to Gd 
binding within the irreversibly injured tissue). We found that the T1 relaxation time 
actually increased in this region (Fig. 45 B). This suggests that Gd did not 
successfully bind to the infarcted area. This unexpected changed may have been due 
to an inconsistent amount of irreversibly damaged tissue following a 40-minute 
ischemic time, or the Gd may have washed out during the heart fixation.  
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Figure 45: Difference in signal intensity between non-infarcted (blue) and infarcted 
tissue (red) seen using the T2 (A) and T1 (B) map in each heart (n=2 per heart) 
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Figure 46: A paired T test analysis was used to determine the difference in signal 
intensity (Y axis) between perfused (n=10) and infarcted tissue (n=10). There was a 
significant difference in signal intensity seen between these regions using both the T1 
and T2 map (p = 0.04 and 0.001 respectively).  
 
h.#Discussion# #
MRI!assessment!of!myocardial!tissue!structure!!
Functional and structural characterization of the infarcted myocardium is important in 
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myocardium, such as in the presence of fibrosis, haemorrhage and oedema, influence 
the signal intensity on T1- and T2- weighted imaging (21, 22, 352).  
Myocardial fibrosis represents a hallmark of pathological remodelling within the 
myocardium (63). Fibrosis reduces cardiac function and plays a major role in cardiac 
arrhythmogenesis (63, 352). Recently within the clinical community, T1 mapping in 
combination with contrast agent uptake has been utilized to characterize tissue 
structure not only after myocardial infarction but also in diffuse fibrosis (339, 353-
355). T1 mapping with contrast enhancement has limitations, such as the need for 
contrast injection and decreased contrast agent relaxivity at high field strength (356). 
In vivo T2 measurements have been proposed as an alternative to assess diffuse 
interstitial fibrosis (357). A decrease in T2 relaxation time has been measured ex vivo 
in the myocardium of diabetic rats and was associated with increased collagen content 
(358).  In vivo T2 measurements have also been used to noninvasively quantify 
myocardial fibrosis in diabetic mice at 11.75T and were shown to strongly correlate 
with myocardial fibrosis assessed by histological methods (18). 
 
Recently, attention has also been directed towards the development of myocardial T2 
quantification and mapping techniques. T2-weighted (T2w) MRI is especially 
sensitive to water and can highlight oedematous areas (359, 360). The long T2 
relaxation times of water-bound protons are used to generate a water-specific contrast 
when applying T2-weighted sequences, resulting in a high signal intensity of 
oedematous tissue (21).  
T2* mapping can also be used to obtain information on tissue structure (339, 361). 
T2* contrast has been explored as a tool to diagnose the presence of haemorrhage and 
myocardial iron (348, 359, 362, 363).  Reperfusion of severely ischemic myocardium 
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also leads to interstitial haemorrhage, which may be an important marker for 
irreversible microvascular damage (20, 364). Recently, it was demonstrated that T2* 
has the potential to image fibrosis in the infarct zone (20, 365). The potential of T2* 
mapping to image myocardial haemorrhage and fibrosis was evaluated in a recent 
study of IR-induced injury in mice and found to be a useful addition to late 
gadolinium enhancement (LGE) for follow up of myocardial remodelling and 
prediction of recovery from infarction (366). Interestingly in this study, a considerable 
infarct observed on day 1 (based on a large LGE positive area), was difficult to detect 
using LGE on day 7 and 28, suggesting considerable recovery of the area-at-risk. 
However, T2* maps performed on day 7 and day 28 revealed low T2* values in the 
infarct area, indicating that the infarct had not recovered (366). Changes in T2* 
contrast in ischemic regions were associated with iron and collagen depositions and 
were found to correlate with reversibility of ischemic injury and infarct maturation 
(366). Thus, changes in T2* can be associated with infarct age, reversibility of the 
injury, and can give an indication of the myocardial structural variability throughout 
infarct maturation (366).   
MRI!Imaging!of!infarct!size!and!area!at!risk!!
Infarct size 
LGE is considered the gold standard to assess infarct size after MI and has been 
shown to predict functional recovery and mortality (18, 19). In a LGE scan, T1-
weighted imaging is performed after injecting a gadolinium-based contrast agent to 
delineate injured myocardium (352).  
LGE imaging exploits the substantially different acceleration of longitudinal magnetic 
relaxation (T1 relaxation) in healthy tissue compared with infarcted tissue after the 
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administration of a T1-shortening contrast agent (341). The extracellular contrast 
agent gadolinium-DPTA (Gd-DTPA) rapidly diffuses from the vascular space into 
most extracellular tissue fluid, but not the intracellular space (7). In the presence of 
Gd-DPTA the T1 of tissues is potently shortened, resulting in increased signal on T1w 
images (7). In acutely infarcted tissue, Gd tissue kinetics are altered, resulting in 
delayed washout secondary to decreased functional capillary density, permeability 
and coronary flow rates and increased volume of distribution secondary to loss of cell 
membrane integrity allowing Gd-DPTA to diffuse into the cellular compartment. 
Overall, this results in accumulation and lingering of Gd-DPTA in the infarcted 
tissue, resulting in a shorter T1 (7, 352).   
Practically, in order to perform LGE imaging, an inversion recovery sequence can be 
performed to manually set the inversion time (TI) in order to null “normal” remote 
myocardium, thus highlighting the greatest image intensity difference between 
normally perfused and infarcted tissue (367). This allows direct quantification of the 
spatial extent of the focal scar. At high field strength, there is an extremely high 
correlation between histological findings and LGE in ex-vivo rat hearts (345).  
The time delay between injection of Gd-DPTA and image acquisition may affect the 
extent of LGE. In a rat model of MI, during the first 5 minutes after Gd-DPTA 
injection, delayed enhancement overestimated the size of histologically measured 
infarct by 20-40% (368, 369). When the TI was optimized, the extent of delayed 
enhancement was stable over time from 7-42 minutes after contrast injection in 
patients with reperfused AMI (370). Infarct volume measured with MRI was seen to 
remain consistent from 20-60 min after contrast administration (371).  
Until recently, the assessment of infarct size in small animals in high magnetic fields 
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has been performed using a ‘cine gradient echo pulse sequence’ with a high dose of 
gadolinium chelates (369). This type of MRI protocol is limited in its ability to 
accurately delineate both the viable and non-viable myocardium post infarction (343, 
372). The use of an inversion recovery T1w approach has become an accepted 
modality for the clinical diagnosis of MI. (373, 374). Chapon et al. demonstrated that 
an inversion recovery pulse sequence could be used to discriminate infarct from non-
infarcted myocardium in small rodents at 9.4T (343). 
Area at Risk 
Accurate quantification of area-at-risk is important in studies aimed at determining 
the efficacy of infarct size-reduction therapies. Measurement of area-at-risk in 
addition to infarct size allows determination of myocardial salvage and thus 
therapeutic efficacy (346, 375).  
Despite being salvaged, the myocardium in this region is altered by ischemia. The 
development of oedema, secondary to inflammation, is one of the features of the area-
at-risk, often occurring early, even after brief episodes of myocardial ischemia (351). 
In the setting of the acutely reperfused infarct, the relationship of myocardial oedema 
to irreversible myocardial injury provides information on the salvageable myocardium 
within the area-at-risk and is thus a guide to therapy (376). In a recent study, Gd-
DTPA concentration was not seen to be significantly increased in reversibly injured 
ischemic myocardium (377). 
T2-weighted sequences are very sensitive to water-bound protons and have been 
shown to successfully visualize infarct-related oedema (355, 357). T2-weighted 
images were first shown to represent area-at-risk in an ex-vivo canine model of both 
non-reperfused and reperfused MI, confirming a tight relationship between 
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myocardial T2 and tissue-water content (378). Ugander et al. validated T2-weighted 
and pre-contrast T1-weighted images as measures of the area-at-risk against whole-
heart microsphere reference standards (346). T2-weighted images have been used to 
image salvageable myocardium in humans (376). Pulse sequences for T2-weighted 
cMRI optimized for imaging humans do not directly apply to mice due to the use of 
higher magnetic field strengths and 10-fold greater heart rate in mice compared with 
humans (379). Beyers et al, recently developed a T2-weighted protocol for mice, 
allowing in vivo imaging of area-at-risk, which showed a good correlation with 
histological measures of area-at-risk (379). 
Histological!assessment!of!Area=at=risk/Infarct!size!
Historically, histological sections have been used to visualise and measure the 
myocardial scar using stains specific for connective tissue in the extracellular space 
(380). Histology is widely utilized to quantify infarct size in mice, however this 
method is not ideal as it is a terminal measurement, resulting in the destruction of 
tissue preventing further functional or biochemical analysis (375). 
Non-invasive imaging offers the advantage of allowing the comparison of infarct size 
before and after an intervention longitudinally, in the same animal (341). Importantly, 
this circumvents the need for euthanasia at each time point and minimizes animal 
numbers. A tight correlation between MRI and TTC infarct volumes has been 
observed in multiple studies (381, 382). In preclinical studies, post-mortem 
histological analysis is currently considered the gold standard for measuring infarct 
size. Current methods include perfusing the heart with Evans blue and TTC to 
quantitate the area-at-risk and infarct size (347).  
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TTC is a redox indicator used to differentiate between metabolically active and 
inactive cells and tissues (8). Tissue with dysfunctional mitochondria does not stain 
with TTC and results in a pale appearance (371). To delineate the area-at-risk, at the 
end of reperfusion period, the coronary arteries are re-occluded and hearts are 
perfused with Evans Blue to stain the perfused tissue dark blue, while the area-at-risk 
remains unstained (383).  
The limitations of this method relate to the accuracy and reproducibility of this 
technique. Particularly with regards to accurate delineation of the infarct borders and 
area-at-risk zone. Manual slicing of fresh tissue results in thick tissue slices and thus 
there are assumptions made on how the tissue within the middle of the slice reflects 
that visualised on the surface of the slice (347). Visual interpretation and planimetry 
of heart sections can be subjective in cases with poor viable:nonviable contrast due to 
haemoglobin residues within the necrotic regions or TTC-induced geometric 
distortion of the sample. These issues are particularly significant when working with 
the small mouse heart (347). 
TTC and LGE techniques have been demonstrated to be highly correlated (17). 
Grieve et al was the first to propose and describe the automated 3D MRI technique, 
resulting in an improved robustness in measuring salvageable tissue (347). This 
technique replaces the need for manual slicing of the heart and allows whole-heart 
analysis. The user can scroll through slices of the 3D dataset for segmentation and 
quantification of the ROI, removing many of the disadvantages associated with 
histological methods of assessment (Table 3) 
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Table 3: Advantages and disadvantages of Evans blue/TTC technique VS Ex vivo 3D 
MPIO/Gd MRI approach (modified from (347)). Blue panel: relevant to both 
techniques. Green coloured – considered as an advantage, red panel – considered less 
advantageous. 
Evans Blue/TTC 3D MPIO/Gd MRI 
Postmortem assessment, excluding serial measurements 
 
Requires religation of LAD under anaesthesia 
 
Requires manual cutting of fresh tissue 
into ~1mm slices. Results in 
approximately 6-8 slices/heart 
High resolution, manual slicing not 
required.  
Assumption that area-at-risk /MI is the 
same throughout the volume of the 1mm 
slice 
No assumption required as large number 
of slices and high resolution. Able to 
“scroll” through slices 
Evans blue can diffuse across the border 
zone of the area-at-risk and increases 
error. TTC staining can be variable and 
“dominate” Evans Blue making it 
difficult to determine the border zone 
Border zones are seen clearly even 
>24hrs after fixing. 
Requires manual tracing of borders and 
calculation of volumes for MI/ area-at-
risk 
Allows 3D digital analysis and 
automated segmentation 
Requires tail vein injection Requires two tail vein injections  
 
 
In preclinical models it is important assure the accuracy of measurements when 
developing novel imaging techniques. In this study, we used a combination of T1, T2 
and T2* contrast acquired using 3DFLASH, 3DMSME and 2D spin echo sequences 
from six mouse hearts having undergone an ischemic insult and reperfusion.   
We demonstrated that both the FLASH and 3DMSME sequences were able to detect 
the area-at-risk, however there was a mismatch in size noted between the sequences. 
The 3DMSME consistently measured a larger area-at-risk when compared with the 
FLASH sequence; possible explanations for this are discussed henceforth. T2 
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sequences have been used clinically to delineate oedema (350, 351), however, there 
remains considerable controversy regarding the reliability and robustness of this as a 
measure of area-at-risk (384, 385). Given that MPIO provide excellent negative 
contrast and remain intravascular they may represent a more reliable method for 
quantifying area-at-risk. We propose that there may be less ambiguity by measuring 
regions delineated by MPIO accumulation compared to oedema quantification. 
Secondly, the FLASH sequence was of higher resolution than the 3DMSME 
sequence, thus potentially resulting in less partial volume error. Furthermore, T2-
weighted pulse sequences optimized for human imaging do not directly apply to mice 
due to the use of higher magnetic field strengths and 10-fold greater heart rate in mice 
compared with humans (379). Beyers et al, developed a T2-weighted protocol for 
mice, allowing in vivo imaging of area-at-risk, which showed a good correlation with 
histological measures of area-at-risk (379). The study reported an echo time of 60 ms, 
which provided a high contrast between normal and oedematous tissue. Thus, this 
method could also be useful in evaluation area-at-risk in vivo however, technically 
this is very difficult and potentially less accurate compared to our high-resolution ex-
vivo imaging techniques. 
i.#Conclusion# #
In this study, we describe a high-resolution 3D MRI technique to identify the area-at-
risk using MPIO in place of the well-described Evans blue/TTC approach. This 
method is likely to reduce the potential for measurement error and allow access to 
high-resolution 3D images of the entire LV. In this study we demonstrated that high-
resolution cMRI can provide a quantitative measurement of area-at-risk. This 
technique has the potential to allow improved robustness and accuracy in quantifying 
salvageable tissue in models of myocardial IR and may eventually have translational 
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application. The 3DFLASH sequence with MPIO may represent a more accurate and 
robust technique when determining the area-at-risk compared to the 3DMSME 
sequence. Moreover, both T1 and T2 maps were able to distinguishing between the 
non- and infarcted regions. 
Limitations! ! !
 
This study had some limitations these are described below: 
 
• The assessment of area-at-risk, infarct size and perfused ROI were based on 
visual assessment, which has the potential to result in inter-operator and intra-
operator variability, this error was not assessed.  
• The image segmentation was performed manually with the potential for error 
in accurately demarking the border zone for the ROI.  
• The fixation protocol may have affected the kinetics of Gd binding to the 
irreversibly injured tissue. The area-at-risk was different for each mouse 
(planned), although in retrospect it may have been better to aim for a similar 
area-at-risk between mice.  
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5.2#Part#B:#Hexarelin#as#a#cardioprotective#agent#in#ischemic#heart#disease##
5.2.1$ Hexarelin$ treatment$ preserves$ myocardial$ function$ and$ reduces$ cardiac$
fibrosis$in$a$mouse$model$of$acute$myocardial$infarction$(75)$$ $
#
The results from the following chapter have been published as outlined on page (v) 
 
a.#Abstract# #
 
Aims: Ischemic heart disease (IHD) is a leading cause of morbidity and mortality 
worldwide. Growth hormone secretagogues (GHS) have been shown to improve 
cardiac function in models of IHD. This study aimed to determine whether hexarelin 
(HEX), a synthetic GHS, preserves cardiac function and morphology in a mouse 
model of myocardial infarction (MI).  
Methods and Results: MI was induced by ligation of the left descending coronary 
artery in C57BL/6J mice followed by vehicle (VEH; n=16) or HEX (0.3 mg/kg/day; 
n=16) administration for 21 days. MI-injured and sham mice were subjected to 
magnetic resonance imaging to measure left ventricular (LV) function, mass and 
infarct size at 24 hours and 14 days post-MI. MI-HEX mice displayed a significant 
improvement (P<0.05) in LV function compared with MI-VEH mice after 14 days 
treatment. 
A significant decrease in LV mass, interstitial collagen and collagen concentration 
was demonstrated with chronic HEX treatment, accompanied by a decrease in TGF-
β1 expression, myofibroblast differentiation and an increase in collagen-degrading 
MMP-13 expression levels in MI-HEX mice. Furthermore, heart rate variability 
analysis demonstrated that HEX treatment shifted the balance of autonomic nervous 
activity towards a parasympathetic predominance and sympathetic downregulation. 
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This was combined with a HEX-dependent decrease in troponin-I, IL-1β and TNF-α 
levels suggestive of amelioration of cardiomyocyte injury.  
Conclusion: These results demonstrate that GHS may preserve ventricular function, 
reduce inflammation and favourably remodel the process of fibrotic healing in a 
mouse model of MI and hold the potential for translational application to patients 
suffering from AMI 
b.#Introduction#
Ischemic heart disease (IHD) is a leading cause of morbidity and mortality worldwide 
(3, 386). A variety of risk factors contribute to the development of heart failure post 
myocardial infarction (MI) and ultimately cumulate in structural changes within the 
myocardium leading to left ventricular (LV) dysfunction. A key event in the 
progression of heart failure is the pathological remodelling of the ventricle secondary 
to cardiac fibrosis. Cardiac fibrosis has been identified as both a primary and causal 
driver of disease and has become an important therapeutic target in heart failure 
patients (12). Stiff fibrotic tissue affects myocardial electrical transmission leading to 
arrhythmias, contributes to diastolic and systolic dysfunction and can ultimately result 
in heart failure (12). The mechanisms that underpin the stimulation of cardiac fibrosis 
are not fully understood and interventions targeting excessive fibrosis as a result of 
MI are of major therapeutic importance (13, 14).  
Growth hormone secretagogues (GHS) have been recently identified as compounds 
that stimulate growth hormone (GH) release from the pituitary gland through the G 
protein-coupled receptor (GHS-R) expressed mainly within the pituitary and 
hypothalamus (25, 387). The endogenous ligand, ghrelin, was originally isolated from 
the stomach wall in 1999 (26). GHS have many functions other than the control of 
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GH release. Ghrelin plays a major role in the regulation of systemic metabolism and 
has been shown to exert a number of central and peripheral actions such as regulation 
of food intake, control of energy balance, glucose metabolism and insulin release, and 
stimulation of gastric acid secretion and motility (388, 389).  The GHS-R is expressed 
in many peripheral organs including the stomach, intestine (390), pancreas (391), 
kidney (392), heart and aorta (393). GHS have been demonstrated to have several 
cardiovascular effects suggested by the presence of GHS-R on blood vessels and 
ventricular tissue (149). Hexarelin (HEX), a synthetic hexapeptide belonging to the 
GHS family has been reported to feature cardiovascular activity and is recognized to 
be both chemically more stable and functionally more potent than ghrelin  (45, 394). 
The GHS-R appears to mediate the action of HEX (42, 45). The anti-fibrotic effects 
of GHS have been investigated with promising results in various models of cardiac 
injury such as doxorubicin cardiotoxicity isoproterenol administration, myocardial 
infarction and spontaneous or diabetes-associated hypertension (395). 
The present study was designed to investigate the therapeutic effects of HEX on 
myocardial function and cardiac fibrosis using a murine model of MI. Here, we 
demonstrate a preservation of systolic and diastolic function measured by cardiac 
magnetic resonance imaging (cMRI) and a HEX-dependent attenuation of cardiac 
fibrosis . We propose that HEX prevents cardiac fibroblasts from acquiring a pro-
inflammatory and fibrogenic phenotype, preventing excessive collagen synthesis and 
cardiac fibrosis. This may be mediated by HEX’s influence on inflammation and the 
autonomic nervous system evidenced by a reduction in inflammatory cytokines, 
parasympathetic predominance and sympathetic down-regulation respectively. Thus, 
the findings of this study indicate that HEX may target fibrotic pathways and preserve 
LV function in a mouse model of MI.   
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c.#Materials#and#methods# #
Animal models of MI: 
Ethical approval  
All experiments were approved by the Animal Ethics Committee of the University of 
Queensland and were performed in accordance to national guidelines (Ethics number 
SBMS/200/13/NHMRC). The investigators understand and comply with the ethical 
principals of the Journal of Physiology.  
MI was induced in 12-14 week old male C57BL/6JArc inbred mice (weight 25-30g) 
(n=32) (JAX stock number: 000664) by permanent ligation of the left anterior 
descending coronary artery (LAD). Mice were anaesthetized using a combination of 
medetomidine (1mg/kg) and ketamine (75mg/kg) administered by intraperitoneal 
injection, intubated and supported by a small animal ventilator (Harvard Apparatus) 
with tidal volume and respiratory rate calculated based on body weight (396). 
Anaesthetic depth was monitored by assessment of the pedal reflex and heart rate by 
electrocardiographic (ECG) monitoring. A left-sided thoracotomy was performed and 
the LAD was ligated 2mm below the left auricular appendage using 7-0 Prolene. 
Successful occlusion was confirmed by visualization of a pallor region in combination 
with characteristic ECG changes. Sham-operated mice underwent the same procedure 
excluding ligation of the LAD. The chest was closed using 6-0 polydioxanone and the 
musculature and cutaneous tissues closed using a 5-0 non-absorbable suture.  
After completion of the surgery the mice were administered atipamezole (1mg/kg 
subcutaneous (SC)), carprofen analgesia (5mg/kg SC) and this was continued once 
daily for 48 hours post-procedure. A 0.5ml bolus of saline was administered SC on 
recovery. The mice were recovered in an oxygen- and heat-supplemented 
environment and then moved to their standard housing consisting of a temperature- 
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and heat- controlled environment with 12-hour light/dark cycles and provided with 
free access to food and water ad libitum where they remained until the completion of 
the study.  
Hexarelin and vehicle administration: 
HEX (0.3 mg/kg/day) or vehicle (VEH) was administered to each mouse SC within 
the 15-minute period prior to LAD ligation. Similarly, mice undergoing the sham 
procedure received either VEH or HEX treatment. All mice received their respective 
treatments once daily throughout the 21-day study period. The HEX dose was chosen 
based on similar studies by Mao et al (45, 104).  
Cardiac Magnetic Resonance Imaging (cMRI):  
cMRI was performed at both 24 hours and 14 days post LAD ligation or sham 
procedure in all animals.  Mice were imaged using a 30cm-diameter horizontal bore 
Bruker Biospec 9.4 Tesla (T) small animal MRI scanner equipped with a BGA 12S 
HP 660 mT/m gradient set. MRI data was acquired with an 86mm i.d. quadrature 
transmit coil and a 2x2 phase array receive coil, running Paravision 5.1. (Bruker 
Biospin, Ettlingen, Germany).  
Animal preparation: 
Anaesthesia was induced in an induction chamber using 5% isoflurane in 100% 
medical grade oxygen with a flow rate of 1 L/minute. The mouse was positioned in a 
purpose-built cradle (Bruker, Germany) and maintained with 1.5-2% isoflurane in 1-2 
L/min oxygen via a nose cone. Core temperature was monitored using a rectal probe 
and maintained with a warm water circulation system incorporated into the animal 
bed. A SAII Monitoring system (Small Animal Instruments, NY, USA) was used to 
measure ECG, using a 3-lead system with surface Ag-AgCl electrodes and respiration 
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was monitored with a pressure-transducer, from which a respiratory gating signal 
could be derived. 
cMRI Protocol: 
Gadopententate dimeglumine (Gd-DTPA) (0.3 mmol/kg Magnevist, Bayer, Germany) 
was administered by intravenous (IV) infusion into the lateral tail vein of the mouse. 
Following standard pre-scan calibration, 2- and 4-chamber view scout scans were 
acquired, from which a single mid-cavity short-axis slice was planned. Cine imaging 
was performed with a retrospectively-triggered (self-gated) INTRAGATE gradient-
echo sequence (338), with the following parameters: TR = 5.6 ms, TE = 2.6 ms, flip 
angle = 10 degrees, number of movie frames = 20, slice thickness = 1mm, matrix 
=512 x 512, field-of-view (FOV) = 4 x 4 cm
2
. This resulted in 78 x 78 um in-plane 
resolution, with ~5mins acquisition per slice. Seven to nine short-axis slices with no 
slice gap were acquired to cover the heart from apex to base. Late gadolinium 
enhancement (LGE) images in the slice locations described above were acquired 10-
15 minutes after IV Gd-DTPA and assessed for LGE. 
Determination of cardiac functional parameters and LV mass: 
MRI images, in DICOM format, were processed with Osirix (340) software. The end-
diastolic and end systolic phases were identified on a slice-by-slice basis and both the 
endocardial and epicardial borders were traced. The LV end systolic volume (ESV), 
end diastolic volume (EDV), stroke volume (SV) and ejection fraction (EF) were 
computed from the traced borders and LV mass was obtained by multiplying the 
volume by the specific gravity of 1.05 g/cm
3
 (341).  
Determination of infarct volume: 
The LGE images were windowed to maximise the signal from the hyperintense region 
and null that from the non-enhanced region. Manual planimetry was performed on 
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each slice and the hyperintense region and total LV myocardial area was calculated. 
Slice hyperintense areas were multiplied by the slice thickness and summed to 
calculate the infarct volume as a percentage of LV myocardial volume.  
Measurement of the chronic infarct: midline length measurement: 
In addition to infarct volume, the infarct length was quantified, 14 days post-MI, 
using an alternative cMRI approach described as a “midline-length measurement”. 
This technique was modified from Takagawa et al (342). Briefly, the midline infarct 
length was determined by measuring the midline length of the infarct that included 
50% of the whole thickness of the myocardial wall. The LV myocardial midline was 
measured as a midline circumference. All measurements were taken in diastole. 
Infarct size was calculated by dividing the sum of midline infarct length from all 
sections by the sum of the midline circumference from all sections and multiplying by 
100.  
Post mortem measurement of Infarct size:  
At the endpoint of the study mice were euthanized by cervical dislocation. In a subset 
of mice, the hearts were rapidly excised, trimmed of extracardiac tissue and flushed 
with saline to remove any remaining blood. Hearts were fixed in OCT compound at -
20°C for 15 minutes and transected into 6-8 short axis slices of 1mm thickness using 
a Zivic Mouse Heart Slicer Matrix (Zivic Instruments). Slices were thawed and 
immersed in 1% triphenyl tetrazolium chloride (TTC) in PBS at 37°C for 20 minutes 
whilst being constantly agitated. The slices were fixed in 10% neutral-buffered 
formalin overnight and each slice photographed on each side with a digital camera 
mounted on a stereomicroscope (Nikon C51). Manual planimetry of viable and non-
viable tissue was performed using ImageJ (397). Specifically, the total LV area and 
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MI were manually traced for each image and MI size was determined as a percentage 
of LV mass.  
Histology and morphometric analysis: 
Serial paraffin-embedded LV sections from each group of mice studied were stained 
with 0.1% picrosirius red to detect interstitial collagen deposition. Additional serial 
LV sections from each corresponding group of mice studied were 
immunohistochemically stained for selected markers associated with collagen 
turnover; utilizing polyclonal antibodies to transforming growth factor (TGF)-β1 (sc-
146; 1:200 dilution; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and 
matrix metalloproteinase (MMP)-13 (the predominant collagenase in mice; ab75606; 
1:100 dilution; Abcam; Redfern, NSW, Australia); or a monoclonal antibody to α-
smooth muscle actin (α-SMA; a marker of myofibroblast differentiation; M0851; 
1:250 dilution; DAKO Antibodies, Carpinteria, CA, USA). Detection of primary 
antibody staining was detected using DAKO Envision anti-rabbit or ARK 
biotinylation kits, respectively, and 3,3-diaminobenzidine. Morphometric analysis of 
picrosirius red- and immunohistochemically-stained sections was performed using 
Aperio software (Leica Biosystems, North Ryde, NSW, Australia) on whole tissue 
sections per mouse. In each case, the percentage staining of each marker analysed per 
section was derived and expressed as the fold changes relative to the SHAM-VEH 
group, which was expressed as 1. 
Hydroxyproline analysis: 
Equivalent frozen portions of LV tissue from each animal studied were lyophilized to 
dry weight measurements before being hydrolysed in 6M hydrochloric acid for 
determination of their hydroxyproline content, as described previously (333). 
Hydroxyproline values were converted to collagen content by multiplying by a factor 
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of 6.94 (based on hydroxyproline representing approximately 14.4% of the amino 
acid composition of collagen in most mammalian tissues (334), further expressed as a 
percentage of the tissue dry weight (to yield collagen concentration), and finally 
expressed as the relative change, compared to the SHAM-VEH group (which was 
expressed as 1). 
Heart rate variability analysis: 
Heart rate variability (HRV) analysis was performed 21 days after MI or sham 
procedure. ECG signals were recorded using a physiological analysing system (Bio 
Amp, AD Instruments, CA, USA). Mice were anaesthetized with isoflurane and ECG 
signals were recorded for a minimum of 20 minutes after heart rate stabilization. 
Using a technique described in (335); autonomic nervous system function was 
examined by power spectral analysis of HRV (LabChart Pro 7.0, ADInstruments, 
Australia). Heart rate was used to generate a power spectral density curve using a fast 
Fourier transformation. The area under the curve was calculated for the very-low-
frequency (VLF: 0-0.15Hz), low-frequency (LF: 0.15-1.5Hz), and high-frequency 
(HFr: 1.5-5Hz) band, based on previous studies (335). From these, the parameters: 
LF, HFr, normalized LF power (nLF), normalized HF power (nHFr), and ratio of LF 
to HFr power (LF/HFr) were calculated as described in (88).  
Cytokine and Troponin-I determination:  
Blood samples were collected from mice at both 24 hours and 21 days after the 
procedure. The blood was allowed to clot appropriately and samples were centrifuged 
for serum removal and stored at -80
0
 C until assayed. The serum concentrations of 
troponin-I (cTnI), interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α were 
measured using a MILLIPLEX® map assay according to the manufacturer’s 
instructions (Merck Millipore).   
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Statistical analysis 
Data expressed as the mean +/- SEM or relative mean +/- SEM. Statistical analysis 
was performed using GraphPad Prism 7. Differences between groups were analysed 
by one-way ANOVA using either a Bonferroni or Newman Keuls post-hoc test to 
allow for multiple comparisons between groups. Unpaired t-test was applied to 
comparisons between two groups. P <0.05 was considered statistically significant.  
d.#Results#
cMRI measurement of cardiac function:  
LVEF, EDV, ESV: 
There was a significant reduction in EF in MI-VEH and MI-HEX mice 24 hours post 
LAD occlusion. However, a trend towards a preservation of EF was observed in the 
MI-HEX group compared with the MI-VEH group (Fig. 47A). After 14 days 
treatment, HEX treatment significantly improved EF compared to MI-VEH mice 
(HEX: 49.25% +/- SEM 2.3; VEH: 36.96%+/- SEM 3.82) (Fig. 47B). 
The MI-VEH group showed a significant increase in EDV 24 hours post-MI. These 
changes were completely reversed with 14 days of HEX treatment (Fig. 47C). LV 
ESV was also significantly elevated after 14 days in the MI-VEH group, which again 
was entirely reversed with HEX treatment (Fig. 47D). These results suggested that 
HEX treatment may preserve both systolic and diastolic function post-MI.  
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Figure 47: Cardiac functional parameters measured by cMRI:  
Ejection fraction (%), LV end-diastolic volume, LV end-systolic volume measured 
post-MI/sham procedure with or without HEX treatment.  
(A). EF 24 hours post-procedure, (SHAM-VEH (n=5), SHAM-HEX (5), MI-VEH 
(7), MI-HEX (7)); (B). EF 14 days post-procedure (n=6/5/10/11); (C). LV EDV 14 
days post-procedure (n=6/5/10/11); (D). LV ESV 14 days post-procedure 
(n=6/5/10/11). 
Data in all figures expressed as mean ± SEM; 
***
p<0.001, 
****
p<0.0001, versus 
SHAM-VEH group; 
#
p<0.05, 
##
p<0.01, versus MI-VEH group; 
+
p<0.05, 
++++
p<0.0001, versus SHAM-HEX group. 
cMRI, cardiac magnetic resonance imaging; EDV, end diastolic volume; ESV, end 
systolic volume.  
 
Infarct assessment: 
Infarct volume was determined using cMRI and manual planimetry to calculate 
infarct volume as a percentage of LV myocardial volume (IV%) after 24 hours. Both 
treatment groups exhibited observable infarction after 24 hours (Fig. 48Aa,b), there 
was no significant difference in IV% between MI-HEX and MI-VEH treated groups 
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at this time point (Fig. 48B). This was confirmed by TTC staining in a subset of 
animals post mortem.  
Following 14 days of permanent LAD ligation, VEH and HEX-treated mice exhibited 
observable myocardial infarction as assessed by LGE. Infarct volume was 
significantly reduced (3-fold) following HEX treatment (HEX 6.13 +/- 1.11; VEH: 
15.21 +/- SEM 2.63) (Fig. 48C). Similarly, when infarct size was assessed using the 
midline-length measurement approach using cMRI, a significant reduction in infarct 
midline-length was observed following HEX treatment (Fig. 48D). The midline-
length measurement for MI-VEH mice was 2-fold greater than that assessed by the 
volume approach. In chronic infarcts, the length-based approach has been 
demonstrated to measure the extent to which the infarct scar radially covers the wall 
of the LV, without being influenced by thinning of the wall, thus this is likely to 
explain the different values obtained by the two measurement approaches. The 
midline-length approach may represent a superior measure to assess chronic infarcts 
(342). 
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Figure 48: Infarct size measured by cMRI.  
(A). Representative LGE images acquired using a T1-weighted INTRAGATE 
gradient-echo sequence 24 hours post LAD ligation. The hyperintense region 
represents the infarcted tissue (indicated by white arrows); (a). HEX-treated (b). 
VEH-treated. 
(B). Myocardial infarct size assessed 24 hours post-MI (IV%), (n=7/7).  
(C). Myocardial infarct size 14 days post-MI, infarct size assessed via IV% approach, 
or (D). via midline-length approach, (n=10/10) 
##
P<0.01 versus MI-VEH group. 
IV%, Infarct volume %.  
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LV size: 
LV myocardial mass was determined using cMRI 24 hours and 14 days post-
procedure. There was a significant difference in mass between MI-VEH and the 
respective SHAM-VEH group after 24 hours, while this was not apparent within the 
MI-HEX group. At this acute time point, there is unlikely to be any significant effect 
on remodelling but it is thought that these changes may reflect differences in 
inflammation and/or oedema (Fig. 49A). Cardiac mass was significantly elevated 
after 14 days in the MI-VEH group. This increase was entirely reversed by HEX 
treatment (Fig. 49B).  
To further evaluate cardiac hypertrophy, heart weight (HW) was compared 21 days 
post-procedure. Tibial length (TL) was used as an adjustment factor as body weight 
and growth tendencies were found to depend on whether MI or sham operation was 
performed (45). HW/TL ratios did not differ between the two sham groups. The MI-
VEH HW/TL was significantly higher than the SHAM-VEH group. There was a trend 
towards a decreased HW/TL ratio in the MI-HEX group compared with the MI-VEH 
group (Fig. 49C). Thus the HW/TL results were consistent with our cMRI myocardial 
mass data.    
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Figure 49: Assessment of LV mass and heart weight.    
LV myocardial mass (mg) assessed by cMRI after: (A). 24 hours, (SHAM-VEH/HEX 
(5), MI-VEH/HEX (7)); (B). 14 days post-MI/sham procedure with or without HEX 
treatment, (n=6/5/10/11).  
(C). Heart weight compared 21 days post-procedure. Tibial length (TL) was used as 
an adjustment factor, (n=6/5/5/6).  
*
p<0.05, 
**
p<0.01, 
***
p<0.001, versus SHAM-VEH group; 
##
p<0.01, versus MI-VEH 
group. 
TL, tibial length.  
 
The effect of HEX on MI-induced cardiac remodelling: 
To determine the effect of HEX on LV fibrosis in MI, mice were treated with HEX or 
VEH daily for 21 days.  
LV collagen deposition: 
Picrosirus red staining of the myocardium was used to detected changes in interstitial 
collage deposition and was markedly increased in the MI-VEH group compared to 
that from the SHAM-VEH group. The presence of HEX (MI-HEX) was seen to 
almost completely reverse the aberrant post-infarct interstitial collagen deposition 
S
H
A
M
-V
E
H
 
S
H
A
M
-H
E
X
 
M
I-V
E
H
M
I-H
E
X
0
50
100
150
M
y
o
c
a
rd
ia
l 
m
a
s
s
 (
m
g
)
*
S
H
A
M
-V
E
H
 
S
H
A
M
-H
E
X
 
M
I-V
E
H
M
I-H
E
X
0
20
40
60
80
100
M
y
o
c
a
rd
ia
l 
m
a
s
s
 (
m
g
) *** 
##
S
H
A
M
-V
E
H
 
S
H
A
M
-H
E
X
M
I-V
E
H
M
I-H
E
X
0
2
4
6
8
10
H
W
/T
L
 (
m
g
/m
m
)
**
A 
C 
B 
 138 
measured compared with the MI-VEH group (Fig. 50A). Left ventricular collagen 
deposition assessed by hydroxyproline analysis was also significantly higher in MI-
VEH mice compared to their SHAM-VEH counterparts, while chronic treatment with 
HEX resulted in almost a 2-fold reduction in LV collagen concentration (Fig. 50B).  
TGF-β1, α-SMA, MMP-13: 
LV TGF-β1 (Fig. 50C) and α-SMA-associated myofibroblast (Fig. 50D) 
immunostaining was significantly increased; while LV MMP-13 staining (Fig. 50E) 
was significantly reduced in MI-VEH mice compared to that measured in SHAM-
VEH mice. 
HEX (MI-HEX) therapy normalized the aberrant MI-induced increase in TGF-β1 
(Fig. 50C) and α-SMA (Fig. 50D) expression, and increased MMP-13 levels to 6-fold 
of that measured in the MI-VEH group (Fig. 50E). These results suggested that HEX 
had a regulatory effect on cardiac remodelling and cardiac fibrosis post-MI.   
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Figure 50: Histology and morphometric analysis.  
(A). Interstitial LV collagen content measured by picrosirus red staining, (n=6/5/6/7); 
(B). LV collagen concentration, measured by hydroxyproline analysis, (n=6/5/4/7); 
(C). TGF-β1 (6/5/5/6), (D). α-SMA (5/6/5/7) and (E). MMP-13 
immunohistochemistry staining (n=6/5/5/6) measured 21 days post-MI/sham 
procedure with or without HEX treatment. 
The right column displays representative sections from each treatment group 
corresponding to the selected markers and methods described above.  
*
p<0.05, 
***
p<0.001, 
****
p<0.0001, versus SHAM-VEH group; 
##
p<0.01, 
####
p<0.0001, 
versus MI-VEH group; 
+
p<0.05, 
++
p<0.05; versus SHAM-HEX group 
 
Troponin-I and Cytokine Measurements: 
There was a 3-fold increase in cTn-I after 24 hours in the MI-VEH group compared 
with the MI-HEX group (VEH 40697pg/ml +/- SEM 7568; HEX 13200pg/ml +/- 
SEM 7551). HEX treatment was found to significantly prevent the rise in cTnI (Fig. 
51A).  There was no significant difference in cTnI between the MI-VEH and MI-
HEX group after 21 days but a trend towards a reduction in cTnI was maintained in 
the MI-HEX group.   
In MI-VEH mice, serum TNF-α (Fig. 51B) and IL-1β  (Fig. 51C) were significantly 
increased 24 hours post-MI compared to SHAM-VEH counterparts and there was a 
trend towards increased IL-6 levels (Fig. 51D). The acute MI-induced aberrant 
increase in TNF-α (VEH 9.94pg/ml +/- SEM 0.38; HEX 4.63pg/ml +/- SEM 1.6) 
(Fig. 51A) and IL-1β (VEH 9.21pg/ml +/- SEM 2; HEX 4.47pg/ml +/- SEM 0.6) (Fig. 
51B) was normalized by HEX (MI-HEX) treatment, while IL-6 levels were 
unaffected by HEX administration (Fig. 51C). In comparison, there were no 
differences noted in cytokine levels between MI-HEX and MI-VEH-treatment at the 
21-day time point (data not shown).  
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Figure 51: Serum assessment of: (A).Troponin-I (pg/ml) (n=4/4/5/5); (B). TNF-
a (pg/ml) (n=4/4/4/4); (C). IL-1b (pg/ml) (n=3/3/4/5); (D). IL-6 (pg/ml) (n=4/4/5/4).  
Serum levels assessed 24 hours post-MI/sham procedure with or without HEX 
treatment.  
*
p<0.05, 
**
p<0.01, versus SHAM-VEH group; 
#
p<0.05, versus MI-VEH group. 
 
Heart rate variability (HRV): 
HRV was examined 21 days after sham operation or permanent LAD occlusion. HRV 
analysis is considered a sensitive, non-invasive, indirect measure of cardiac 
autonomic tone that has been extensively validated (335, 398). LF/HFr is used to 
represent cardiac sympathetic nervous activity (SNA), whereas nHFr represents 
parasympathetic nervous activity (PNA) (335). LF/HFr was markedly increased (Fig. 
52A) while nHFr was significantly reduced (Fig. 52B) in MI-VEH mice compared to 
that measured from their SHAM-VEH counterparts. HEX-treatment (MI-HEX group) 
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normalized the MI-induced loss of nHFr and increase in LF/HFr (Fig. 52) back to that 
measured in SHAM-VEH mice, thereby indicating a simultaneous enhancement in 
PNA and reduction in sympathetic tone.  
 
 
 
Figure 52: Heart rate variability analysis.  
Electrocardiographic data recorded 21 days post-MI/sham procedure with or without 
HEX treatment. (A): Sympathetic nerve activity represented by low-frequency power 
(LF/HFr), (n=4/5/4/8). (B): Parasympathetic nerve activity represented by high-
frequency power (nHFr), (n=4/5/4/8).  
*
p<0.05, versus SHAM-VEH group; 
##
p<0.01, versus MI-VEH group.  
HF, high frequency; LF, low frequency; nHF, normalized high frequency power.    
 
e.#Discussion#
In this study we have demonstrated that HEX treatment can preserve cardiac function 
and tissue characteristics in mice after acute MI. This was shown by an improvement 
in systolic and diastolic function, a lower cardiac mass and HW/TL ratio in MI-
injured mice after chronic HEX therapy. One of the major findings of this study was 
the ability of HEX to significantly reduce measures of cardiac fibrosis after MI. The 
anti-fibrotic properties of HEX may be associated with an underlying anti-
inflammatory mechanism, indicated in this study by a decrease in the 
proinflammatory cytokines TNF-α and IL-1β and significant reduction in cTnI levels. 
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Furthermore, this treatment was seen to shift the balance of autonomic nervous 
system activity towards a parasympathetic predominance as evidenced by a lower 
LF/HFr ratio and higher nHFr measured by HRV analysis.  
HEX administration has been demonstrated to result in marked protection against 
myocardial stunning with almost complete recovery of LV function post-reperfusion 
in senescent rats. A simultaneous reduction in creatine kinase concentration suggested 
HEX-mediated preservation of cardiomyocyte integrity (399). Locatelli et al, 
concluded that short-term pre-treatment with HEX counteracted ischemic damage in 
perfused hearts of hypophysectomised rats mediated through cardiac-specific 
receptors and independent of GH-release (400). The effect of HEX was investigated 
in normal subjects and in patients with severe GH deficiency with similar conclusions 
(401). Specifically, a similar increase in LVEF was seen after HEX treatment in: 
normal subjects, patients with ischemic cardiomyopathy and those with severe GH 
deficiency, this was independent of GH-release. Interestingly, in this study, acute IV 
administration of HEX had a positive inotropic effect in patients with ischemic 
cardiomyopathy-induced severe LV dysfunction but failed to stimulate heart 
contractility in patients with severe LV dysfunction due to dilated cardiomyopathy 
(401). 
Cardiac fibrosis and remodelling  
After myocardial injury, multiple neurohormonal factors and cytokines drive changes 
in cardiomyocytes and fibroblasts that collectively result in cardiac remodelling (12) 
(Fig. 53). MI leads to progressive ventricular remodelling, increased myocardial wall 
stress and ultimately results in heart failure (126).  During ventricular remodelling, 
collagen, the main component of the extracellular matrix (ECM) increases. If 
sustained increases in wall stress exceed that of the compensatory capacity of the 
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heart, degradation of the extracellular matrix and alterations of the collagen network 
progressively result in alterations of LV morphology and function. Continued 
accumulation of collagen impairs diastolic function and compromises systolic 
mechanisms (14).  
The anti-fibrotic effects of GHS have been investigated in various models of cardiac 
injury (42, 395). Interventions targeting excessive fibrosis as a result of MI are of 
major therapeutic importance in the treatment of heart failure (13, 14). HEX treatment 
may allow normalization of wall stress and preservation of diastolic and systolic 
function, helping to prevent changes in ventricular wall and chamber dimensions. In 
this study, HEX therapy blunted changes in LV mass and significantly reduced 
interstitial LV collagen content and collagen concentration. These findings represent 
the therapeutic potential of HEX to alleviate degenerative hypertrophic adaptive 
changes leading to LV dysfunction.  
Inflammation and remodelling 
HEX has been demonstrated to protect cardiomyocytes against angiotensin (AT)-II-
induced apoptosis by inhibiting activation of caspase-3, Bax mRNA expression and 
increasing the expression of Bcl-2 (402). In addition to inhibition of apoptosis, anti-
inflammatory strategies may represent another therapeutic approach to mitigate 
cardiac fibrosis. Timely activation of the endogenous pathways that inhibit 
inflammation is important to prevent the catastrophic consequences of uncontrolled 
inflammation on cardiac geometry and function post myocardial infarction (12). 
Induction of pro-inflammatory cytokines, such as IL-1 and TNF-α play an important 
role in acquisition of a pro-inflammatory phenotype by cardiac fibroblasts during the 
early stages following MI and have been demonstrated to play a role in cardiac 
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remodelling and progression of heart failure (70). This study demonstrated the ability 
of HEX to reduce the presence of serum IL-1β and TNF-α in a model of MI (Fig. 51).  
Sustained presence of inflammatory cytokines leads to activation of MMPs and 
results in ventricular dilation through slippage of collagen (73). Our data suggests that 
HEX may increase the degradation of collagen through increased MMP activity 
demonstrated by an increase in MMP-13 expression after chronic HEX treatment. Xu 
et al. also observed similar findings in a study where spontaneously hypertensive rats 
were treated with HEX (403). In this study, treatment resulted in a significant 
reduction in cardiac fibrosis, attenuation of LV hypertrophy, diastolic dysfunction and 
reduced blood pressure. HEX increased MMP-2 and MMP-9 activity and decreased 
myocardial mRNA expression of TIMP1 suggesting an increased degradation of 
collagen (403). Thus, we propose that HEX may reverse the mechanisms that lead to 
progressive LV dysfunction, at least in part, through inhibition of the inflammatory 
response and regulation of collagen turnover.  
Myofibroblast activation 
Compared with cardiomyocytes, cardiac fibroblasts are much less vulnerable to 
oxidant stress following coronary occlusion (404). Given their resistance to ischemic 
death, location and abundance within the cardiac interstitium, fibroblasts are ideally 
suited to sense microenvironmental alterations following myocardial injury and 
initiate the inflammatory response (405). In vitro, the response of cardiac fibroblasts 
to hypoxia is the acquisition of a pro-inflammatory and fibrogenic phenotype 
characterized by myofibroblast transdifferentiation, enhanced cytokine expression and 
collagen synthesis (406). It has been suggested that there is direct involvement of 
fibroblasts in activation of the inflammatory reaction post-infarction (405). TGF-β1 
 146 
expression is markedly augmented following infarction and has been found to have 
profound effects on fibroblast phenotype and function, inducing myofibroblast trans-
differentiation, upregulating matrix protein synthesis and stimulating the synthesis of 
protease inhibitors such as TIMP-1 (12, 407). Our study demonstrated a significant 
reduction in α-SMA expression in HEX-treated mice in combination with a decrease 
in TGF-β1. This suggests decreased activation of myofibroblasts secondary to a HEX-
mediated reduction in TGF-β1 and inflammatory cytokines. Preventing TGF-β1 
activation in a myofibroblast-specific manner has promising therapeutic perspectives 
and HEX may represent a novel pharmacological agent to target this pathway.  
Extensive evidence also suggests a crucial role of the renin-angiotensin aldosterone 
(RAAS) system in activation of infarct myofibroblasts (12). The fibrogenic effects of 
the RAAS are mediated, at least in part, through activation of growth factors such as 
TGF-β1 (408). HEX has been shown to suppress ATII and TGF-β1-induced cardiac 
fibroblast proliferation and collagen synthesis in cultured rat cardiac fibroblasts (409). 
Our study demonstrated a significant reduction in TGF-β1 expression in HEX-treated 
mice. Thus suggesting that HEX’s ability to influence post-infarct fibrotic healing 
may involve the ability to suppress the expression and effect of pro-fibrotic factors 
(such as TGF-β1), that promote fibrogenesis; inhibit myofibroblast differentiation and 
myofibroblast-induced collagen synthesis; and augment MMP-13-induced collagen 
breakdown. The combined actions of which favour a net reduction in aberrant 
collagen content.  
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Figure 53: Hexarelin: proposed mechanisms of action (see text):  
MI induces dynamic alterations in fibroblast phenotype, initiates an inflammatory 
response and activates neurohormonal pathways that collectively result in cardiac 
remodelling, mechanical dysfunction and electrical disturbances in the failing heart, 
increasing the risk of sudden cardiac death (SCD) (12).  
TFG-β1 is markedly augmented following MI and is the most potent profibrotic 
cytokine known, causing excessive extracellular matrix production, inducing its own 
secretion and driving myofibroblast activation (12). Inflammatory cytokines exert 
potent pro-inflammatory actions on cardiac fibroblasts & can negatively affect LV 
function. Similarly, the RAAS & SNA play a critical role in activation of 
myofibroblasts and influence LV remodelling & dysfunction (12, 67).  
HEX may attenuate and actively reverse cardiac remodelling and myocardial fibrosis 
by targeting these pathways (indicated by “x”) and thus holds promise in returning the 
failing heart to a functional state.  
RAAS, renin angiotensin aldosterone system; SNA, sympathetic nervous activation. 
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Autonomic nervous system  
It is well known that activation of efferent vagal nerve fibres can modulate local and 
systemic inflammatory responses through activation of the ‘cholinergic anti-
inflammatory pathway’ (165). The vagus is suggested to play a central role in GHS-
observed effects and is an important link between the nervous and immune systems. 
Ghrelin has been shown to have several anti-inflammatory properties involving vagus 
activation (42, 234, 328).  The restoration of parasympathetic tone has emerged as a 
promising therapeutic approach to normalize autonomic imbalance and inhibit the 
progression of heart failure (214, 410). Furthermore, SNA in patients with MI has 
been shown to contribute significantly to disease progression and prognosis (410). 
Accumulating clinical and experimental evidence indicates that inhibition of cardiac 
SNA improves survival and mitigates LV remodeling and dysfunction post-MI (11, 
90). In the present study, chronic HEX treatment was demonstrated to modulate the 
autonomic nervous system by blunting SNA and enhancing PSA, and influence the 
inflammatory response induced by MI. 
Limitations  
HEX administration immediately prior to ligation represents a potential limitation. 
Timely reperfusion strategies act to limit infarct development, thus more logically, 
therapy would be initiated at this point, prior to reperfusion. The effect of reperfusion 
was not investigated in this study and represents a downfall.  
The temporal histopathological and functional infarct changes in mouse models of MI 
vary when compared to acute myocardial infarction patients, thus representing a 
limitation of this model. 
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f.#Conclusion#
In this study we have demonstrated that HEX treatment has a clear effect on 
myocardial function, fibrosis and inflammation in a mouse model of MI. 
Pharmacological strategies targeting fibrogenic growth factors and anti-inflammatory 
effects may hold promise in prevention of cardiac remodelling and attenuation of 
diastolic and systolic dysfunction. Modulation of the autonomic nervous system by 
HEX may offer a novel cardioprotective strategy by acting to modulate the 
inflammatory reaction and fibrotic pathways.  
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5.3#Part#C:#Hexarelin#as#a#cardioprotective#agent#in#reperfused#ischemic#heart#
disease# #
5.3.1$ Hexarelin$ targets$ inflammation$ and$ neural$ pathways$ to$ preserve$ cardiac$
function$in$a$reperfused$model$of$myocardial$ischemia$in$mice$
#
The results from the following chapter have been published as outlined on page (vi) 
 
a.#Abstract# #
 
Acute myocardial ischemia and reperfusion injury (IRI) underly the detrimental 
effects of coronary heart disease on the myocardium. Despite the ongoing advances in 
reperfusion therapies, there remains a lack of effective therapeutic strategies for 
preventing IRI. Growth hormone secretagogues (GHS) have been demonstrated to 
improve cardiac function, attenuate inflammation and modulate the autonomic 
nervous system (ANS) in models of cardiovascular disease. Recently, we 
demonstrated a reduction in infarct size after administration of hexarelin (HEX), in a 
murine model of myocardial infarction. In the present study we employed a 
reperfused ischemic (IR) model, to determine whether HEX would continue to have a 
cardioprotective influence in a model of higher clinical relevance 
Myocardial ischemia was induced by transient ligation of the left descending coronary 
artery (tLAD) in C57BL/6J mice followed by HEX (0.3mg/kg/day; n= 20) or vehicle 
(VEH) (n=18) administration for 21 days, first administered immediately prior-to 
reperfusion. IR-injured and sham mice were subjected to high-field magnetic 
resonance imaging to assess left ventricular (LV) function, with HEX-treated mice 
demonstrating a significant improvement in LV function compared with VEH-treated 
mice. A significant decrease in interstitial collagen, TGF-β1 expression and 
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myofibroblast differentiation was also seen in the HEX-treated mice after 21 days. 
HEX treatment shifted the ANS balance towards a parasympathetic predominance; 
combined with a significant decrease in cardiac troponin-I and TNF-α levels, these 
findings were suggestive of an anti-inflammatory action on the myocardium mediated 
via HEX.   
In this model of IR, HEX appeared to rebalance the deregulated ANS and activate 
vagal anti-inflammatory pathways to prevent adverse remodelling and LV 
dysfunction. There are limited interventions focusing on IRI that have been successful 
in improving clinical outcome in acute myocardial infarction (AMI) patients, this 
study provides compelling evidence towards the translational potential of HEX where 
all others have largely failed.  
 
b.#Introduction#
Ischemic heart disease is a major cause of death and disability worldwide (3, 386). 
Myocardial ischemia occurs when coronary blood flow and oxygen availability are 
insufficient to meet the requirements of the heart (3).  The consequences of this are 
dependent on the nature and severity of the ischemic episode and the elapsed time to 
subsequent re-establishment of coronary blood flow (3).    
During AMI, occlusion of a coronary artery territory leads to myocyte necrosis. 
Without reperfusion or collateral blood supply, complete necrosis ensues. In the 
absence of reperfusion, very few interventions are able to limit infarct development 
(8, 411). The most effective and well established therapeutic strategy for reducing 
myocardial ischemic injury and infarct size is timely myocardial reperfusion through 
thrombolytic therapy or percutaneous coronary intervention (PPCI) (3). Although 
necessary for tissue salvage, reperfusion may lead to further complications including 
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diminished cardiac contractile function, arrhythmias and irreversible cell injury 
leading to necrosis and apoptosis (9). The introduction of early reperfusion therapies 
have substantially reduced mortality and morbidity amongst AMI patients, however, 
there remains no effective therapy for the prevention of myocardial IRI and its 
sequelae (3). Early arrhythmias can often prove fatal and chronic LV remodelling and 
heart failure continue to be major determinants of prognosis after AMI (11).  
Activation of the sympathetic nervous system (SNS) in patients with AMI has been 
shown to contribute significantly to disease progression and prognosis (410). 
Autonomic imbalance, characterized by vagal withdrawal and sympathetic 
predominance has been linked to impaired cardiovascular (CV) function and elevated 
mortality in patients with heart failure, ventricular arrhythmias, IRI and hypertension 
(151, 154). Traditionally, the CV function of the vagus nerve (VN) has entailed 
regulating sinus rhythm and atrioventricular node conduction. However, recent 
evidence indicates that the VN can have profound effects on CV function, 
remodelling, arrhythmias, IRI and mortality (155). Reduced vagal tone, characterized 
by depressed heart rate variability (HRV) and blunted baroreflex sensitivity is closely 
related to disease progression and poor clinical outcomes in AMI and heart failure 
patients (156, 412, 413).  
Inflammation is an important component of myocardial ischemic injury and heart 
failure (214). It has been well established that enhancing parasympathetic tone 
decreases inflammation in various models of physiologic insult, such as cecal ligation 
and puncture, lipopolysaccharide injection, severe burn injury, traumatic brain injury 
and myocardial IRI (165, 215, 216, 250). Traditionally, CV drugs have had little 
influence on cytokines or the inflammatory reflex present in heart failure, thus, 
modulating the inflammatory response may represent a potential therapeutic strategy 
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to protect against myocardial IRI and improve recovery of cardiac function (414).  
Growth hormone secretagogues (GHS), a class of synthetic peptides stimulating 
growth hormone release through binding of the G-protein coupled receptor (GHS-R) 
have been demonstrated to have CV actions (42, 149). A number of studies have 
demonstrated the protective effects of the synthetic hexapeptide, hexarelin (HEX) in 
AMI, IR injury and cardiac fibrosis (42, 47, 75, 415). There are accumulating studies 
that describe the application of GHS in CV disease clinical trials with promising 
results (53, 393), however there remains a paucity of data detailing the mechanisms 
underlying these effects. In preclinical disease models, there is evidence supporting 
the indirect cardioprotective action of GHS through central and peripheral modulation 
of the ANS (42, 75, 149, 416). 
The present study was designed to examine the effects of HEX on LV function and 
tissue characteristics in a mouse model of myocardial IR. A key event in the 
progression to heart failure is the pathological remodelling of the LV secondary to 
cardiac fibrosis (12). In a recent publication we demonstrated the ability of HEX 
therapy to significantly reduce measures of cardiac fibrosis in myocardial-infarct 
injured mice using a permanent infarct model (75). Unfortunately, this model is not 
readily applicable to the human clinical setting, where early reperfusion therapy is 
paramount to improving outcome in AMI, thus, there is a clear need for studies 
employing reperfusion techniques at the preclinical level to allow for translational 
application. This study represents one of the first in vivo myocardial IR studies 
employing chronic HEX therapy. 
c.#Materials#and#Methods#
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All experiments were approved by the Animal Ethics Committee of the University of 
Queensland and were performed in accordance to national guidelines (Ethics number 
SBMS/200/13/NHMRC). 
 
IR Surgical protcol 
Myocardial IR was induced in 12-14 week old male C57BL/6JArc inbred mice 
(n=38) (JAX stock number: 000664) by transient ligation of the left anterior 
descending coronary artery (tLAD). Mice were anesthetized by intraperitoneal 
injection of medetomidine (1mg/kg) and ketamine (75mg/kg), intubated and 
supported by a small animal ventilator (Harvard Apparatus) with tidal volume and 
respiratory rate calculations described previously (396). A left-sided thoracotomy was 
performed and the LAD was ligated 3mm below the left auricular appendage using a 
7-0 Prolene suture threaded through a 2mm piece of sterile PE10 tubing. The tubing 
was heat-flared at the end in contact with the heart, creating a blunt “foot-print”, 
enabling occlusion of the LAD once tension was applied to the free ends of the suture. 
Successful occlusion was confirmed by visualization of a pallor region distal to the 
site of ligation along with characteristic electrocardiography changes. The suture was 
ligated at the distal end of the tubing for the specified 40-minute ischemic time. 
Sham-operated mice underwent the same procedure excluding ligation of the LAD.  
After 40 minutes of ischemia (or sham procedure) the suture was released and 
removed with the PE tubing, allowing reperfusion. The chest was closed using 6-0 
polydioxanone and the musculature and cutaneous tissues closed using a 5-0 non-
absorbable suture.  
On recovery, the mice were administered atipamezole (1mg/kg) and a subcutaneous 
(SC) injection of carprofen (5mg/kg) and 0.5ml saline SC.  The mice were recovered 
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in an oxygen- and heat-supplemented environment and subsequently moved to their 
standard housing environment where they remained for 21 days whilst the 
experimental data was collected. 
 
Treatment administration 
HEX (0.3mg/kg/day) or VEH was administered SC to each mouse immediately prior 
to reperfusion. Similarly, mice undergoing the sham procedure also received either 
VEH or HEX treatment. This dose was chosen based on previous studies 
demonstrating a cardioprotective effect (45). All mice then received their respective 
treatments once daily throughout the 21-day study period. 
 
Assessment of myocardial injury, inflammation and remodelling  
 
Cytokine and Cardiac troponin (CnT)-I determination  
 
Blood samples were collected 24 hours and 21 days post tLAD ligation or sham 
procedure. The blood was allowed to clot and samples were centrifuged. The serum 
was immediately removed and stored at -80°C until assayed. The serum 
concentrations of CnT-I, interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α 
were measured at 24 hours and 21 days post-operatively using a MILLIPLEX® map 
Assay according to the manufacturer’s instructions (Merck Millipore).   
 
HRV analysis 
 
HRV analysis was performed 21 days post tLAD ligation or sham procedure. ECG 
signals were recorded using a physiological analyzing system (Bio Amp, AD 
Instruments, CA, USA). Mice were anaesthetized with isoflurane and ECG signals 
were recorded for a minimum of 20 minutes once the heart rate (HR) had stabilized. 
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ANS function was examined by power spectral analysis of HRV (LabChart Pro 7.0, 
ADInstruments, Australia) where HR was used to generate a power spectral density 
curve using a fast Fourier transformation (88, 335). The area under the curve was 
calculated for the very-low-frequency (VLF: 0-0.15Hz), low-frequency (LF: 0.15-
1.5Hz), and high-frequency (HF: 1.5-5Hz) bands, with ranges based on previous 
studies (335). The parameters: LF, HF, normalized LF power (nLF), normalized HF 
power (nHF), and the ratio of LF to HF power (LF/HF) were calculated as described 
in (88).  
 
Histology and morphometric analysis  
Serial transverse paraffin-embedded LV sections from each group of animals studied 
were stained with 0.1% picrosirius red to detect interstitial collagen deposition. 
Additional serial transverse LV sections from each corresponding group of animals 
studied were immunohistochemically stained for selected markers associated with 
collagen turnover; utilizing a polyclonal antibodies to transforming growth factor 
(TGF)-b1 (sc-146; 1:200 dilution; Santa Cruz Biotechnology Inc., Santa Cruz, CA, 
USA) and matrix metalloproteinase (MMP)-13 (the predominant collagenase in mice; 
1:100 dilution; ab75606; Abcam; Redfern, NSW, Australia); or a monoclonal 
antibody to a-smooth muscle actin (a-SMA; a marker of myofibroblast differentiation; 
M0851; 1:250 dilution; DAKO Antibodies, Carpinteria, CA, USA). Detection of 
primary antibody staining was detected using DAKO Envision anti-rabbit or anti-
mouse kits, respectively, and 3,3-diaminobenzidine. Morphometric analysis of 
picrosirius red- and immunohistochemically-stained sections was performed using 
Aperio software (Leica Biosystems, North Ryde, NSW, Australia) on whole tissue 
sections (corrected for the area of tissue stained) per animal. In each case, the 
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percentage staining of each marker analyzed per section was derived and expressed as 
the fold changes relative to the SHAM-VEH group, which was expressed as 1. 
 
Assessment of myocardial function  
High-field cardiac MRI  
Mice were imaged using a 30cm-diameter horizontal bore Bruker Biospec 9.4 Tesla 
(T) small animal MRI scanner equipped with a BGA 12S HP 660 mT/m gradient set. 
MRI data was acquired with a 86mm i.d. quadrature transmit coil and a 2x2 phase 
array receive coil, running Paravision 5.1. (Bruker Biospin, Ettlingen, Germany). 
 
Animal preparation   
Anesthesia was induced using 5% isoflurane in 100% medical grade oxygen with a 
flow rate of 1 L/minute into an induction chamber. The mouse was positioned in a 
purpose-built cradle (Bruker, Germany) and maintained with 1.5-2% isoflurane in 1-2 
L/min oxygen via a nose cone. Core temperature was monitored using a rectal probe 
and maintained with a warm water circulation system incorporated into the animal 
bed. A SAII Monitoring system (Small Animal Instruments, NY, USA) was used to 
record the electrocardiogram, using a 3-lead system with surface Ag-AgCl electrodes. 
Respiration was monitored with a pressure-transducer, from which a respiratory 
gating signal could be derived. 
 
Protocol 
Gadopententate dimeglumine (Gd-DTPA) (0.3 mmol/kg Magnevist, Bayer, Germany) 
was administered by intravenous (IV) infusion into the lateral tail vein of the mouse. 
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Following standard pre-scan calibration, 2- and 4-chamber view scout scans were 
acquired, from which a single mid-cavity short-axis slice was planned. Cine imaging 
was performed with a retrospectively-triggered (self-gated) INTRAGATE gradient-
echo sequence (338), with the following parameters: TR = 5.6 ms, TE = 2.6 ms, flip 
angle = 10 degrees, number of movie frames = 20, slice thickness = 1mm, matrix 
=512 x 512, field-of-view (FOV) = 4 x 4 cm
2
. This resulted in 78 x 78 um in-plane 
resolution, with ~5mins acquisition per slice. Seven to nine short-axis slices with no 
slice gap were acquired to cover the heart from apex to base. Late gadolinium 
enhancement (LGE) images in the slice locations described above were acquired 10-
15 minutes after IV Gd-DTPA (Fig. 54). 
 
Figure 54: Representative cMRI images with LGE. Representative LGE images 
acquired using a T1–weighted INTRAGATE gradient-echo sequence 24 hours post-
transient LAD ligation. The hyperintense region represents the infarcted tissue 
(indicated by arrow). (A). Sham; (B). tLAD.  
cMRI, cardiac magnetic resonance imaging; LGE, late gadolinium enhancement; 
tLAD, transient ligation of the left descending coronary artery. 
 
 
Functional analysis  
cMRI images, in DICOM format, were processed with Osirix (340) software. The 
end-diastolic and end- systolic phases were identified on a slice-by-slice basis and 
A B Scale!bar!=!1mm 
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both the endocardial and epicardial borders were traced. The LV end systolic volume 
(ESV), end diastolic volume (EDV), stroke volume (SV) and ejection fraction (EF) 
were computed from the traced borders and LV mass was obtained by multiplying the 
volume by the specific gravity of 1.05 g/cm
3
 (341). 
 
Statistical analysis  
The data was expressed as mean +/- SEM or relative mean +/- SEM. Statistical 
analysis was performed using GraphPad Prism 7. Differences between groups were 
analysed by one-way ANOVA using a Newman Keuls post-hoc test to allow for 
multiple comparisons between groups. Unpaired t-test was applied to comparisons 
between two groups. P <0.05 was considered statistically significant.  
 
d.#Results#
Assessment of myocardial injury, inflammation and remodelling 
CTn-I 
In excess of a 4-fold increase in cTn-I was observed 24 hours post tLAD ligation in 
the IR-VEH compared with the IR-HEX group (Fig. 55A, left column). Thus, by 
protecting against cardiomyocyte injury after IR, HEX treatment appeared to 
significantly prevent an acute rise in cTnI.  There was no significant difference in 
cTnI between the IR-VEH and IR-HEX group after 21 days (Fig. 55A, right column). 
 
Cytokines   
Serum IL-1β, IL-6 and TNFα levels were determined 24 hours and 21 days post-sham 
operation or tLAD occlusion.  
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HEX treatment was found to prevent the significant rise in TNFα seen in the IR-VEH 
group (Fig. 55B). There were no significant differences noted in IL-6 or IL-1β levels 
between the groups at either time point, although there was a trend towards reduction 
in each of the respective inflammatory cytokines’ within the IR-HEX group (Fig. 
55C/D). 
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Figure 55: Serum assessment of: (A). Troponin-I (pg/ml), (n= Sham-VEH (4), Sham-
HEX (4), IR-VEH (4), IR-HEX (5) left & IR-VEH (5), IR-HEX (5) Right); (B). TNF-
a (pg/ml), (n=4/4/3/4)/(5/5); (C). IL-6 (pg/ml). (n=4/4/4/4/3)/(4/3); (D). IL-1b 
(pg/ml), (n=4/4/4/5)/(4/4).  
Serum levels assessed 24 hours (left column) and 21 days (right column) post-
procedure in sham-injured mice and mice undergoing IR procedure with or without 
HEX treatment.   
Data expressed as mean ± SEM; 
*
p<0.05, 
**
p<0.01, versus Sham-VEH group; 
#
p<0.05, 
##
p<0.01, versus IR-VEH group. 
HEX, hexarelin; IR, ischemia reperfusion; LAD, left descending coronary artery; 
VEH, vehicle. 
 
 
HRV   
HRV was examined in mice 21 days post-procedure. HRV analysis is considered an 
indirect measure of cardiac autonomic tone (335, 398). LF/HF is used to represent 
SNS activity, whereas nHF represents parasympathetic nervous activity (335).  
The IR-HEX group demonstrated a parasympathetic predominance and sympathetic 
down-regulation based on a significantly lower LF/HF ratio and higher nHF 
compared with the IR-VEH group (Fig. 56A, B respectively). 
 
Figure 56: Heart rate variability analysis.   
Electrocardiographic data recorded 21 days after sham surgery or transient LAD 
occlusion with or without HEX treatment. (A): Sympathetic nerve activity 
represented by low-frequency power (LF/HF); (B): Parasympathetic nerve activity 
represented by high-frequency power (nHF), (n=4/5/7/9) 
Data expressed as mean ± SEM; 
#
p<0.05, 
##
p<0.01, versus IR-VEH group.  
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HEX, hexarelin; HF, high frequency; IR, ischemia reperfusion; LAD, left descending 
coronary artery; LF, low frequency; nHF, normalized high frequency power; VEH, 
vehicle.  
 
 
LV mass and heart weight (HW) 
LV mass was determined using cMRI 24 hours and 21 days post procedure. There 
were no significant differences in LV mass at either of these time points (Fig. 57A/B).  
To evaluate cardiac hypertrophy, heart weight was measured 21 days post-procedure. 
Tibial length (TL) was used as an adjustment factor.  
HW/TL ratios did not differ between the groups (Fig. 57C), thus our HW/TL data was 
reflective of our cMRI-determined LV mass results.    
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Figure 57: Assessment of myocardial mass and heart weight.    
Myocardial mass (mg) assessed by cMRI after: (A). 24 hours post tLAD ligation, 
(n=4/4/8/11); (B). 21 days post-procedure (n=5/5/7/8) in sham-injured mice and mice 
undergoing IR procedure with or without HEX treatment.  
Heart weight (C). measured post-mortem after 21 days (n=4/4/8/8). Tibial length (TL) 
was used as an adjustment factor.  
The data is expressed as mean +/- SEM. There were no significant differences in 
myocardial mass or HW/TL ratio between groups.   
cMRI, cardiac magnetic resonance imaging; HEX, hexarelin; HW, heart weight; IR, 
ischemia reperfusion; LAD, left descending coronary artery; LV, left ventricle; TL, 
tibial length; VEH, vehicle.  
 
 
Histology and morphometric analysis 
Picrosirius red staining of the myocardium was used to detected changes in interstitial 
collagen (IC) deposition. IC content was significantly increased in the IR-VEH group; 
the presence of HEX was seen to suppress this aberrant post-IR IC deposition 
(without affecting basal IC) (Fig. 58A).  
TGF-β1 (Fig. 58B) and a-smooth muscle actin (SMA)-associated myofibroblast, 
arteriole and artery immunostaining (Fig. 58C) was significantly increased in the IR-
VEH group compared to that measured in Sham-VEH counterparts. TGF-β1 and a-
SMA were both significantly suppressed by HEX-treatment post-IR. There was also a 
trend towards increased MMP-13 levels in the IR-HEX group compared to that 
measured in the IR-VEH group (Fig. 58D). These results suggest that HEX had a 
regulatory effect on cardiac remodelling and fibrosis post-IR.   
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Figure 58: Histology and morphometric analysis   
(A). Interstitial LV collagen content measured by picrosirius red staining (n=4/3/5/4); 
(B). TGF-β1, (n=3/3/6/5); (C). α-SMA, (n=3/4/4/4); (D). MMP-13 (n=4/4/4/4), 
immunohistochemistry staining measured in sham-injured mice and mice undergoing 
IR with or without HEX treatment 
The right column displays representative low power photomicrograph sections from 
each treatment group corresponding to the selected markers and methods described 
above. Low power (whole mount) sections of heart have been selected to demonstrate 
the transmural staining with regional differences that would not be as clearly 
observable at high power.  
Data expressed as mean ± SEM; 
*
p<0.05, versus Sham-VEH group; 
#
p<0.05, versus 
IR-VEH group. 
HEX, hexarelin; IR, ischemia reperfusion; LV, left ventricle; VEH, vehicle. 
 
 
Analysis of LV function  
Twenty-four hours post IR/sham procedure: 
EF (%) was significantly reduced in the IR-VEH compared to the SHAM-VEH 
group; HEX treatment was seen to completely prevent this reduction. Both IR-VEH 
and IR-HEX groups showed a significant increase in EDV 24-hours post-IR. The 
significant elevation in ESV seen within the IR-VEH was limited by HEX treatment 
(Fig. 59A).  
Twenty-one days post procedure: 
EF% remained significantly reduced in the IR-VEH group, whereas a normalization 
of EF% was observed in the IR-HEX group. Similarly, the IR-HEX group displayed a 
normalization in ESV after the 21 days of HEX therapy. There was no significant 
difference in LV EDV between the groups at this time point (Fig. 59B). 
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Figure 59: Cardiac functional parameters measured by cMRI.   
(a). Ejection fraction (%), (b). LV end-diastolic volume, (c). LV end-systolic volume 
measured in sham-injured mice and mice undergoing transient LAD occlusion (IR) 
with or without HEX treatment.  
(A). 24 hours post-procedure, (n=4/4/14/13); (B). 21 days post-procedure 
(n=4/5/14/15)  
Data expressed as mean ± SEM; 
*
p<0.05, 
**
p<0.01, 
***
p<0.001, 
****
p<0.0001, versus 
Sham-VEH group; 
#
p<0.05, 
##
p<0.01, 
####
p<0.0001, versus IR-VEH group; 
+
p<0.05, 
versus Sham-HEX group. 
cMRI, cardiac magnetic resonance imaging; HEX, hexarelin; IR, ischemia 
reperfusion; LAD, left descending coronary artery; LV, left ventricle; VEH, vehicle.  
 
 
e.#Discussion##
There is a clear need to determine therapeutic strategies to protect the myocardium 
from the detrimental effects of IRI. Although improvements in myocardial 
reperfusion continue to take place with new antiplatelet and thrombolytic agents, 
there remains to be no effective therapeutic strategy for preventing myocardial IRI 
(3). In this study we demonstrated that HEX administration reduced serum 
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inflammatory cytokines profiles and cTn-I, reflecting an overall reduction in 
cardiomyocyte injury (417). Downstream, the effects of chronic HEX treatment 
resulted in significantly reduced measures of cardiac fibrosis and an overall 
preservation in LV function.  Additionally, HEX treatment was seen to shift the 
balance of ANS activity towards a parasympathetic predominance. These findings 
provide evidence towards the cumulative effects of simultaneous sympathetic down-
regulation, vagal enhancement and activation of anti-inflammatory pathways to 
prevent adverse LV remodelling and dysfunction.  
At the hospital, reduction in AMI ischemic injury requires a treatment protocol that 
minimizes the door-to-PPCI time. Most preclinical studies in this field consist of a 
surgical protocol involving permanent ligation of the LAD (without allowing 
reperfusion of the ischemic tissue)(45, 75, 104). Therefore these studies fail to clearly 
assess the critical interaction of ischemia, reperfusion injury and the subsequent 
therapeutic intervention. By employing an IR model, the current study closely 
simulates the critical “door-to-PPCI time” concept; therefore representing a superior 
model and evidence towards the potential value of HEX in AMI patients. 
 
Relevance of the autonomic nervous system and inflammation  
The high mortality in myocardial infarction has been strongly associated with an 
acute and sustained increase in cardiac SNS activity (11, 88, 410). Although chronic 
therapeutic interventions have been developed for chronic heart failure, it is the period 
immediately after AMI, before autonomic modulation of cardiac function becomes 
irreversibly activated, that appears to be critical for optimizing short and long-term 
outcome by therapeutic intervention (11). Targeting adverse SNS activation and 
uncontrolled inflammation immediately post-infarction appears to offer a chronic 
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cardioprotective advantage by preventing adverse fibroblast activation, ventricular 
remodelling and dysfunction. There is accumulating clinical and experimental 
evidence that indicates inhibition of cardiac sympathetic nerve activation improves 
survival and mitigates LV remodelling and dysfunction post-MI (11, 90). 
 
GHS and the autonomic nervous system  
Early treatment with the endogenous GHS ghrelin has been shown to reduce the 
incidence of ventricular arrhythmias and improve early survival prognosis by 
preventing the early increase in cardiac sympathetic nervous system activation 
(CSNA) in rodent models of MI (90). CSNA inhibition was maintained for at least 2 
weeks after a single bolus of ghrelin, resulting in attenuation of cardiac dysfunction, 
remodelling and reduced mortality (11). Comparable findings were demonstrated with 
chronic ghrelin treatment (91). Similarly, mice that received one oral dose of HEX 
treatment within 30 minutes of permanent LAD ligation were observed to have a 
higher ejection fraction 14 days after MI with lowered plasma epinephrine and 
dopamine levels. These results suggest that early GHS therapy preserves chronic 
cardiac function after AMI (104).  
In a recent study, ghrelin knock-out mice were employed to demonstrate the crucial 
role of endogenous ghrelin in preventing CSNA, reducing the incidence of 
arrhythmias and improving survival prognosis post-AMI (145). Catecholamine 
concentrations were dramatically increased after AMI in ghrelin KO mice, reflective 
of stronger sympathetic nerve activation in this group. Endogenous ghrelin was 
demonstrated to prevent adverse ventricular remodelling and preserve myocardial 
function (145). Interestingly, the beneficial effect of ghrelin was abolished after 
blockade of the VN (88). Furthermore, it has been suggested that in healthy human 
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subjects ghrelin may suppress CSNA and stimulate cardiac PS nerve activity, (92) 
with the sympatho-inhibitory effects of ghrelin not found to be evident in 
vagotomised humans (86).  
 
The cholinergic anti-inflammatory pathway and GHS 
Excessive immune-mediated inflammatory responses in reaction to myocardial injury 
have been shown to have deleterious effects on post-infarction LV remodelling and 
dysfunction and can influence progression to heart failure (418). A timely, well-
orchestrated inflammatory response is critical to achieve successful infarct healing in 
patients surviving an AMI (418). It has been well established that increasing 
parasympathetic tone, through vagal nerve stimulation (VNS) can decrease 
inflammation in various models of physiologic insult, including myocardial IRI, cecal 
ligation and puncture, LPS injection, severe burn injury and traumatic brain injury 
(215-217, 419). Thus, pharmacological stimulation of the VN may offer a novel 
approach to anti-inflammatory therapy in AMI-patients.  
A multitude of studies highlight the importance of the role of the VN in the 
physiological functions of GHS (328). Ghrelin is known to cross the blood-brain 
barrier and is produced both centrally and within the periphery (288). The nodose 
ganglion is a constellation of vagal afferent neurons that synthesize the ghrelin 
receptor (GHS-R). These receptors are transported to their vagal afferent terminals, 
such as those located within the digestive tract for regulation of energy metabolism 
and food intake (148). Studies have also demonstrated the existence of the GHS-R 
within the infarcted myocardium (91). Co-staining with acetylcholine-esterase 
suggests that the GHS-R is localized within the VN terminals in the heart and sends 
afferent projections to the nucleus tractus solitaries (NTS), a major CV control centre 
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within the brain (147). The ghrelin receptor has also been localized to the dorsal 
motor nucleus of the vagus (87, 420). It has been demonstrated that GHS-R mediates 
the action of HEX and HEX is recognized to be both chemically more stable and 
functionally more potent than ghrelin (44, 421). Peripherally, GHS have been 
demonstrated to act on the cardiac vagal afferent nerve, resulting in a reflex decrease 
in sympathetic activity in rats with MI (90, 91).  
Furthermore, it has been well described that activation of efferent VN fibres can 
modulate local and systemic inflammatory responses, through the ‘cholinergic anti-
inflammatory pathway’ (CAP) (165). The CAP is mediated through vagal efferent 
firing leading to an acetylcholine-dependent interaction with the a-7 nicotinic 
acetylcholine receptor (a7nAChR) subunit on monocytes and macrophages and 
ultimately a reduction in inflammatory cytokine production (165). Activation of the 
CAP is possible via VN stimulation or pharmacologically via administration of 
selective a7nAChR agonists or inhibitors of acetylcholinesetase (165).  
 
GHS, inflammation and vagal activation  
GHS have been shown to have several anti-inflammatory properties involving vagus 
activation. Intravenous ghrelin administration in septic mice has been shown to 
decrease levels of pro-inflammatory cytokines mediated through the VN (196). 
Ghrelin administration has been demonstrated to decrease TNF-α and IL-6, increase 
cardiac output, organ perfusion and reduce mortality in rat models of endotoxemia 
and polymicrobial sepsis, again mediated via the VN (196, 219, 422, 423). Vagotomy 
has been demonstrated to completely prevent these effects (196). Furthermore, ghrelin 
has been demonstrated to have no direct effect on cytokine release from Kupffer cells 
or peritoneal macrophages isolated from normal rats, suggesting an indirect anti-
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inflammatory mechanism (196).  
Inflammation has been demonstrated to play a major role in IRI (214). GHS has been 
demonstrated to activate the CAP in various IR models, Wu et al demonstrated that 
administration of ghrelin after gut IR attenuated excessive inflammation and reduced 
organ injury through the rapid activation of the CAP (231). In a rat model of renal IR, 
ghrelin administration during reperfusion was found to attenuate both systemic and 
renal-specific inflammatory responses, also mediated through the VN (232, 424). The 
absence of endogenous ghrelin has been shown to result in severe cardiac hypertrophy 
and diastolic dysfunction in a mouse model of pressure-overload cardiac hypertrophy. 
Inhibition of the CAP was thought to be responsible for these adverse processes and 
administration of ghrelin was shown to reverse these effects (235). 
 
The cardioprotective actions of HEX in AMI 
Myocardial infarction leads to progressive ventricular remodelling, increased 
myocardial wall stress and possible progression to heart failure (63). Following 
ischemia, alterations in the collagen network can result in progressive changes in LV 
morphology and function with an increase in interstitial collagen likely to impair both 
diastolic and systolic function (14).  
Post-infarction repair requires timely suppression of the inflammatory response to 
prevent catastrophic consequences of uncontrolled inflammation on cardiac geometry 
and function (63). Studies suggest a direct involvement of fibroblasts in activation of 
the post-infarction inflammatory reaction. TGF-β1 is markedly augmented following 
infarction, is a potent pro-fibrotic cytokine and has profound effects on fibroblast 
phenotype and function, including activation of myofibroblasts. Preventing TGF-β1 
activation in a myofibroblast-specific manner holds promise in counteracting cardiac 
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fibrosis (63).  
Our recent work demonstrated a reduction in inflammatory cytokines and 
improvement in LV function in a mouse model of MI, thought to involve activation of 
the CAP. In this study, HEX influenced postinfarct fibrotic healing, likely by 
involving the suppression of profibrotic factors and favouring a net reduction in 
aberrant collagen content (75). Furthermore, Huang et al. recently demonstrated that 
HEX protected cardiomyocytes from IR injury partly through modification of the IL-1 
signalling pathway via activation of the GHS-R (47).  
In this current study, we demonstrated a HEX-mediated decrease in TGF-β1 
expression and myofibroblast differentiation post-myocardial IR. Several studies have 
shown that TGF-β1 is a key stimulator of myofibroblast differentiation post-MI (13, 
425). MMP-9 and TGF-b1 also both play key roles in the progression of post-MI 
remodeling (263, 264) and inflammatory cytokines such as IL-1 can regulate 
fibroblast phenotype. The activation of MMPs may influence changes in extracellular 
matrix degradation (ECM) and collagen deposition (47, 74, 265).   
Thus, via vagal enhancement and activation of the cholinergic anti-inflammatory 
pathway, combined with simultaneous suppression of the acute rise in SNS activation, 
HEX appears to mitigate adverse inflammation. Furthermore, this anti-inflammatory 
action appears to downregulate TGF-β1 expression and myofibroblast differentiation 
as part of its potential therapeutic effects (75) (Fig. 60).  
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Figure 60: In response to myocardial IR HEX actives endogenous neural pathways to 
restrain adverse inflammation and plays a role in inhibiting pathways of pathological 
LV remodelling 
 Myocardial ischemia initiates SNS activation and an acute inflammatory response; 
inflammatory cytokines exert pro-inflammatory actions on cardiac fibroblasts and can 
result in LV dysfunction.  TGF-B1, a potent pro-fibrotic cytokine, is increased 
following MI and can cause excessive ECM production and myofibroblast activation. 
By suppressing inflammatory pathways and sympathetic activation HEX appears to 
attenuate these negative effects on cardiac remodelling and dysfunction. Additionally, 
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pharmacological stimulation of vagal pathways by HEX appears to decrease levels of 
proinflammatory cytokines through activation of the CAP 
 
f.#Conclusion#
Targeting autonomic imbalance by augmentation of parasympathetic tone has 
emerged as a promising therapeutic approach for management of ischemic heart 
disease and heart failure (214). The VN is suggested to play a central role in GHS-
observed effects and acts as an endogenous mechanism to regulate the immune 
response and inflammation (42). In the present study, HEX treatment was 
demonstrated to modulate the ANS and influence the inflammatory response induced 
by myocardial IR. Our results demonstrate that HEX may have an important influence 
on balancing the sympathetic and parasympathetic nervous system and modulating 
adverse inflammatory pathways in response to AMI. Pharmacological stimulation of 
the VN by HEX may offer a novel cardioprotective strategy against IRI by preventing 
myofibroblast activation and LV remodelling in AMI.  
 
Clinical relevance 
The research field of cardio-protection has been plagued by numerous failed attempts 
to translate promising therapeutic strategies for preventing myocardial ischemic injury 
discovered in the basic science laboratory into the clinical setting (3). A major factor 
underlying this failure entails the inappropriate use of experimental animal models. In 
our previous study we were able to clearly demonstrate the cardioprotective effect of 
HEX therapy in a mouse model of permanent MI, however, the translational aspect of 
this model is limited. HEX as an emerging therapeutic agent for prevention of 
myocardial IRI has shown promise in this study using a clinically relevant model, 
where HEX was administered prior to myocardial reperfusion (removal of the 
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coronary ligature), representing a protocol that could be employed in the reperfusion 
unit. Therefore, this study signifies a noteworthy contribution to the field of cardio-
protection.  
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6.&Discussion& &&
6.1#Concluding#remarks# #
The work undertaken throughout this thesis comprises comprehensive longitudinal 
studies investigating the therapeutic effects of HEX on myocardial function, cardiac 
inflammation and fibrosis by employing murine models of IHD. Given that HEX is a 
stable and potent hexapeptide compared with its unstable natural counterpart ghrelin 
(and can be administered orally) (43), HEX offers potential advantages as a 
therapeutic agent in IHD. These properties have been clearly demonstrated in Chapter 
5. 
Throughout this work we have successfully illustrated the ability of HEX to 
significantly reduce measures of cardiac fibrosis in myocardial-infarct injured mice 
using models readily applicable to the human clinical setting. Thus, this work satisfies 
the critical need to employ reperfusion techniques at the preclinical level to allow for 
more seamless translational application to the Coronary Care Unit. We have also 
described novel cMRI techniques allowing accurate assessment of myocardial 
function, the extent of infarction and salvageable tissue. These measures represent 
important variables for the assessment of therapeutic efficacy and prognosis in the 
AMI patient. Overall, not only do these findings address the aims of this thesis, but 
also represent a noteworthy contribution to the field of cardio-protection.  
 
6.2#Inflammation#–#a#link#between#the#brain#and#heart?## #
The field of cardioprotection has been fraught with ongoing failed attempts to 
translate promising therapeutic strategies for AMI from the laboratory to the clinical 
setting (3). Failure of these therapies has been somewhat attributed to the influence of 
age, comorbidities and chronic pharmacotherapy in the clinical patient compared to 
 178 
that of their disease-free preclinical model-counterparts. Therefore, there is a critical 
need for more detailed and mechanistic preclinical studies that examine 
cardioprotection in relation to concurrent comorbidities (9).    
 
As discussed throughout this thesis, chronic systemic inflammation has been 
increasingly recognized as a major risk factor for CVD (426). An adverse 
inflammatory response has been implicated in the pathophysiology of primary CVD 
and conversely, inflammation-induced myocardial injury and dysfunction has been 
seen as a sequalae of various systemic diseases (155, 214). Metabolic diseases such as 
obesity, diabetes and IBD exhibit strong inflammatory underpinnings and have been 
associated with increased risk of CVD (426, 427). Thus, it could be speculated that 
CVD might be linked with the pro-inflammatory state induced by metabolic disease.  
The development of ventricular dysfunction associated with metabolic disease is 
likely to be multifactorial, with putative mechanisms including insulin resistance, 
metabolic disturbances, endothelial dysfunction, myocardial fibrosis, autonomic 
dysfunction and myocyte damage (428). Proinflammatory cytokines could be viewed 
as the common denominator here, given their involvement in all of these 
pathophysiological processes (428, 429) (Fig. 61). 
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Figure 61: We propose that GHS negatively influence the proinflammatory state by 
modulating inflammatory cytokines (broken arrow). Inflammatory cytokines are 
likely to represent common link between the pathophysiologial changes culminating 
in LV dysfunction. 
 
 
CVD is often associated with systemic diseases such as obesity and type 2 diabetes 
mellitus (T2DM) (430). GHS-mediated enhancement of cholinergic signaling via the 
inflammatory reflex may offer a two-fold protective advantage by firstly suppressing 
obesity-associated inflammation and secondly, the cardiovascular implications linked 
with this pro-inflammatory state (431) (Fig. 64). There continues to be a definite need 
for discovery of new treatments for T2DM, metabolic syndrome and associated 
disease processes. Ghrelin is an endogenous peptide that may target common steps in 
the pathogenesis of these diseases. Ghrelin may represent an effective cholinergic 
modulator, capable of alleviating inflammation and metabolic complications (Fig. 
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62). HEX is likely to have similar effects. 
 
Figure 62: Obesity, metabolic and cardiovascular disease are linked to chronic 
inflammation. These diseases are associated with a chronic inflammatory state and 
activation of the sympathetic nervous system. GHS protects against this dysfunction 
by modulating sympathetic nervous system as well as the afferent and efferent arm of 
the inflammatory reflex (see text for further detail). Thus, ghrelin has multifactorial 
protective influences in both metabolic and CVD.  
 
Ghrelin is a critical molecule facilitating interactions between the gut, brain and 
immune system (307). The nodose ganglion synthesizes ghrelin receptors and these 
receptors are transported to their vagal afferent terminals within the gastrointestinal 
tract (148). Afferent VN signaling is activated by cytokines or EEC derived peptides, 
constituting the gut-brain axis (Fig. 63 & 64) (148).  It seems likely that the appetite-
regulating peptide ghrelin is a crucial factor in the anatomical link mediating this 
pathway. In a scenario not dissimilar to the gut, the GHS-R has been localized within 
the VN terminals in the heart and sends afferent projections to the NTS (87, 91, 147). 
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In a comparable way to the gut, the heart and the brain also appear to communicate 
bidirectionally through anatomical and humoral pathways mediated by cytokines and 
neuropeptides (Fig. 63) (288).   
Production of immunomodulatory enteroendocrine hormone peptides can regulate our 
immune system to influence inflammation in metabolic disease (286), however, it also 
seems likely that these peptides can regulate inflammation in CVD through a similar, 
if not identical pathway. Thus, we propose the existence of the “heart-brain axis” 
whereby ghrelin (or the synthetic analogue HEX) may act as important mediators to 
activate the cardiac VN both centrally and peripherally. 
GHS appear to represent a crucial link in the gut-brain axis and the similar heart-
brain axis whereby they act to modulate inflammation.  
 
Figure 63: An inflammatory/hypoxic/ischemic insult induces the production of 
inflammatory cytokines (orange circles). Afferent VN signaling is activated by 
cytokines or neuroendocrine peptides, such as ghrelin (green circles) by binding to the 
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GHS-R. The efferent arm of the CAP is activated and suppresses the immune 
response. Key: CAP, cholinergic anti-inflammatory pathway; H, Hypothalamus; NG, 
nodose ganglion; NTS nucleus tractus solitaries.   
 
 
 
6.2.1#The#gutPbrain#axis#and#ghrelin#### $
Several lines of evidence indicate that activity of the VN is impaired in obesity (277). 
Enhancing cholinergic signaling can suppress obesity-associated inflammation and 
adverse implications, including insulin resistance, hyperglycemia, and CVD (169, 
277, 289). Mice fed a high-fat diet have displayed evidence of gastrointestinal 
inflammation. This inflammation has been seen to spread to the VN ganglion cells 
and hypothalamus through the vagal afferent pathway distributed along the 
gastrointestinal tract (148, 432). It is plausible that a similar phenomenon occurs 
following myocardial injury/ inflammation in CVD and is mediated via the cardiac 
vagal afferent nerve (Fig. 64 & 65).  
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Figure 64: The Gut-brain-Heart Axis and HEX. In the enteric system, an insult results 
in the induction of inflammatory cytokines and liberation of neuroendocrine 
mediators from enteroendocrine cells that subsequently activate the afferent enteric 
vagus nerve. Similarly, an ischemic insult in the heart induces inflammatory cytokine 
release; it is possible that this insult also stimulates release of endogenous ghrelin. 
GHS can bind to the GHS-R localized in the vagal nerve terminals of the heart and 
activate the cardiac vagal afferent nerve. Furthermore, IHD, through mechanisms 
reducing cardiac output (ie, systolic dysfunction, arrhythmias) result in hypoperfusion 
of the gastrointestinal tract, this “insult” will further liberate inflammatory cytokines 
and neuroendocrine mediators from the EEC to activate the vagal afferent nerve 
(orange arrow). This may explain how mediators from the gut can influence cardiac 
inflammation. Exogenous HEX can peripherally activate the afferent VN and 
centrally, the CAP. The activated CAP blunts inflammation (blue arrows). Key: CAP, 
cholinergic anti-inflammatory pathway; EEC, enteroendocrine cells; H, hypothalamus; 
NTS, nucleus tractus solitarius. Light green circles represent ghrelin, orange circles 
represent inflammatory cytokines. 
 
 Ghrelin plays a crucial role in regulating gastrointestinal inflammation and there is 
strong evidence supporting its protective influence (307). Ghrelin has been 
demonstrated to modulate intestinal mucosal immunity directly by acting on immune 
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cells such as macrophages to suppress pro-inflammatory cytokine production & 
indirectly via VN stimulation (307). High serum ghrelin levels have been reported in 
IBD patients and in experimental colitis (307, 308, 316, 433).  In contrast, plasma 
ghrelin is decreased in obesity and negatively correlated with body mass index (306). 
It is thought that increased ghrelin levels in inflammatory gastrointestinal disease 
could result as a consequence of tissue injury stimulating the production of 
endogenous ghrelin in response to intestinal inflammation and damage (307). Thus 
increased ghrelin expression could be interpreted as a response to counteract the pro-
inflammatory response as part of a counterbalance feedback mechanism (307).  
Alterations in the VN response towards appetite-regulating peptides have been 
demonstrated to occur in the obese state (148). High fat diet-induced obese mice 
showed blunted ghrelin signaling in the nodose ganglion via a mechanism involving 
in situ activation of inflammation (289). Furthermore, expression of the ghrelin 
receptor in both the hypothalamus and nodose ganglion was downregulated in high fat 
diet-fed mice (289). It is thought that ghrelin resistance in the obese state may be 
caused by dysregulation of ghrelin signaling via the vagal afferent nerve (289). 
Despite the dysregulation of afferent vagal nerve signaling in obesity, it is likely that 
exogenous activation of efferent vagal pathways by GHS (ie, pharmacological 
stimulation of the CAP) will maintain their anti-inflammatory actions. Furthermore, 
activation of the CAP may ultimately modulate the pro-inflammatory state in the 
obese patient by resulting in negative feedback inhibition of inflammatory cytokine 
production in these patients (Fig. 65). This has been largely unexplored.   
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Figure 65: Afferent vagal nerve signaling normally activated by cytokines or 
neuroendocrine peptides, however this response is blunted in obesity (indicated by 
dotted line). Never the less, it is likely that pharmacological activation of the CAP by 
exogenous administration of GHS will suppress the pro-inflammatory cytokines 
contributing to the pro-inflammatory phenotype of the obese patient, down-regulating 
inflammation.  
6.2.2#The#heartPbrain#axis#and#ghrelin### # $ $
The ANS has profound and complex effects on cardiovascular function, remodelling 
and mortality (155, 214). GHS appear to modulate outcome and progression of IHD 
by influencing the ANS and vagal anti-inflammatory pathways. 
Ghrelin activates the VN, the release of ghrelin is similarly promoted by VNS (215). 
ACH administration and muscarinic receptor agonists also increase ghrelin secretion, 
whereas muscarinic receptor antagonists decrease secretion (434). Additionally, 
studies have demonstrated that activation of sympathetic nerves increase ghrelin 
secretion (435), ghrelin-producing cells also express β1-adrenergic receptors and 
norepinephrine can stimulate ghrelin release via these receptors directly. Ghrelin 
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secretion in response to SNA may represent a negative feedback mediator for 
sympathetic activation (434).  
Ghrelin has been implicated as a biomarker and prognostic indicator for patients with 
chronic heart failure (133). Lower levels of ghrelin have been demonstrated in chronic 
heart failure patients and correspond to the severity of heart failure diagnosis (133). 
Similarly, in rat model of MI, decreased levels of plasma and cardiac ghrelin were 
expressed, however, increased GHS-R expression was observed. Plasma ghrelin was 
shown to correlate negatively with LV end diastolic pressure (436). Matsumoto et al. 
reported that serum ghrelin levels were significantly decreased in association with 
myocardial infarct size and cardiac function in AMI patients (437). With regards to 
systemic disease, circling levels of ghrelin were significantly decreased in a rat model 
of sepsis with a marked elevation in GHS-R expression in early sepsis (219, 220, 222, 
223). 
Interestingly, exercise training has been demonstrated to increase ghrelin levels in 
patients in the setting of HFpEF. Patients with lower ghrelin levels at baseline were 
found to experience a more pronounced increase in ghrelin under a training 
intervention (58). Exercise training has been demonstrated to reduce mortality in MI 
patients though improving ANS control (438). Chronic benefits of exercise training 
are thought to be associated with improvement in baroreflex sensitivity with an 
increase in vagal activity and reduction in sympathetic activity to the heart, 
reticuloendothelial system and other tissues including the brain, liver, spleen and 
gastrointestinal tract. It is thought that this autonomic remodeling is directly 
associated with an improved local and systemic inflammatory profile, thereby 
reducing cardiovascular risk and enhancing survival post-MI (438). It is interesting to 
speculate that ghrelin may play a (primary?) role in the protective effects resulting 
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from exercise training, this is likely through ghrelin-mediated autonomic modulation 
(Fig. 66).  
 
 
Figure 66: Influence of exercise training on the ANS and inflammation (see text). 
Green arrows represent down regulation, blue arrows represent enhancement. 
Exercise training has been shown to increase ghrelin levels in the setting of heart 
failure, it is unclear whether this is the case in all inflammatory states/diseases.  
 
In patients with end stage chronic heart failure, LV dysfunction and cardiac cachexia 
are observed. This catabolic state is associated with hormonal changes and cytokine 
activation (439). Ghrelin has been demonstrated to have an anti-cardiac cachexia 
effect and is upregulated in cachexic patients with chronic heart failure (57, 440). 
Considering that ghrelin is closely involved with energy balance, it is possible that 
altered plasma ghrelin levels in the cachectic chronic heart failure patient may 
represent a compensatory mechanism for the proinflammatory state (441). Plasma 
ghrelin levels are seen to increase in association with a decrease in body mass index 
and an increase in plasma TNF-︎ level in patients with chronic heart failure. 
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Specifically, plasma ghrelin increased when patients developed cardiac cachexia. 
Exogenous administration of ghrelin in rats with severe chronic heart failure was seen 
to attenuate cardiac cachexia and improve cardiac structure and function (57, 439). In 
conclusion, in the advanced stage of cardiac cachexia, ghrelin may be upregulated to 
address the catabolic-anabolic energy imbalance and proinflammatory disease state 
(289, 442, 443). 
Overall, there is a complex relationship that exists between plasma and tissue ghrelin, 
GHS-R expression and energy balance – particularly with the added dimension of 
cardiac (or metabolic) disease. This is demonstrated by the complexity of the 
“cachexic” CVD patient with upregulated circulating ghrelin versus the “obese” CVD 
patient with lower circulating ghrelin but upregulation of the GHS-R. There is no 
doubt that ghrelin plays a significant & multi-modal role in the “metabolic-
inflammatory-CVD” patient and it is clear that, detailed investigations are required to 
clarify the role of ghrelin and energy homeostasis in the context of CVD. None-the-
less, there is clearly a therapeutic advantage of exogenous GHS administration in the 
“CVD-metabolic” patient.  
6.2.3#Autonomic#modulation# # $
It is interesting to note that the cardioprotective effects of VNS in animal models have 
not yet been replicated in human clinical studies (274). Importantly, it is worthy to 
note that patients enrolled in VNS- studies were diagnosed with chronic 
cardiovascular disease without markers of inflammation (214). Thus, it could be 
postulated that those with long-standing fibrotic cardiomyopathic diseases may not 
benefit from the anti-inflammatory action defined by that of VNS. To support this 
hypothesis, acute IV HEX administration has not been shown to increase LV ejection 
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fraction in human patients with dilated cardiomyopathy with severe left ventricular 
dysfunction whereas an increase in ejection fraction has been observed in patients 
with ischemic cardiomyopathy (401). Those suffering from an acute event, for which 
there is an initial inflammatory insult (with the potential for cardiac remodelling) may 
be more likely to have beneficial response to VNS (214, 272). To our knowledge, this 
has not yet been investigated clinically. 
Given that mortality in MI has been strongly associated with an adverse and sustained 
increase in CSNA initiated acutely post-infarction (11, 88), targeting adverse 
processes such as SNS activation and uncontrolled inflammation immediately post-
infarction may also offer a chronic cardioprotective advantage by ameliorating down-
stream pathways culminating in fibroblast activation, ventricular remodelling and 
dysfunction. Cardioprotective effects have been demonstrated with early ghrelin & 
HEX administration in models of IHD (42, 104, 444).   
Given these findings, it might be reasonable to conclude that GHS therapy may be 
more effective in the CVD patient characterized by acute, inflammatory insults. 
Secondly this would also highlight the importance of early therapeutic administration 
of GHS in IHD patients. None-the-less, ghrelin clearly has effects in chronic CVD 
and this may also relate to its influence on systemic inflammation, energy balance and 
metabolic disease, particularly in the multifactorial context that characterizes the 
typically comorbid CVD patient. These concepts need desperate ongoing 
investigation in both the preclinical and clinical realms.  
Finally, it is critically important that CVD is not seen as an isolated disease entity and 
needs to be thought of in the context of its comorbidities and risk factors. It is likely 
that GHS target multiple areas of cardiovascular and metabolic disease and thus may 
represent a unique therapeutic agent for clinical cardiovascular medicine.  
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7.&Conclusion& &future&directions&
AMI is associated with considerable morbidity and mortality. With more than a 
million patients hospitalized annually, heart failure continues to be one of the most 
challenging conditions to prevent and manage (445, 446). To date, there remains a 
clear lack of effective therapeutic agents available to target the adverse processes 
involved in the progression of AMI. This work has provided novel insight into the 
action of HEX in the setting of AMI and has specifically demonstrated that HEX 
therapy can improve myocardial function, reduce inflammation and infarct size in a 
mouse models of IHD.  
The development of therapeutic approaches to protect the ischemic heart requires 
preclinical studies that examine cardioprotection specifically in relation to 
complicating disease states and risk factors (9).  Important future directions 
highlighted from this work include utilizing disease models representative of the 
target clinical population (i.e, models with metabolic disease, T2DM, obesity, 
hypertension). Future studies are critical in order to assess the therapeutic response to 
HEX in models with such comorbidities. Recently, Tan et al generated a mouse model 
of obesity, hyperglycemia and mild kidney pathology and induced a hypertrophic 
phenotype by transverse aortic constriction (447), these types of models are critical 
for advancing investigation assessing the therapeutic efficacy of pharmacological 
agents in the setting of comorbidities..  
Recently, the metabolic pathway involving CD36, a fatty acid transporter and energy 
substrate supplier to the heart (403) has been identified as a receptor of HEX with the 
potential to mediate GHS actions in the heart (44).  Furthermore, CD36 has been 
advocated as a potential antifibrotic target in renal proximal tubule fibrosis (448) and 
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lung fibrosis in mice (449). This pathway is worthy of further investigation in relation 
to HEX’s action in IHD but was beyond the scope of this thesis.  
Although animal data indicates that VNS can affect remodelling and survival 
outcomes in CVD, similar data has not yet translated into the clinical realm. There 
does, however, appear to be a relationship between VN activation and inflammation 
in humans (208). To date, there have been no direct clinical studies assessing the 
application of VNS in AMI patients (450). As a pharmacological activator of the 
CAP, it would also seem prudent to assess the therapeutic response to HEX in the 
AMI compared with that of the patient with chronic fibrocardiomyopathic 
cardiovascular disease.  
Finally, once these questions have been answered, there will ultimately be a need to 
employ clinical trials assessing HEX as a therapeutic agent in the IHD-metabolic 
patient.  
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9.1##Ethical#Approval#Certificate#
#
Mice - genetically modified (MKR, Mix, Adults, Institutional Breeding Colony)
10 Jun 2015 Mod #11 144 144
Mice - non genetically modified (C57BL/6, Male, Adults, Institutional Breeding Colony)
11 Sep 2013 Initial approval - pilot study 12 12
31 Dec 2013 Use in 2013 (from 2014 MAR) 0 12
11 Jun 2014 Initial approval - post pilot study 240 252
14 Aug 2014 Mod #7 30 282
29 Aug 2014 Mod #6 30 312
Description Amount Balance
Approval Details
UQ Research and Innovation
Director, Research Management Office
Nicole Thompson
Animal Ethics Approval Certificate 28-Aug-2015
Please check all details below and inform the Animal Welfare Unit within 10 working days if anything is incorrect.
Activity Details
Chief Investigator: Professor Chen Chen, Biomedical Sciences
Title: Protective effect of growth hormone releasing peptide on heart function after 
ischemia/reperfusion
AEC Approval Number: SBMS/200/13/NHMRC
Previous AEC Number: SBMS/055/13/NHMRC
Approval Duration: 10-Oct-2013 to 10-Oct-2016
Funding Body: Internal Funds - UQ, NHMRC
Group: Anatomical Biosciences
Other Staff/Students: Frederik Steyn, Xinli Zhang, Karine Mardon, Tamara Paravicini, Katrina Geary, Nyoman 
Kurniawan, Gary Cowin, Hayley McDonald, Zoe Schoefield, Lili Huang
Summary
Subspecies Strain Class Gender Source Approved Remaining
Mice - genetically 
modified
MKR Adults Mix Institutional 
Breeding Colony
144 144
Mice - non 
genetically 
modified
C57BL/6 Adults Male Institutional 
Breeding Colony
422 319
Permits
Provisos
This approval is subject to a pilot study in experiment one. The Committee determined that work beyond the pilot study is 
subject to Committee approval of the pilot study report.
Location(s): St Lucia Bldg 76 - Chemistry (SCMB)
St Lucia Bldg 81 - Otto Hirschfeld
St Lucia Bldg 57  - Centre of Advanced Imaging
Cumbrae-Stewart Building
Research Road
Brisbane Qld 4072 Australia
Animal Welfare Unit
UQ Research and Innovation
The University of Queensland
+61 7 336 52925 (Enquiries)
+61 7 334 68710 (Enquiries)
+61 7 336 52713 (Coordinator)
animalwelfare@research.uq.edu.au
uq.edu.au/research
Page 1 of 2
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Please note the animal numbers supplied on this certificate are the total allocated for the approval duration
1. When ordering animals from Animal Breeding Houses
2. For labelling of all animal cages or holding areas.  In addition please include on the label, Chief Investigator's name and 
contact phone number.
3. When you need to communicate with this office about the project.
It is a condition of this approval that all project animal details be made available to Animal House OIC.
(UAEC Ruling 14/12/2001)
The Chief Investigator takes responsibility for ensuring all legislative, regulatory and compliance objectives are satisfied 
for this project.
This certificate supercedes all preceeding certificates for this project (i.e. those certificates dated before 28-Aug-2015)
Please use this Approval Number:
10 Dec 2014 Mod #8 30 342
31 Dec 2014 Use in 2014 (from 2015 MAR) -103 239
8 Apr 2015 Mod #10 80 319
